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Abstract 
Colorectal cancer liver metastases (CLM) remain a significant cause of cancer-
related morbidity and mortality. Central to their survival and growth is the process of 
tumour angiogenesis. Current clinical anti-angiogenic therapies target vascular 
endothelial growth factor signalling, but resistance to therapy is problematic. The 
aim of this study was to identify proteins critical for CLM endothelial cell (CLMEC) 
survival that could be targeted for the development of new anti-angiogenic 
therapies. 
 
CLMECs and endothelial cells of normal adjacent liver (LECs) were isolated from 
patients undergoing curative resection. The two cell types were superficially similar, 
exhibiting markers and functional characteristics expected of endothelial cells. 
However, a number of differences in protein expression were identified, one of 
which was the previously unrecognised upregulation of the WEE1 checkpoint-
kinase, a target of the small molecule WEE1 inhibitor AZD1775, currently in clinical 
trials. AZD1775 monotherapy was shown to inhibit proliferation and migration of 
CLMECs. Investigation of the underlying mechanism suggested induction of 
double-stranded DNA (DS-DNA) breaks due to a critical nucleotide shortage, which 
then led to caspase-3 dependent apoptosis. The implication for CLMEC tube 
formation was striking, with AZD1775 inhibiting branching tube formation by 83%. 
AZD1775 also had direct anti-cancer activity in a p53-mutated colorectal cancer cell 
line (HT29). In combination with 5-FU it caused increased caspase-3 dependent 
apoptosis because of DS-DNA breaks, not premature mitosis, which is thought to 
be the mechanism of AZD1775 toxicity when used in combination with DNA-
damaging agents. 
 
- vi - 
Proteomic screening of matched LECs and CLMECs identified a further 157 
differentially expressed proteins, including up-regulation of the established 
endogenous angiogenesis inhibitors thrombospondin-1 and vascular endothelial 
growth factor receptor-1. The mechanosensitive, Ca2+ permeable ion channel 
Piezo1 was identified as another potential anti-angiogenic target in CLMECs. 
Modulation of the Piezo1 channel with the newly discovered Piezo1 activator Yoda1 
is demonstrated for the first time in CLMECs and shown to induce phosphorylation 
of endothelial nitric oxide synthase. 
 
This study has identified a number of proteins that are differentially expressed in 
CLMECs, which could be targeted for the development of anti-angiogenic therapies 
in the treatment of CLM. AZD1775 has anti-angiogenic activity in CLMECs and 
Piezo1 represents another target which can be investigated in future studies.  
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Chapter 1: Introduction 
 
Colorectal cancer is a global health problem with an estimated 1.4 million cases 
and 693,900 deaths occurring per year (Torre et al., 2015). In the United Kingdom, 
over 41,000 people are diagnosed with colorectal cancer annually, a trend that has 
slowly increased over the last 50 years (Cancer Research UK, 2016). Advancing 
diagnostic technology, increasing resources and the introduction of a national 
screening program have helped improve disease detection, however, outcomes for 
patients with metastatic colorectal cancer remain poor. 
 
This chapter will review the biology of colorectal cancer and how this has shaped 
current treatment options. Reasons for treatment failure, including metastatic 
spread to the liver, will be considered and how angiogenesis and tumour 
endothelial cells are essential to this process. Finally, current anti-angiogenic 
treatments will be reviewed including their efficacy in metastatic colorectal cancer 
and associated side effects.  
1.1  Historical Perspective 
Cancer appears in the medical literature as early as 1600 BC in the Edwin Smith 
papyrus, where the oldest description of the disease exists. However, the origin of 
the word cancer is attributed to ancient Greece and the Hippocratic physicians who 
used the word karkinoma, meaning “crab”, to describe non-healing “cancer” (Weiss, 
2000). This is thought to refer to the distension of localised veins in advanced 
breast cancer that had the appearance of the legs of a crab. 
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With regard to colorectal cancer, its signs and symptoms were observed as early as 
the 14th century by the English surgeon John of Arderne. He recognised the 
progressive and destructive nature of the disease “so this sickness lurks within in 
the beginning, but after the passage of time it ulcerates and emerges eroding the 
anus”. Despite this, no form of excisional surgery was performed for at least 400 
years. It was not until the eighteenth century when Giovanni Morgagni proposed 
excision of the rectum for rectal cancer that surgery was considered a therapeutic 
option (Galler et al., 2011). In 1826 Jacques LisFranc performed the first successful 
excision of a rectal tumour. He went on to perform nine more resections, but 
haemorrhage and sepsis were common and mortality rates were high (Galler et al., 
2011). 
 
With the advent of anaesthesia and asepsis there was an explosion of surgical 
techniques for excising rectal cancer, but recurrent disease was problematic and 
seemed inevitable. In England, William Ernest Miles noted the problems of local 
recurrence in his own patients. Out of 57 perineal resections, 54 patients (95%) 
developed local recurrence, most commonly within the first 6 months of resection 
(Miles, 1908). Through postmortem dissections he noted the pattern of recurrence 
and designed an operation to remove the rectum and the “upward direction of 
spread” that he coined the “radical abdominoperineal resection”. In a 1908 Lancet 
article Miles reported 12 procedures (Miles, 1908). He calculated a 42% mortality 
rate (5 deaths) with 7 survivors tumour-free at one year.  
 
Subsequent surgical developments have been focused on improving excisional 
techniques to limit local recurrence and metastatic disease. The most significant of 
these being the anterior resection with “total mesorectal excision” developed by 
- 3 - 
 
 
Richard Heald. Based on the embryological development of the hindgut, this 
sphincter preserving operation involves resection of the tumour and mesorectum en 
bloc to the level of the levator muscles. Heald’s technique led to local recurrence 
rates of 3.6% (Heald and Ryall, 1986).  
1.2  Current Treatment of Colorectal Cancer 
Surgical excision remains the mainstay of treatment for colorectal cancer. The 
twenty-first century has seen the advent of laparoscopic and robotic colorectal 
cancer surgery techniques with comparable oncological outcomes to open surgery 
(Green et al., 2013, Mak et al., 2014, Vennix et al., 2014, Feroci et al., 2016). 
Improvements in anaesthesia, peri- and post-operative care have also led to 
significant reductions in operative morbidity and mortality. However, the long-term 
prognosis for patients with colorectal cancer has only modestly improved over the 
last 30 years. In 1985, 58.1% of patients diagnosed with colorectal cancer were still 
alive at 5-years, compared to 67.2% in 2008 (Surveillance Epidemiology and End 
Results (SEER) Program, 2016). 
 
Once a diagnosis of colorectal cancer is established the local and distant extent of 
the disease must be determined to provide a framework for planning treatment 
(Table 1). The Tumour Node Metastasis (TNM) staging system from the American 
Joint Committee on Cancer (AJCC) is the preferred staging system for colorectal 
cancer (Table 2). Broadly speaking, patients are divided into four stages, with stage 
IV (distant metastatic disease at the time of diagnosis) carrying the worst prognosis 
with a five-year survival of just 5.7% (Edge et al., 2010). 
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Table 1 The Tumour Node Metastasis (TNM) Classification System 
The TNM classification system is used for staging colorectal cancers. “T” refers to 
the size or direct extent of the primary tumour, “N” refers to the amount of regional 
lymph node involvement and “M” refers to the presence or absence of metastatic 
disease.  
 
 
 
Primary Tumour (T) Regional Lymph Node (N) Distant Metastasis (M)
T0: No tumour N0: No regional lymph node 
metastases
M0: No distant 
metastases
T1: Invades submucosa N1a: Metastasis in one 
regional lymph node
M1a: Metastases 
confined to one organ
T2: Invades muscularis
propria
N1b: Metastases in two-
three regional nodes
M1b: Metastases in 
more than one organ
T3: Invades into 
pericolorectal tissues
N1c: Tumor deposit(s) in the 
subserosa, mesentery, or 
nonperitonealised peri-colic 
or peri-rectal tissues without 
regional nodal metastasis
T4a: Penetrates visceral 
peritoneum
N2a: Metastases in four-six
regional nodes
T4b: Invades/Adherent to 
other organs
N2b: Metastases in seven or 
more regional nodes
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Table 2 The AJCC Colorectal Cancer Staging System 
Patients diagnosed with colorectal cancer are given a stage based upon their TNM 
score. Staging is important in deciding what treatment strategy is most appropriate. 
A higher stage indicates more advanced disease and therefore a worse prognosis. 
   
 
 
 
 
 
 
 
Stage T N M
I T1 N0 M0
T2 N0 M0
IIa T3 N0 M0
IIb T4a N0 M0
IIc T4b N0 M0
IIIa T1-2 N1 M0
T1 N2a M0
IIIb T3-T4a N1 M0
T2-3 N2a M0
T1-2 N2b M0
IIIc T4a N2a M0
T3-4a N2b M0
T4b N1-N2 M0
IVa Any T Any N M1a
iVb Any T Any N M1b
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For patients with colorectal cancer the aim of surgery is complete excision of the 
tumour, the major vascular pedicle, and the lymphatic drainage basin of the 
affected colonic segment. Post-operative (adjuvant) chemotherapy may also be 
used to eradicate micro-metastases, thereby reducing the likelihood of disease 
recurrence. This is most beneficial to patients with stage III (lymph node positive) 
disease. The survival benefit of adding oxaliplatin to fluoropyrimidines, such as 5-
Fluorouracil (5-FU), a regime known as FOLFOX, has been demonstrated in 
multiple randomised controlled clinical trials, with an approximate 30% reduction in 
the risk of disease recurrence and a 22-32% reduction in mortality compared to 
surgery alone (Benson, 2005, Kuebler et al., 2007, Andre et al., 2009). 
 
Neoadjuvant chemoradiotherapy is an increasingly used strategy for patients with 
rectal adenocarcinoma. However, the only definitive indication for neoadjuvant 
chemoradiotherapy is T3/T4 disease. The seminal German Rectal Cancer Study 
reported at 46 months median follow-up that pre-operative chemoradiotherapy was 
associated with a significantly lower pelvic relapse rate than post-operative 
chemoradiotherapy (6% vs. 13%) (Sauer et al., 2004). The difference persisted with 
longer follow-up, although it was of a lower magnitude at 10 years (7% vs. 10%) 
(Sauer et al., 2012). The benefit of adjuvant chemotherapy in patients receiving 
neoadjuvant chemoradiotherapy is unclear (Bujko et al., 2010, Kiran et al., 2012). 
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1.3  Failure of Treatment 
1.3.1  Local Recurrence 
Despite radical surgery with or without adjuvant therapy, up to 15% of patients with 
colorectal cancer will experience a local recurrence within 5 years (Palmer et al., 
2007). Recurrent rectal cancer carries significant morbidity in the form of severe 
pain, bleeding, discharge and poor quality of life (Camilleri-Brennan and Steele, 
2001). Untreated, the prognosis is poor with a median survival of just 7 months 
(Nielsen et al., 2011). Selected patients with locally recurrent disease can be 
treated with curative intent using multimodality therapy. Five-year survival rates of 
35-50% with acceptable morbidity have been reported with this approach in 
recurrent rectal cancer (Harji et al., 2012).   
 
1.3.2  Metastatic Disease 
Colorectal cancer can spread by lymphatic and hematogenous dissemination, as 
well as by contiguous and transperitoneal routes. The intestinal tract drains via the 
portal venous system and therefore the first site of hematogenous dissemination is 
usually the liver. From there other metastatic sites include the lungs and the brain.  
 
Half of patients undergoing curative treatment for colorectal cancer ultimately die 
from the disease and liver metastases remain the major cause of death (Oliphant et 
al., 2013). Approximately 25% of colorectal cancer patients will present with 
synchronous liver metastases and up to 50% will develop metachronous liver 
metastases, most commonly within the first three years of diagnosis (Vatandoust et 
al., 2015). Unlike other solid tumours, metastatic disease is often confined to the 
liver and 30% of patients with stage IV colorectal cancer have metastases limited to 
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the liver. This pattern of metastatic disease provides a unique opportunity for 
treatment with curative intent that is not often possible with other advanced 
cancers.  
1.4  Development of Colorectal Cancer Liver Metastases 
1.4.1  Colorectal Cancer Biology 
The luminal surface of the large intestine is lined by epithelial cells that form 
invaginations called crypts. At the base of each crypt are intestinal stem cells that 
differentiate into specialised epithelial cells including columnar absorptive cells and 
mucus-secreting goblet cells. Colorectal cancer results from the progressive 
accumulation of genetic and epigenetic changes that lead to the transformation of 
normal colonic epithelium to colonic adenocarcinoma (Kheirelseid et al., 2013). In 
1990, Fearon and Vogelstein proposed the multistep genetic hypothesis for 
colorectal tumourigenesis (Fearon and Vogelstein, 1990). In this, a progression 
from normal bowel mucosa to adenoma to carcinoma is supported by accumulating 
mutations in known oncogenes and tumour suppressor genes (Figure 1). 
Phenotypically, the resulting cancerous cells have six common hallmarks; self-
sufficiency in growth signals, insensitivity to anti-growth signals, the ability to evade 
apoptosis, limitless replicative potential, sustained angiogenesis and the ability to 
invade and metastasise (Hanahan and Weinberg, 2000). 
 
- 9 - 
 
 
 
Figure 1 The Adenoma Carcinoma Sequence 
The progression from normal epithelium to adenoma to carcinoma is accompanied by increasing genetic and epigenetic alterations in known 
tumour suppressor genes and oncogenes. Adapted from Davies et al (2005). APC= Adenomatous Polyposis Coli, KRAS= V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog. (Davies et al., 2005) 
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1.4.2  The Metastatic Cascade 
The defining histopathological characteristic of a carcinoma is invasion across the 
basement membrane, an extracellular network of proteins and collagen. This 
signals the invasive nature and metastatic potential of a carcinoma. In order for a 
cancer to metastasise a sequence of five steps must successfully take place 
(Figure 2). The steps are invasion, intravasation, survival in the circulation, 
extravasation and metastatic colonisation (Mina and Sledge, 2011). Cancers are 
biologically heterogeneous containing geneotypically diverse subpopulations of 
tumour cells, each of which has the potential to undertake the five steps to 
metastasise (Fidler, 2003).  Comparisons have been made between the successful 
metastatic cell and a decathlon champion, who must be proficient in all the steps 
and not just a few to succeed (Fidler, 1990).  
 
Metastatic colonisation is not a random process. The “seed and soil” hypothesis 
was proposed in 1889 by the English surgeon Stephen Paget to explain the pattern 
of metastatic spread in breast cancer (Paget, 1889). He suggested that tumour cells 
(“the seed”) preferentially grow in the microenvironment of select organs (“the soil”). 
His view was challenged in 1928 by the American pathologist James Ewing, who 
proposed that metastatic dissemination was limited by mechanical factors resulting 
from the anatomical structure of the vascular system (Ewing, 1928). Nearly a 
century later however, it was Paget’s hypothesis that was proven to be correct (Hart 
and Fidler, 1980). 
 
Only a small number of primary tumour cells that enter the circulation give rise to 
metastases. Fidler reported that 24 hrs after injection of 125iodine-iodo-deoxyuridine 
labelled B16 melanoma cells into C57BL/6J mice, less than 0.1% of tumour cells 
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were still viable, and that less than 0.01% of these cells survived to produce 
metastases (Fidler, 1970). This prompted the question of whether metastatic 
disease represents the fortuitous survival and growth of a few neoplastic cells or 
whether it represents the selective growth of unique subpopulations of malignant 
cells that are endowed with special properties (Fidler, 2003).  
 
Several molecular and cellular observations support the “seed and soil” hypothesis. 
This includes the fact that endothelial cells lining the blood vessels of different 
organs express different adhesion molecules (Nicolson, 1988) and that tumour cells 
expressing the corresponding receptor may therefore bind and arrest in specific 
tissues. Furthermore, there is evidence supporting a role for chemokines in the 
chemo-attraction of tumour cells (Muller et al., 2001).   
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Figure 2 The Metastatic Cascade 
In order for a cancer to metastasise a series of events must all successfully take 
place. After a period of growth in the primary cancer, tumour cells enter thin walled 
venules and gain access to the circulation. Most circulating tumour cells are rapidly 
destroyed, however, a small number are able to travel to distant organs where they 
become trapped as they adhere to endothelial cells within the capillary bed. 
Extravastion occurs as the tumour cells pass into the organ parenchyma. Finally, 
the tumour cells must proliferate within the parenchyma to complete metastatic 
colonisation. Adapted from Fidler (2003). (Fidler, 2003). 
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1.4.3  Progression of Colorectal Cancer Liver Metastases 
Colorectal cancer most commonly metastasises to the liver. Once detached from 
the primary colorectal cancer, tumour cells are transported through the hepatic-
portal circulatory system to reach the liver. They arrest in the hepatic sinusoids, 
which are specific hepatic capillary networks (Figure 3). Located within the 
sinusoidal lumen, or in close proximity to the sinusoidal wall are cells that play a key 
role in extravasation; sinusoidal endothelial cells, Kupffer cells and hepatic stellate 
cells.  The progression of colorectal cancer liver metastases (CLM) is divided into 
four phases (Paschos et al., 2014): 
 
1) Microvascular phase of liver-infiltrating malignant cells 
2) Interlobular micrometastases phase 
3) Angiogenic micrometastases phase 
4) Established hepatic metastases phase 
 
The first phase mainly occurs within sinusoids and is predominantly mediated by 
sinusoidal endothelial cells. During this phase they produce both tumouricidal and 
tumourigenic effects that result in either colorectal cancer cell destruction or liver 
colonisation. For instance, they form a major scavenger cell system and accomplish 
receptor-mediated endocytosis and pinocytosis (Smedsrod et al., 2009), but are 
also capable of expressing adhesion molecules, such as E-selectin, which mediate 
colorectal cancer cell attachment, facilitating extravasation into the hepatic 
parenchyma (Laferriere et al., 2001).     
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Figure 3 The Hepatic Sinusoid 
Pictorial representation of a hepatic sinusoid, which mixes oxygen-rich blood from the hepatic artery with nutrient-rich blood from the 
portal vein. A single layer of endothelial cells line the hepatic sinusoids and they are separated from hepatocytes by the space of Disse. 
Adapted from Frevert et al (2005). (Frevert et al., 2005) 
 
 
 
Central 
Vein
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The adherence of colorectal cancer tumour cells to liver sinusoidal endothelial cells 
is critical for extravasation and hepatic colonisation. Although colorectal cancer 
tumour cells bind to selectins in hepatic sinusoids, the bonds are weak and do not 
guarantee stable cell adhesion (Paschos et al., 2014). Integrin-mediated tumour cell 
adhesion and changes in the binding affinity of integrins are necessary for stable 
tumour cell adhesion and subsequent migration and colonisation (Haier and 
Nicolson, 2001). These stronger bonds overcome the force of hydrodynamic blood 
flow. Shortly after adhesion, colorectal cancer cells begin to migrate through the 
pores of sinusoidal endothelial cells and the space of Disse to reach hepatocytes 
within 48 hrs (Shimizu et al., 2000). At the point of extravasation, immunological 
cells including cytotoxic T-cells, monocytes and macrophages are activated in the 
extra-sinusoidal space. Ultimately, a few colorectal cancer tumour cells evade the 
host response and successfully cause micro-metastases in the hepatic 
parenchyma. The transition to macroscopic metastases may take weeks or months 
and is reliant on the process of angiogenesis to create new blood vessels to supply 
the oxygen and nutrients required for increased growth. Recent evidence suggests 
that CLM themselves are also able to shed intact tumour cells with invasive 
potential, suggesting that the “seed” may be able to leave the “soil” once again 
(Rahbari et al., 2016). 
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1.5  Treatment of Colorectal Cancer Liver Metastases 
1.5.1 Conservative 
The majority of patients with CLM are not amenable to curative surgery. 
Conservative treatment includes symptom control (analgesia, anti-emetics) and 
nutritional support. Median survival is just 8 months (Rocha and Helton, 2012).  
 
1.5.2 Surgical Resection 
The only curative treatment for CLM is surgical resection. In surgical case series, 
five-year survival rates of up to 58% have been reported when combined with 
adjuvant chemotherapy (Choti et al., 2002, Abdalla et al., 2004, Fernandez et al., 
2004). The percentage of patients suitable for resection is a moving target as 
surgeons have differing views of what is resectable. Nevertheless, the majority of 
patients with CLM are not surgical candidates because of the tumour size, location, 
multifocality, or inadequate hepatic reserve. 
 
Even when hepatic resection with curative intent is performed, 70-80% of patients 
will experience a recurrence, most commonly within the first two years (Tomlinson 
et al., 2007). Recurrence occurs equally at intrahepatic and extrahepatic sites 
(Misiakos et al., 2011). Repeat resection is feasible in 10-15% of patients with 
intrahepatic recurrence and five-year survival rates of 29% have been reported 
(Adair et al., 2012).   
 
Criteria for hepatic resection have changed over the last decade, with increasing 
focus on what should be left after the resection. Previous criteria, including size, 
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location and number of tumours and presence of extrahepatic disease have largely 
been abandoned. Current criteria include a complete resection with tumour-free 
surgical margins (R0 resection), sparing at least two liver segments having an 
independent inflow, outflow, and biliary drainage. The size of the liver remnant after 
resection should not be less than 20% of the total liver volume (Misiakos et al., 
2011). This can be accurately predicted pre-operatively with magnetic resonance 
imaging (MRI).  
 
1.5.3 Systemic Neoadjuvant Chemotherapy 
“Conversion therapy” describes the use of induction chemotherapy in patients with 
initially unresectable CLM. Up to 36% of patients with initially unresectable disease 
who receive induction chemotherapy can go on to have a complete R0 resection 
(Falcone et al., 2007, Malik et al., 2015) with five-year survival rates of 30-35% 
(Rivoire et al., 2002, Adam et al., 2004).  
 
1.5.4 Systemic Adjuvant Chemotherapy 
Evidence of a survival benefit for patients receiving adjuvant chemotherapy 
following surgery is lacking. Two multi-centre randomised clinical trials in the 1990s, 
the FFCD and ENG trials, compared six months of post-operative systemic 5-FU 
and leucovorin versus observation alone following hepatic resection. In a combined 
analysis of both trials, although there were improvements in median progression-
free survival and overall survival with the adjuvant chemotherapy group, the results 
were not statistically significant (Mitry et al., 2008).  
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The chemotherapeutic agents used in the above trials are considered inferior by 
today’s standards. The combination of newer drugs including oxaliplatin, irinotecan, 
bevacizumab and cetuximab have improved survival in patients with unresectable 
metastatic colorectal cancer (as will be discussed later), however, there are limited 
data on their use in an adjuvant setting for resected CLM.  
 
1.5.5 Regional Adjuvant Chemotherapy 
As CLM derive their blood supply from the hepatic artery, regional hepatic intra-
arterial (HIA) chemotherapy following metastasectomy offers a potential advantage 
in drug delivery. Unfortunately results from randomised clinical trials have been 
poor. A German trial in 1998 was closed prematurely when interim analysis showed 
that patients who received HIA chemotherapy (5-FU and leucovorin) after surgery 
had a worse median survival compared to surgery alone (Lorenz et al., 1998). More 
recent studies have combined HIA chemotherapy with systemic chemotherapeutic 
agents with promising results (House et al., 2011, Bolton et al., 2012). Randomised 
controlled clinical trials are ongoing assessing the efficacy of combined HIA and 
systemic chemotherapy, however at present the routine use of HIA chemotherapy 
after hepatic resection has not gained widespread acceptance.  
 
1.5.6 Systemic Palliative Chemotherapy 
For patients with unresectable CLM, chemotherapy can be used in a palliative 
setting to extend survival. Initially 5-FU and leucovorin afforded patients a median 
survival of 14 months, but this was increased to 19 months with the sequential use 
of newer cytotoxic agents including oxaliplatin and irinotecan (de Gramont et al., 
2000, Goldberg et al., 2004). The introduction of biologically targeted therapies, 
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such as bevacizumab and cetuximab, has further prolonged survival rates up to 30 
months (Hurwitz et al., 2004, Van Cutsem et al., 2011, Loupakis et al., 2014). 
 
1.5.7 Radiofrequency Ablation 
Radiofrequency ablation (RFA) uses a needle electrode to deliver high frequency 
alternating current from the tip of the electrode to the surrounding tissue. Ions within 
the tissue follow the change in the direction of the current causing frictional heating 
of the tissue up to 60°C resulting in coagulative necrosis. RFA can be applied via 
open, laparoscopic or percutaneous approaches.  
 
A wide range of five-year survival rates (14-55%) and recurrence rates (4-60%) 
have been reported for RFA treatment of CLM (Wong et al., 2010). RFA is well 
tolerated, however the reported mortality rate is 0-2% and major complication rate 
is 6-9% (Wong et al., 2010). There have been no randomised clinical trials 
comparing RFA with surgical resection with or without adjuvant chemotherapy for 
patients with resectable CLM. A 2012 Cochrane review concluded there is 
insufficient evidence to recommend RFA as a radical oncological treatment for CLM 
(Cirocchi et al., 2012).  
 
1.5.8 Transarterial Chemoembolisation 
Transarterial chemoembolisation (TACE) is a minimally invasive procedure that 
combines cytotoxic drug infusion with embolisation of the tumour’s blood supply. 
Small embolic particles coated with chemotherapeutic agents are injected through a 
catheter into the arteries feeding CLMs under radiological guidance.  
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In a multi-centre randomised trial, 74 patients with unresectable CLM were 
assigned to TACE in the form of drug-eluting beads preloaded with irinotecan 
(DEBIRI) or systemic irinotecan, fluorouracil and leucovorin (FOLFIRI). The DEBIRI 
group had a significantly higher overall survival compared to the FOLFIRI group (22 
vs. 15 months) (Fiorentini et al., 2012). Further larger randomised trials are needed 
to confirm TACE provides superior outcomes to systemic chemotherapy regimens 
including oxaliplatin. No trials to date have compared surgical resection with TACE. 
 
1.5.9 Microwave Hyperthermia and Interstitial Laser Ablation 
Also known as microwave coagulation, the surgical technique of microwave 
hyperthermia was first reported in 1979 and uses a microwave coagulator, which 
simultaneously cuts and coagulates the tumour tissue (Tabuse, 1979). It can be 
applied using an open technique or percutaneously. In a randomised clinical trial, 
30 patients with resectable CLM were assigned to laparotomy and ultrasound-
guided microwave hyperthermia or hepatic resection. One-, two- and three-year 
survival rates were similar between the two groups, with the microwave 
hyperthermia group having significantly less intra-operative blood loss (Shibata et 
al., 2000). 
 
Interstitial laser ablation use is limited to specialist centres. Nevertheless, there are 
several reports of success in treating CLM (Christophi et al., 2004, Vogl et al., 2004, 
Pech et al., 2007). In the largest series, 603 patients underwent MRI-guided laser-
induced interstitial thermotherapy for CLM. The reported five-year survival rate was 
37% (Vogl et al., 2004).  
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1.5.10 Percutaneous Ethanol Injection 
Percutaneous ethanol injection techniques have been widely used for the treatment 
of small hepatocellular carcinomas and have been shown to be effective in causing 
complete tumour necrosis in 30-56% of CLM (Giovannini and Seitz, 1994, Giorgio 
et al., 1998). However, there are limitations to the technique including the inability to 
access some lesions.  
 
1.5.11 Cryotherapy 
Cryotherapy involves the delivery of liquid nitrogen or argon gas directly into CLM. 
This is achieved under ultrasound guidance using a specially designed probe and 
results in the formation of ice crystals causing destruction of tumour cells. A 
Cochrane review of one randomised clinical trial with a high degree of bias 
concluded that cryotherapy should not be used for the treatment of CLM outside the 
context of clinical trials (Bala et al., 2013). 
 
1.5.12 Hepatic Transplant 
Liver transplant was conceived as an ideal curative treatment for CLM as it leads to 
an R0 resection and eliminates the potential of recurrence in the liver remnant. This 
is particularly valuable in patients with unresectable disease. The SECA study was 
an open, prospective pilot study where 21 patients with unresectable CLM 
underwent liver transplant. Five-year overall survival rates were impressive, with a 
reported estimate at 60% (Hagness et al., 2013). However, extra-hepatic disease 
recurrence rates were high, with 19 out of 21 patients experiencing a recurrence 
after a median time of 6 months, most commonly in the lungs (17 patients). There 
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were also a number of major complications. Two patients had hepatic artery 
thrombosis requiring re-transplantation and there were five re-operations for post-
operative haemorrhage/haematoma.   
 
In a comparative analysis, the results of the SECA study were analysed against 
results of the NORDIC VII study, a randomised multi-centre clinical trial assessing 
first-line chemotherapy regimes in patients with unresectable CLM. Disease free 
survival in both groups was similar (8-10 months), however the overall five-year 
survival rate was 56% in patients undergoing transplantation compared to just 9% 
in patients receiving first-line chemotherapy (Dueland et al., 2015). The 
extraordinary differences in overall survival were attributed to the pattern of disease 
recurrence. In patients undergoing liver transplant the primary site of recurrence 
was the lungs, whereas the patients who received first-line chemotherapy most 
commonly had progressive liver metastases. Furthermore, the pulmonary 
metastases in patients occurring in patients who had undergone transplant were 
small, slow growing and often amenable to further treatment including pulmonary 
resection and ablation. 
 
Hepatic transplant for CLM is controversial. Critics point out that donor livers are a 
scarce resource (Chapman, 2013, Martins et al., 2015). Furthermore, with nearly 
100% of transplanted patients experiencing recurrence, is liver transplant for CLM 
truly a curative procedure or merely a procedure to extend life? If it is the latter, 
should patients with unresectable CLM be offered liver transplants with the same 
priority as patients with conventional indications for hepatic transplant? Hagness 
and colleagues point out that liver grafts are currently allocated for patients with 
recurrent hepatitis C, which has a five-year survival rate of less than 50% (Hagness 
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et al., 2013). Is it justifiable to perform hepatic re-transplant in patients with 
recurrent hepatitis C cirrhosis, while denying patients with unresectable CLM a liver 
transplant, knowing that the outcome is at least similar, if not superior? Clearly 
hepatic transplant for CLM as a treatment is in its infancy. Not only are more multi-
centre, prospective, randomised trials required for validation of these results, but 
further work on risk-stratification for patient selection and cost-effectiveness must 
also be undertaken. 
 
1.5.13 Biological Agents 
Cetuximab (Erbitux®) and panitumumab (Vectibix®) are monoclonal antibodies that 
bind with high affinity to the extracellular domain of the human epidermal growth 
factor receptor (EGFR). As their affinity for the EGFR is up to ten-fold higher than 
endogenous ligands, they block their binding, inhibiting receptor function. EGFR 
activation leads to stimulation of several intracellular signalling pathways including 
Ras-Raf-MEK-ERK and PI3K-AKT-mTOR, which ultimately result in increased 
cellular proliferation and decreased apoptosis (Scaltriti and Baselga, 2006). Up to 
75% of colorectal cancer cells express EGFR (Goldstein and Armin, 2001), 
however it is not fully clear if this level of expression is translated to metastatic cells 
also (Tol and Punt, 2010). Resistance to anti-EGFR therapy is found in patients 
with KRAS mutations, as this results in constitutive activation of the Ras-Raf-MEK-
ERK signalling pathway, which is independent of EGFR activation by ligand binding 
(Benvenuti et al., 2007). For this reason the use of cetuximab and panitumumab is 
limited to patients with wildtype KRAS metastatic colorectal cancer.  
 
The CRYSTAL trial reported the benefit of adding cetuximab to first-line irinotecan 
containing therapy for patients with EGFR-positive, wildtype KRAS, unresectable 
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metastastic colorectal cancer. Patients receiving FOLFIRI and cetuximab had 
significantly better overall survival (23.5 vs 20 months). Furthermore, an increased 
number of patients also underwent metastasectomy with R0 margins (Van Cutsem 
et al., 2011). The benefit of cetuximab with oxaliplatin based regimes is less clear 
as results from randomised clinical trials are mixed. The OPUS trial reported that 
patients with wildtype KRAS had a significantly improved response rate (57% vs. 
34%) and median progression-free survival, (8.3 vs. 7.2 months) when cetuximab 
was added to FOLFOX4 compared to FOLFOX4 alone (Bokemeyer et al., 2011). 
However, the MRC COIN (Maughan et al., 2011) and NORDIC VII (Tveit et al., 
2012) trials found no progression-free survival benefit with the addition of cetuximab 
to patients with wildtype KRAS metastatic colorectal cancer receiving oxaliplatin 
based chemotherapy.  
 
A number of biological anti-angiogenic agents have been shown to improve 
outcomes in metastatic colorectal cancer. Angiogenesis and its potential for 
targeted therapeutics will be discussed in more detail in the subsequent sections.  
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 1.6 Angiogenesis  
1.6.1 The Cardiovascular System 
The cardiovascular system consists of the heart, arteries, arterioles, capillaries, 
venules and veins, which together circulate blood and transport nutrients, oxygen, 
carbon dioxide and hormones throughout the body. It is the first organ system to 
develop and become functional in the embryo. This, in part, reflects the 
fundamental need for a vascular system that can deliver nutrients and remove 
catabolic products from growing organs and tissues. The de novo formation of 
blood vessels, termed vasculogenesis, results from the differentiation of mesoderm-
derived endothelial precursor cells and predominates in early embryological life 
(Risau et al., 1988). In adult life, blood vessels form from pre-existing blood vessels 
in a process termed angiogenesis.  
 
Angiogenesis is a complex, tightly regulated process that involves the interaction of 
multiple cell types. During adulthood most blood vessels remain quiescent, 
however, endothelial cells retain the ability to “turn on” and rapidly divide in 
response to a physiological stimulus. Physiological angiogenesis does occur in 
adult life in the cycling ovary, wound healing and in the placenta during pregnancy 
(Carmeliet, 2005). However, when these stimuli are excessive pathological 
conditions can arise, notably malignant, ocular and inflammatory disorders 
(Carmeliet, 2005).  
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1.6.2 The Endothelium 
The structure of a blood vessel varies depending upon its function. For example, 
arteries have thick vessel walls to cope with high arterial pressure, whereas veins 
contain valves to prevent the backflow of low pressure blood. All blood vessels are 
lined on their inner surface by a monolayer of endothelial cells (Figure 4). Described 
as the foundation stones of the vascular system, they have important roles in 
physiological processes including the regulation of blood flow and blood pressure, 
but are also implicated in several pathological processes including atherosclerosis, 
hypertension and cancer (Khazaei et al., 2008).  
 
Much of our knowledge regarding endothelial cell physiology and function has 
developed from in vitro studies of Human Umbilical Vein Endothelial Cells 
(HUVECs). The culture of endothelial cells was first reported over forty years ago 
(Jaffe et al., 1973). 
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Smooth Muscle Cell
Figure 4 The Vascular Endothelium 
The vascular endothelium consists of a monolayer of endothelial cells that line the 
inner surface of blood vessels. Image created through Servier Medical Art. 
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1.6.3 Sprouting Angiogenesis 
As implied by its name, sprouting angiogenesis is characterised by sprouts of 
endothelial cells that grow towards an angiogenic stimulus. The basic steps of 
sprouting angiogenesis include; enzymatic degradation of the capillary basement 
membrane, endothelial cell proliferation, migration of endothelial cells, endothelial 
cell tube formation, vessel fusion, vessel pruning, and pericyte stabilization (Adair 
and Montani, 2010).  
 
1.6.3.1 The Role of Hypoxia 
Hypoxia is an important stimulus for sprouting angiogenesis and central to this is 
the transcription factor hypoxia-inducible factor 1 (HIF-1). HIF-1 is an αβ 
heterodimer that was first recognised as a DNA-binding factor that mediates 
hypoxia-inducible transcription of erythropoietin. Both HIF-α and HIF-β exist as a 
series of isoforms. HIF-1β subunits are constitutive nuclear proteins, whereas HIF-
1α subunits are inducible by hypoxia (Pugh and Ratcliffe, 2003). Of the three HIF-α 
isoforms, HIF-1α and HIF-2α are closely related. Both HIF-1α and HIF-2α are able 
to interact with hypoxia response elements (HREs) in promoter regions of genes to 
induce transcriptional activity (Tian et al., 1997). The third isoform, HIF-3α, appears 
to be involved in the negative regulation of this response (Makino et al., 2001).   In 
normoxic conditions hydroxylation at conserved proline residues on HIF-α subunits 
mediates interaction with the von Hippel-Lindau E3 ubiquitin ligase complex. This 
complex targets HIF-α for proteosomal destruction (Ivan et al., 2001). In hypoxic 
conditions HIF prolyl-hydroxylase, the enzyme responsible for the hydroxylation of 
the conserved proline residues, is inhibited since it utilises oxygen as a co-
substrate. This allows HIF-1α to escape inactivation in hypoxic conditions 
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1.6.3.2 The Role of Vascular Endothelial Growth Factor 
HIFs upregulate many genes, however, the induction of vascular endothelial growth 
factor (VEGF) is the most striking, increasing thirty-fold within minutes (Semenza, 
1999, Carmeliet, 2003). The VEGF signalling pathway has been established as the 
major regulator of angiogenesis. There are five protein members of the VEGF 
family; VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PGF). 
These signal proteins bind to three tyrosine kinase receptors; VEGFR-1 (Flt1), 
VEGFR-2 (KDR/Flk1) and VEGFR-3 (Flt4) (Figure 5). VEGF-A is commonly 
referred to as VEGF and is considered the main inducer of angiogenesis by 
signalling through the VEGFR-2 receptor (Ferrara et al., 2003). 
 
VEGFR-2 is a 200-230 kDa tyrosine kinase receptor with a high-affinity for VEGF. It 
is expressed in vascular and lymphatic endothelial cells as well as other cell types 
such as megakaryocytes. Upon activation by VEGF, VEGFR-2 receptor 
dimerization occurs which facilitates auto-phosphorylation of multiple tyrosine 
residues along the cytoplasmic domains of each monomer (Schlessinger, 2000). 
Auto-phosphorylation is crucial for the recruitment of a variety of signalling proteins 
including those responsible for angiogenic activity. 
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Figure 5 Vascular Endothelial Growth Factors and their Receptors 
The five protein members of the VEGF family bind to different VEGF receptors. VEGF-A is commonly referred to as VEGF and 
via VEGFR-2 is the main inducer of angiogenesis. Image created through Servier Medical Art. 
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1.6.3.3 Endothelial Tip, Stalk and Phalanx Cells 
During angiogenesis endothelial cells within the vessel wall are selected for 
sprouting. This is controlled by a balance of pro-angiogenic factors, including VEGF 
and anti-angiogenic factors that promote quiescence including tight pericyte 
contact, certain extracellular matrix molecules and VEGF inhibitors. Favourable 
angiogenic conditions lead to the specification of endothelial cells into tip and stalk 
cells having different morphologies and functional properties. The description of 
“tip” and “stalk” cells was first made in 2003 (Gerhardt et al., 2003). Tip cells are 
polarised, primarily migrate and proliferate very little.  They can adopt a proteolytic 
phenotype and break down the basement membrane (Hughes, 2008). This results 
in a loss of contact with the basement membrane laminin and exposes the cells to 
interstitial collagen. This triggers signalling cascades and cytoskeletal 
reorganisation resulting in sprouting morphogenesis (Rhodes and Simons, 2007). 
Tip cells express high levels of Delta-like ligand 4 (DLL4), platelet derived growth 
factor-β (PDGF-β), VEGFR-2 and VEGFR-3 and have low levels of notch signalling. 
Consistent with the prominent expression of VEGFR-2 in tip cells, endothelial cell 
guidance is controlled by VEGF (Adams and Alitalo, 2007).  
 
Stalk cells are phenotypically and functionally distinct from tip cells. They are highly 
proliferative, form tubes and branches and form a vascular lumen (Thurston and 
Kitajewski, 2008). They also establish junctions with neighbouring cells and 
synthesise basement membrane components (Phng and Gerhardt, 2009). As 
endothelial cells transition from active sprouting to quiescence they adopt a 
“phalanx” phenotype, resembling a phalanx formation of ancient Greek soldiers. 
They are immobile and non-proliferative promoting vessel integrity and stabilisation 
(Bautch, 2009). 
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1.6.3.4 DLL4-Notch Signalling 
VEGF induces the expression of DLL4 in tip cells that binds to its receptors notch1 
and notch4 on adjacent stalk cells (Figure 6). DLL4-notch signalling is important in 
determining how endothelial cells decide both spatially and temporally when to 
adopt tip or stalk phenotypes (Dufraine et al., 2008). DLL4 in tip cells signals 
through notch1 in the adjoining stalk cells to initiate a VEGF feedback loop, limiting 
sprouting by downregulation of VEGFR-2 (Dufraine et al., 2008). The signalling 
pathway functions as a dampening mechanism for preventing excess angiogenesis 
and promoting the orderly development of new vessels (Chung et al., 2010). This is 
evidenced by decreasing levels of DLL4 or blocking notch-signalling both resulting 
in increased sprouting, branching and fusion of endothelial tubes (Sainson et al., 
2005, Ridgway et al., 2006, Noguera-Troise et al., 2006).  
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Figure 6 DLL4-Notch Signalling 
VEGF induces expression of DLL4 in tip cells which binds to notch receptors on adjacent stalk cells and is an 
important mechanism for determining tip and stalk cell phenotypes. Image created through Servier Medical Art. 
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1.6.3.5 Maturation of Blood Vessels 
To form new vascular connections, tip cells need to suppress their motile, 
explorative behaviour upon encountering the tips of other sprouts or existing 
capillaries (Adams and Alitalo, 2007). After the establishment of a vascular plexus, 
a maturation process follows which involves enhancement of tight junctions, 
secretion of basement membrane components and recruitment of perivascular 
cells. The recruitment of pericytes, thought to be the functional equivalent of 
vascular smooth muscle cells, is essential for the maturation of endothelial tubes 
into blood vessels. This is achieved through PDGF-β, which is secreted by 
endothelial cells.  
 
Pericytes signal to endothelial cells to maintain quiescence and regulate vascular 
permeability through Tie/Angiopoietin signalling. The Tie/Ang signalling system 
comprises of two Ang ligands (Ang-1 and -2) and two Tie tyrosine kinase receptors 
(Tie-1 and -2). Pericytes express Ang-1 on their surface that binds to Tie-2 
receptors on the surface of endothelial cells (Figure 7). This tight interaction 
mediates blood vessel stabilisation. Ang-2 expression has antagonistic effects. In 
the switch from quiescent to activated phenotype, the release of Ang-2 from 
endothelial cells antagonises Ang-1 function increasing basement membrane 
degradation and endothelial cell migration (Adams and Alitalo, 2007).       
 
Upon maturation of the blood vessel, blood flows to the newly vascularised area 
increasing oxygen levels and decreasing VEGF levels, bringing an end to 
angiogenesis. 
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Figure 7 Pericyte Stabilisation Through Ang-1/Tie-2 Signalling 
Pericytes express Ang-1 on their surface that binds to Tie-2 receptors on the surface of endothelial cells. This tight 
interaction mediates blood vessel stabilisation. Image created through Servier Medical Art. 
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1.6.4 Intussusceptive Angiogenesis 
An alternative, rapid mechanism for new blood vessel formation is through 
intussusceptive angiogenesis. It was first observed in the rapidly expanding 
pulmonary capillary bed of neonatal rats (Caduff et al., 1986). Here, 1-2 μm holes 
within vascular corrosion casts were shown to correspond to intraluminal trans-
capillary tissue pillars where the capillary wall had invaginated into the vessel 
lumen. The process of intussusceptive angiogenesis is fast, taking minutes to 
hours, as there is no need for endothelial cell proliferation. Instead, endothelial cells 
are remodelled, increasing in volume and becoming thinner.  
 
Typically there are four phases to pillar formation (Djonov et al., 2003). In phase I a 
zone of contact is created between opposing capillary walls. In phase II there is 
reorganisation of the inter-endothelial cell junctions and central perforation of the 
bilayer. In phase III an interstitial pillar core is formed that is invaded by pericytes 
and myofibroblasts that then lay down collagen fibrils. Finally in phase IV the pillars 
increase in girth without undergoing any further change in their basic structure. 
Although the molecular mechanisms behind intussusceptive angiogenesis are not 
fully understood, there are thought to be several key factors that can influence pillar 
formation (Hillen and Griffioen, 2007). 
 
Changes in blood flow dynamics may stimulate the process of intussusceptive 
angiogenesis and has been observed in chick chorioallantoic membranes (Djonov 
et al., 2002). Furthermore, changes in shear stress on endothelial cells can activate 
a biochemical cascade which may lead to cytoskeletal rearrangements. It is 
hypothesised that inhibition of sprouting angiogenesis may stimulate 
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intussusceptive angiogenesis, therefore, it could be a means of drug resistance 
against anti-angiogenic agents (Hillen and Griffioen, 2007).  
 
1.6.5 Tumour Angiogenesis  
In 1971 Judah Folkman published in the “New England Journal of Medicine” 
hypothesising that tumour growth was dependent on angiogenesis and that 
inhibition of angiogenesis could be therapeutic (Folkman, 1971). Referred to as 
“The Father of Angiogenesis”, Folkman was initially criticised for his theories as the 
prevailing opinion of the time was that tumour growth did not depend on 
angiogenesis, rather that tumour vascularity was nonspecific inflammation. Today, it 
is widely accepted that tumours can grow to a size of 1-2 mm3 before their 
metabolic demands are restricted due to the diffusion limit of oxygen and nutrients 
(Hillen and Griffioen, 2007). 
1.6.5.1 Characteristics of Tumour Blood Vessels 
It has long been known that tumour blood vessels are morphologically abnormal. 
The vessels are tortuous with irregular branching patterns and lack the normal 
hierarchical arrangement of artery-arteriole-capillary (Konerding et al., 1999).  They 
also have poor stability due, in part, to defects in pericytes, which are loosely 
attached (Morikawa et al., 2002). These changes can affect blood flow, with some 
vessels having bidirectional flow and some having no blood flow at all.  
 
Functionally, tumour vessels are inappropriately permeable to large 
macromolecules. They are inefficient at both delivering oxygen to the tumour and 
removing waste products. This results in the creation of a hostile tumour 
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microenvironment that is both hypoxic and acidic. Tumours must activate signalling 
pathways that allow adaptation. The expression of growth factors, such as VEGF, 
results in more inefficient angiogenesis that in turn makes the tumour 
microenvironment even more hostile. This vicious circle ensures that a 
microenvironment is created that selects tumours with the most aggressive 
phenotype.  
 
Abnormalities in the tumour vasculature may also lead to tumour progression. 
Fragile, permeable vessels may allow tumour cells to enter the circulation and 
disseminate to distant sites. Deficient pericyte coverage is associated with 
increased metastases in human cancers (Yonenaga et al., 2005). Furthermore, 
correction of these abnormalities in mouse models supresses tumour invasion and 
metastases (Welen et al., 2009, Mazzone et al., 2009). 
 
The abnormal tumour vasculature makes drug delivery difficult. Hypoxia itself can 
cause resistance to radiation and certain chemotherapeutic agents. Jain 
hypothesised that the increased permeability impairs the ability of 
chemotherapeutic agents to reach the tumour site. Therefore, blocking VEGF may 
“normalise” blood flow and improve drug delivery (Jain, 2005). This is supported in 
mouse models where a single dose of bevacizumab (a monoclonal antibody 
targeted against VEGF) decreased microvessel density, vascular permeability and 
interstitial pressure and improved intratumoural perfusion (Dickson et al., 2007).  
Furthermore, clinical studies support the concept of combining bevacizumab with 
chemotherapeutic agents to improve outcomes in patients with advanced colorectal 
cancer (Hurwitz et al., 2004). These findings have led to two conflicting schools of 
thought regarding anti-angiogenic strategies (Carmeliet and Jain, 2011). Should 
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tumour vessels be destroyed resulting in tumour shrinkage due to oxygen 
starvation, or should they be normalised to limit metastatic spread from oxygen-
enriched tumours and improve responses to conventional anticancer treatments?  
 
1.6.5.2 Tumour Endothelial Cells 
Although HUVECs were first isolated in 1973, it was well over twenty-five years 
before tumour endothelial cells (TECs) could be successfully isolated and cultured. 
Several technical limitations have made the study of the biology of TECs difficult. 
TECs are most commonly isolated using an immune-magnetic sorting (IMS) 
technique in which small magnetic beads are coated with endothelial cell surface 
marker antibodies. The most commonly used markers are CD31 and CD146, but 
these are common to endothelial cells from all vessel types (capillary, venous etc.). 
This means cultures are likely a heterogeneous population of endothelial cells. 
Also, IMS is not 100% efficient and contamination with other cell types such as 
fibroblasts is a possibility. Furthermore, the optimal conditions for culturing TECs 
has not been established. In vivo, TECs may be adapted to the toxic tumour 
microenvironment which is hypoxic and acidotic and where they are exposed to 
aberrant forces from chaotic blood flow. Therefore, TECs in vitro may not be an 
accurate representation of TECs in vivo. Nevertheless, it is well known that TECs 
are irregular in shape and size, have ruffled margins and long, fragile cytoplasmic 
projections extending across the vessel lumen (Dudley, 2012). In one of the first 
reports of successful isolation TECs maintained their phenotype, expressed growth 
factor receptors, and were stimulated by typical endothelial cell mitogens 
(Alessandri et al., 1999).   
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More recent studies have shown that tumour angiogenesis is not simply driven by 
pre-existing endothelial cells and that tumour endothelial cells can arise from novel 
sources (Dudley, 2012). VEGF and the hypoxic tumour microenvironment recruits 
endothelial progenitor cells (EPCs) from the bone marrow and/or activates tumour 
resident EPCs. EPCs then either differentiate into endothelial cells or produce 
angiogenic growth factors to stimulate angiogenesis (Marçola and Rodrigues, 
2015). Many aspects of the role played by EPCs in tumour angiogenesis however, 
remain unclear. 
 
St. Croix published the first comprehensive genetic screening of human TECs from 
malignant colorectal cancer tissue (St Croix et al., 2000). Serial analysis of gene 
expression identified 46 transcripts elevated in TECs and 9 novel transcripts 
thought to be specific tumour endothelial cell markers (TEM 1-9). However, 
subsequent studies suggested TEM expression is not restricted to TECs, occurring 
also in normal vascular beds (Seaman et al., 2007), developing tissue (Opavsky et 
al., 2001), fibroblasts and perivascular cells (MacFadyen et al., 2007), the brain 
(Lee et al., 2005) and osteosarcoma cell lines (Halder et al., 2009). Collated 
transcript profiles from multiple studies and multiple tumour types have shown only 
a few overexpressed transcripts to be shared by different tumours including MMP9, 
HEYL and SPARC (Aird, 2009). A number of studies have compared gene 
expression between cultured colorectal cancer derived endothelial cells and normal 
colonic endothelial cells (van Beijnum et al., 2006, Schellerer et al., 2007, 
Jayasinghe et al., 2009, Mesri et al., 2013). No studies to date have analysed 
endothelial cells from CLM. 
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1.6.5.3 Vasculogenic Mimicry 
Vasculogenic mimicry was first reported in 1999 and describes the ability of tumour 
cells to masquerade as endothelial cells (Maniotis et al., 1999). Occurring mainly in 
aggressive tumours, tumour cells are able to de-differentiate to an endothelial 
phenotype and make tube-like structures. This provides tumours with a secondary 
circulatory system independent of angiogenesis.  The exact mechanism underlying 
vasculogenic mimicry is yet to be resolved. Several molecules appear to be 
involved including PI3 kinase, VE-Cadherin and tissue factor pathway inhibitor 2 
(Hillen and Griffioen, 2007). 
 
1.6.5.4 Vessel Co-option 
Although it is generally accepted that tumours start as an avascular mass and 
induce angiogenesis to grow beyond a few millimetres in size, it has been 
suggested that many tumours can grow in an avascular stage in well vascularised 
tissue like the brain and lungs. Known as vessel co-option, tumours can grow along 
existing vessels without inducing an angiogenic response (Holmgren et al., 1995, 
Pezzella et al., 1997). The first evidence for this process was reported in 1999 
(Holash et al., 1999).  In vivo studies reported that 2 weeks after implantation of C6 
glioma cells in rat brains, tumours were well vascularised with vessels that had 
characteristics of normal blood vessels, suggesting vessel co-option. However, 
after 4 weeks, blood vessels had undergone a dramatic regression resulting in a 
secondary avascular tumour mass with massive tumour cell loss. The tumours were 
then rescued by robust angiogenesis at the tumour periphery. The Tie-2 receptor 
antagonist Ang-2 and pro-angiogenic VEGF appear to be key regulators of this 
process.  
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1.6.5.5 Angiogenesis in Colorectal Cancer Liver Metastases 
The liver is a highly vascularised organ and three different patterns of growth of 
CLM have been identified with differing levels of angiogenesis (Vermeulen et al., 
2001). In “pushing-type” growth, metastases compress the surrounding liver 
parenchyma and there is a high level of angiogenic activity. In “desmoplastic” 
growth, metastases are separated from the surrounding liver parenchyma by a rim 
of desmoplastic stroma containing a dense lymphocytic infiltrate and numerous 
capillaries. In “replacement” type growth, tumour cells replace hepatocytes 
maintaining the liver architecture with minimal inflammatory reaction. They have low 
levels of angiogenesis instead co-opting hepatic sinusoids. A combination of these 
growth patterns may exist in patients with multiple liver metastases (Nielsen et al., 
2014).  
 
Understanding the biology of CLM and variability in levels of angiogenesis is 
important and may help predict which patients will respond best to anti-angiogenic 
therapy.  
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1.7 Anti-Angiogenic Agents 
1.7.1 Endogenous Angiogenesis Inhibitors 
Tumour angiogenesis represents an attractive treatment target for cancer 
therapeutics. Disrupting an essential process necessary for tumour growth and 
spread is a logical approach. A number of endogenous angiogenesis inhibitors exist 
(Table 3) and attempts have been made to develop anti-angiogenic agents based 
on these substances. An exhaustive review of each individual substance is beyond 
the scope of this work, however, key substances will be briefly considered. 
 
Endostatin is a 20 kDa c-terminal fragment derived from Type XVIII collagen that 
has broad-spectrum anti-angiogenic activity (Nyberg et al., 2005). This includes; 1) 
Inhibition of cyclin-D1 causing G1 cell cycle arrest and apoptosis, 2) Alteration of 
fibroblast  growth factor (FGF) signal transduction inhibiting migration of endothelial 
cells, 3) Blocking VEGF-mediated signalling through direct interaction with VEGFR-
2, 4) Binding to integrin α5β1 on endothelial cells inhibiting their migration by 
blocking signalling pathways via Ras and Raf, 5) Binding to and inactivating matrix 
metalloproteinases and 6) Blocking tumour necrosis factor-induced activation of c-
Jun NH2-terminal kinase and c-Jun NH2-terminal kinase-dependent proangiogenic 
gene expression. In a phase III clinical trial, the addition of endostar (a recombinant 
human endostatin) to conventional platinum based chemotherapy resulted in a 
significantly increased response rate and median overall survival in patients with 
locally advanced or non-small cell lung cancer (Sun et al., 2013) 
 
 
- 44 - 
 
 
 
Table 3 Endogenous Inhibitors of Angiogenesis 
A number of natural endogenous substances are capable of inhibiting 
angiogenesis. They have been divided into matrix-derived and non-matrix derived.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Matrix Derived Non-Matrix Derived
Arresten Angiostatin
Canstatin Antithrombin III
Endorepellin Chondromodulin
Endostatin Interferons
Fibronectin Interleukins
Fibulin Prolactin Fragments
Thrombospondin-1 and -2 Tissue Inhibitor of Metalloproteinases (TIMPs)
Tumstatin Troponin I
Vasostatin
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Thrombospondins (TSPs) are a family of secreted glycoproteins with anti-
angiogenic functions. There are five family members with TSP-1 and -2 being 
potent inhibitors of angiogenesis. TSP-1 was the first protein to be shown to play a 
critical role as a naturally occurring inhibitor of angiogenesis (Lawler and Lawler, 
2012). The mechanisms by which TSPs regulate angiogenesis are complex, with 
direct and indirect activity. For instance, it can inhibit endothelial cell migration and 
induce endothelial cell apoptosis, but also has indirect effects on growth factors, 
cytokines and proteases that regulate angiogenesis. Surprisingly, a phase II clinical 
trial assessing ABT-510 (a synthetic analogue of TSP-1) for the treatment of 
metastatic melanoma failed to demonstrate any clinical efficacy (Markovic et al., 
2007). 
 
1.7.2 Anti-Angiogenic Drugs used in Metastatic Colorectal Cancer 
Bevacizumab (Avastin®) is a humanised monoclonal antibody targeted against 
VEGF-A. Binding of bevacizumab prevents VEGF from binding to its receptors. Two 
randomised clinical trials have shown that bevacizumab improves overall survival in 
patients with metastatic colorectal cancer when used in conjunction with first- and 
second-line chemotherapeutic agents. In the first study, median overall survival 
improved from 15.6 months in patients with metastatic colorectal cancer receiving 
IFL (5-FU, leucovorin and irinotecan) to 20.3 months in patients who received IFL 
and bevacizumab (Hurwitz et al., 2004). The E3200 trial showed the benefit of 
using bevacizumab as part of a second-line therapy when combined with FOLFOX. 
Median overall survival increased from 10.8 to 12.9 months with the addition of 
bevacizumab compared to FOLFOX alone (Giantonio et al., 2007).  
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Aflibercept (Zaltrap®) is a recombinant fusion protein with receptor components of 
VEGFR-1 and VEGFR-2, which binds multiple ligands including VEGF-A, VEGF-B 
and PGF. It binds to circulating VEGF preventing it from binding to VEGFR-2. 
Aflibercept in combination with FOLFIRI improved overall survival (13.5 vs 12.06 
months), and progression-free survival (6.9 vs. 4.67 months) compared to FOLFIRI 
alone in patients with metastatic colorectal cancer who had progressed with 
FOLFOX therapy (Van Cutsem et al., 2012).  
 
Ramucirumab (Cyramza®) is a human monoclonal antibody directed against the 
extracellular domain of the VEGFR-2 receptor and functions as a VEGFR-2 
receptor antagonist. Ramucirumab in combination with FOLFIRI improved median 
overall survival (13.3 vs. 11.7 months) compared to FOLFIRI alone in patients with 
metastatic colorectal cancer who had disease progression following first-line 
therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (Tabernero et al., 
2015). 
 
Regorafenib is an oral multikinase inhibitor that targets protein kinases involved in 
tumour angiogenesis (VEGFR1-3, Tie-2), oncogenesis (KIT, RET and RAF) and the 
tumour microenvironment (platelet-derived growth factor receptor-β and fibroblast 
growth factor receptor) (Wilhelm et al., 2011). The CORRECT trial, an international, 
multi-centre phase III trial, showed the benefit of regorafenib montherapy in patients 
with metastatic colorectal cancer who had progressed on standard first-line therapy, 
including bevacizumab. Regorafenib improved median overall survival (6.4 vs. 5.0 
months) and progression-free survival (1.9 vs. 1.7 months) compared to placebo 
(Grothey et al., 2013). 
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Agents that target other parts of the angiogenesis pathway are under investigation 
in clinical trials. For instance, EZN-9628 is an anti-sense oligonucleotide inhibitor of 
HIF-1α currently being investigated in patients with liver metastases from advanced 
solid tumours (Clinical trials identifier: NCT01120288). Unfortunately a number of 
agents that showed promising anti-angiogenic activity have had negative results in 
phase III clinical trials. This includes the tyrosine kinase inhibitors sunitinib and 
vatalanib (Hecht et al., 2011, Carrato et al., 2013). A summary of anti-angiogenic 
agents and there efficacy in metastatic colorectal cancer are provided in Table 4. 
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Table 4 Summary of Clinical Trials Investigating Anti-Angiogenic 
Agents in Metastatic Colorectal Cancer 
A number of randomised clinical trials have been undertaken investigating the 
benefit of anti-angiogenic therapy in the treatment of metastatic colorectal cancer. 
In the table, trials have been separated into first-line (no previous chemotherapy) or 
second line (failed conventional chemotherapy). Overall survival (OS) and 
progression-free survival (PFS) outcomes are included. (Hurwitz et al., 2004, Saltz 
et al., 2008, Cunningham et al., 2013, Carrato et al., 2013, Hecht et al., 2011, 
Giantonio et al., 2007, Van Cutsem et al., 2012, Grothey et al., 2013, Tabernero et 
al., 2015) 
 
 
 
 
 
 
 
Indication Therapy Trial Outcome Citation
First line
FOLFIRI +/-
Bevacizumab
AV2119 Improvement in OS 
and PFS.
Hurwitz et al., 2004
FOLFOX or XELOX 
+/- Bevacizumab
NO16966 No Improvement in 
OS. Improvement in
PFS.
Saltz et al., 2008
Capecitabine +/-
Bevacizumab
AVEX Improvement in PFS.
OS N/A.
Cunningham et al., 
2013
FOLFIRI +/- Sunitinib SUN1122 No improvement in
PFS.
Carrato et al., 2011
FOLFOX +/-
Vatalanib
CONFIRM1 No improvement in 
OS and PFS.
Hecht et al.,  2013
Second Line
FOLFOX +/-
Bevacizumab
E3200 Improvement in OS 
and PFS.
Giantonio et al., 2007
FOLFIRI +/-
Aflibercept
VELOUR Improvement in OS 
and PFS.
Van Cutsem et al.,  
2012
Regorafenib vs.
Placebo
CORRECT Improvement in OS. Grothey et al., 2013
FOLFIRI +/-
Ramucirumab
RAISE Improvement in OS 
and PFS.
Tabernero et al., 2015
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1.7.3 Toxicity Associated with Anti-Angiogenic Therapy 
As angiogenesis in the adult is a rare process, it was initially presumed that anti-
angiogenic agents would have limited side effects. However, clinical experience has 
revealed a number of adverse events associated with these drugs. The most 
common adverse events are experienced in the cardiovascular system 
(hypertension, arterial thromboembolic events, ventricular dysfunction, congestive 
heart failure) and urinary system (proteinuria, renal thrombotic microangiopathy). 
Other reported adverse events include haemorrhage, wound complications,  
gastrointestinal perforation, venous thromboembolism and hypothyroidism (Chen 
and Cleck, 2009). Excessive toxicity may necessitate dose reductions or treatment 
breaks, which can limit anti-angiogenic efficacy.        
 
Adverse events generally arise as a direct consequence of VEGFR-2 inhibition. For 
instance, in the case of hypertension, the best documented cardiovascular adverse 
effect with anti-VEGF therapy, VEGFR-2 signalling normally generates nitric oxide 
and prostaglandin I2, which induce endothelial cell dependent vasodilatation in 
vessels. Inhibition of this signalling pathway has the opposite effect, causing 
vasoconstriction. Physiological functions of VEGF/VEGFR-2 signalling and 
consequences of inhibition are summarised in Figure 8. 
 
An obvious concern with the use of anti-angiogenic agents for patients undergoing 
curative liver resection for CLM is what impact they have upon liver regeneration 
and wound healing. However, numerous case-control studies have found no 
difference in post-operative morbidity or mortality with their use (Tamandl et al., 
2010, Chaudhury et al., 2010).  
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VEGF signalling via VEGFR-2 leads to downstream molecular and cellular events including nitric oxide production, endothelial cell 
proliferation and migration. This is important in the regulation of a number of process including angiogenesis and vasodilatation. 
Blockade of VEGF signalling can therefore disrupt a number of physiological processes with pathological consequences including 
impaired wound healing, hypertension, arterial thromoembolic events and cardiac dysfunction. BM= basement membrane, EC= 
endothelial cells, P= phosphorylated residues; PGI2= prostaglandin I2, NO= nitric oxide. Adapted from Chen and Cleck (2009).. 
(Chen and Cleck, 2009) 
Figure 8 VEGF/VEGFR-2 Signalling and Consequences of Inhibition 
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1.7.4 Failure of Anti-Angiogenic Therapy 
Resistance to anti-angiogenic therapy is a problematic issue that, in part, explains 
the variable results observed in randomised clinical trials with anti-angiogenic 
agents. The tumour vasculature is heterogeneous in its response to anti-angiogenic 
agents, with some vessels being sensitive to treatment whilst others are resistant. 
Pre-clinical studies have demonstrated that anti-VEGF therapy can inhibit tumour 
vessel angiogenesis, but is less effective upon established tumour vasculature.  
This is believed to be due to the dependence of nascent tumour vessels on VEGF 
that is lost once the vessel undergoes maturation (Helfrich et al., 2010).  
 
The ability of tumours to signal via alternative angiogenic pathways once the VEGF 
pathway is blocked can also contribute to treatment resistance. Pre-clinical studies 
have identified numerous up-regulated candidates including angiopoietins, EGF, 
fibroblast growth factor 1 and 2 and the delta-notch pathway (Vasudev and 
Reynolds, 2014). Although the logical approach would be to block other signalling 
pathways in conjunction with VEGF, this has yet to be validated clinically and some 
multi-targeted drugs, such as sunitinib, have had negative results in clinical trials 
(Carrato et al., 2013).  
 
Although anti-angiogenic agents should reduce oxygen and nutrient delivery to the 
tumour, there is pre-clinical evidence that tumours can adapt to survive in stressful 
conditions. This may be driven by genetic abnormalities such as mutated p53 (Yu et 
al., 2002). Alternatively, tumours may recruit other mechanisms of tumour 
vascularisation, such as intussusceptive angiogenesis, vasculogenic mimicry and 
vessel co-option. These mechanisms may be independent of VEGF signalling and 
so the tumour can “switch” mechanism once VEGF signalling is blocked. For 
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instance, treatment of mice breast carcinoma allografts with vatalinib significantly 
reduced tumour vascularisation, but upon cessation of therapy the tumour 
vasculature expanded predominantly by intussusceptive angiogenesis (Hlushchuk 
et al., 2008). 
 
Anti-angiogenic agents are expensive. A single dose of bevacizumab costs in 
excess of £1000 (National Institute for Health and Care Excellence, 2010). At 
present the National Institute for Health and Clinical Excellence (NICE) do not 
recommend bevacizumab in combination with oxaliplatin and either 5-FU plus 
leucovorin or capecitabine for patients with metastatic colorectal cancer (National 
Institute for Health and Care Excellence, 2010). Similarly bevacizumab in 
combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is not 
recommended for the treatment of patients with metastatic colorectal cancer that 
have progressed after first-line chemotherapy (National Institute for Health and 
Care Excellence, 2012). This is because, in their opinion, it does not provide 
enough benefit to patients to justify its high costs. NICE also do not recommend the 
use of aflibercept with FOLFIRI for metastatic colorectal cancer that is resistant to 
or has progressed after an oxaliplatin containing regimen (National Institute for 
Health and Care Excellence, 2014). 
 
Concerns regarding the safety and efficacy of current anti-angiogenic agents 
perhaps suggest that interference with the VEGF/VEGFR-2 signalling mechanism is 
not the best approach for designing future therapeutics. Instead, agents which 
directly kill tumour endothelial cells may be preferential. This will require the 
identification of new novel targets important to tumour endothelial cell growth and 
survival.   
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1.8 Summary 
Colorectal cancer liver metastases are a significant cause of cancer-related 
morbidity and mortality. Although an increasing number of patients are undergoing 
curative surgery, the vast majority of patients are treated palliatively. Furthermore, 
for patients that do undergo curative surgery, recurrence rates are high. Central to 
CLM growth and survival is the process of tumour angiogenesis, which is regulated 
by VEGF/VEGFR-2 signalling. Targeting tumour angiogenesis is an attractive 
treatment strategy, whereby tumour blood vessels are destroyed resulting in the 
starvation of oxygen and nutrients leading to tumour shrinkage. Licensed anti-
angiogenic agents target the VEGF/VEGFR-2 signalling pathway and although they 
have had promising results in pre-clinical studies, this has not really translated into 
meaningful improvements in outcomes for metastatic colorectal cancer. This, in 
part, is due to anti-angiogenic therapy resistance, as tumours appear to be able to 
switch to alternative angiogenic mechanisms.  
Tumour blood vessels are morphologically abnormal and are lined on their inner 
surface by tumour endothelial cells. Tumour endothelial cells are genetically and 
phenotypically distinct from other endothelial cell types. Endothelial cells of CLM 
have never been isolated or characterised before. Knowledge of their molecular 
make-up may help better understand the mechanisms associated with anti-
angiogenic therapy resistance. Furthermore, identification of proteins critical to their 
survival may lead to the development of new anti-angiogenic therapies that have 
direct tumour endothelial cell cytotoxicity.  
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Aims and Objectives 
 
Aim 
The overall aim of this research is to identify novel protein targets in endothelial 
cells of colorectal cancer liver metastases that could be used for the development 
of anti-angiogenic therapies for the treatment of CLM. 
Hypothesis 
Compared to normal liver endothelial cells, endothelial cells of colorectal cancer 
liver metastases differentially express proteins that can be therapeutically targeted 
to inhibit tumour angiogenesis. 
Objectives 
 Isolate and culture endothelial cells from CLM. 
 Characterise endothelial cells from CLM using endothelial cell markers and 
functional assays. 
 Analyse RNA interference screening data to identify proteins critical to CLM 
endothelial cell survival. 
 Perform in vitro angiogenesis studies to determine the anti-angiogenic 
potential of identified protein targets. 
 Perform mechanistic studies to determine how identified protein targets 
inhibit angiogenesis. 
 Perform in vitro studies to determine if the identified protein targets have 
direct anti-cancer activity. 
 Use proteomic studies to identify differences in protein expression between 
normal liver endothelial cells and endothelial cells of CLM. 
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Chapter 2: Materials and Methods 
2.1 Cell Lines and Cell Culture 
Human Umbilical Vein Endothelial Cells (HUVECs)  
HUVECs were purchased from Lonza and maintained in Endothelial Cell Basal 
Medium (EBM-2) supplemented with a BulletKitTM. The BulletKitTM contained 2% 
foetal calf serum (FCS) and the following growth factors; 10 ng.ml-1 VEGF, 5 ng.ml-1 
human basic fibroblast growth factor, 1 μg.ml-1 hydrocortisone, 50 ng.ml-1 
gentamicin, 50 ng.ml-1 amphotericin B, and 10 μg.ml-1 heparin. Experiments were 
performed on cells from passage 2-8. 
 
Human Liver Endothelial Cells 
Human liver endothelial cells were obtained fresh from patients undergoing curative 
liver resection for CLM at St. James’s University Hospital, Leeds Teaching 
Hospitals NHS Trust. Matched endothelial cells from CLM and normal liver tissue 
were both grown in EBM-2 supplemented with a BulletkitTM. Cells were passaged 
once 95% confluent and used from passage 1-5.  
 
Mouse Liver Endothelial Cells 
Mouse liver endothelial cells were obtained fresh from mice livers harvested by Dr 
Baptiste Rode (University of Leeds). Cells were plated directly into experimental 
dishes, grown in EBM-2 supplemented with a BulletkitTM and never passaged.   
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Normal Human Dermal Fibroblasts (NHDF) 
NHDF were purchased from Lonza. These cells were cultured in EBM-2 growth 
medium supplemented with a BulletkitTM. Cells were passaged once 95% 
confluent and used from passage 1-8.  
 
HT29 Colorectal Adenocarcinoma Cells  
HT29 cells (ATCC® HTB-38™) were purchased from Sigma. This cell line was 
established in 1964 from the primary tumour of a 44-year-old caucasian female with 
colorectal adenocarcinoma. They have a mutated p53 (Arg-273 to His). Cells were 
cultured in Dulbecco’s Modified Eagle Medium GlutatMAX (Invitrogen) 
supplemented with 10% FCS and 100 units.ml-1 penicillin-streptomycin. 
 
All cells were grown in a 5% CO2 incubator at 37°C. 
 
2.2 Human Liver Endothelial Cell Isolation 
Ethical approval for tissue collection was granted by Yorkshire and the Humber - 
Leeds East Research Ethics Committee (REC Reference No: 14/YH/1001). 
Approval was also granted by Leeds Teaching Hospitals NHS Trust Research and 
Development Department to undertake this research in their hospitals (Reference: 
GS14/1121) and by the Histopathology Department (Reference: 
300/PATHRES/14). Patients undergoing curative liver resection for CLM provided 
fully informed written consent to take part in the study. Each participant was 
assigned a study number, and a form containing medical history was generated.  
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Tissue was taken immediately following surgical resection in the operating theatres 
at St. James’s University Hospital, Leeds. Tumours were visually and manually 
located within the specimen. A 2.5 cm x 2.5 cm x 2.5 cm incision was made into the 
tumour avoiding the centre and any obvious areas of necrosis. A similar slice of 
macroscopically normal liver tissue was also taken at least 2.5 cm away from the 
tumour. The tissue samples were stored in separate 50 mL falcon tubes containing 
EBM-2 supplemented with a BulletKitTM and transported on ice.  
 
Isolation of endothelial cells was undertaken in a sterile manner in a tissue culture 
hood assigned for use with human tissues. The protocol was adapted from a 
previously published technique (van Beijnum et al., 2008).  Tissue was minced 
using two scalpel blades and re-suspended in a dissociation solution consisting of 9 
mL 0.1% Collagenase II, 1 mL 2.5 units.ml-1 Dispase, 1 µM Calcium Chloride and 1 
μM Magnesium Chloride in Hanks Buffer solution per sample. The tissue-
dissociation mix was incubated at 37°C for 45 mins in a MACSMix Tube Rotator 
(Miltenyi Biotech) to provide continuous agitation.  
 
Following enzymatic digestion, the samples were passed through 100 μm and 40 
μm cell strainers to remove any undigested tissue. Cells were washed twice in 
magnetically-activated cell sorting (MACS) buffer consisting of; Phosphate Buffered 
Saline (PBS), EDTA 2 mM and 0.1% Bovine Serum Albumin (BSA) pH 7.2. The 
washed pellets were suspended in 20 mL red blood cell lysis buffer consisting of 
0.206 g Tris base, 0.749 g NH4Cl in 100 mL PBS pH 7.2 for 10 mins. Cells were 
washed for a final time in MACS buffer before the pellet was incubated with 200 µL 
of dead cell removal paramagnetic microbeads per 1 x107 cells (Miltneyi Biotec) in 
MACS buffer at room temperature for 15 mins. After incubation, the cells were 
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passed through an LS column prepared with 1 x binding buffer (Miltenyi Biotec) in a 
magnetic field (MiniMACS Separator, Miltenyi Biotec). The column retains apoptotic 
and dead cells, meaning the eluate consists of live cells only.  
 
IMS was used to select CD31 positive cells (Figure 9). Live cells were incubated 
with 30 µL FcR blocking reagent and 30 µL CD31-conjugated paramagnetic 
microbeads for 15 mins at 4 ˚C under continuous agitation. After incubation, the 
solution was passed through an MS column prepared with MACS buffer. CD31 
positive cells were retained in the column and CD31 negative cells passed through 
as eluate. CD31 positive cells were washed through with warm EBM-2 media 
supplemented with a BulletKitTM and the CD31 selection process was repeated for 
a second time to help reduce contamination with other cell types. After the second 
selection, cells were placed in one well of a 6-well plate and incubated in a 5% CO2 
incubator at 37˚C. Medium was changed at 12 hrs and then every 48 hrs until 
confluent. Cells were used from passage 1-5. 
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Figure 9 Immuno-Magnetic Selection of CD31-Positive Cells 
1. After the generation of a single-cell suspension, cells are incubated with CD31-magentic beads. 2. The CD31-magentic beads bind to 
CD31 positive cells only. 3. The suspension is passed through a column in a magnetic field where CD31-positive cells are retained and 
CD31-negative cells pass through as eluate. 4. CD31-positive cells are flushed through and cultured. MB = Magnetic beads. Image 
created through Servier Medical Art. 
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2.3 Mouse Liver Endothelial Cell Isolation 
Mouse liver endothelial cell isolation also used an IMS technique similar to human 
liver endothelial cell isolation. Mouse livers were harvested by Dr Baptiste Rode 
(University of Leeds). The entire liver was minced using 2 scalpel blades and re-
suspended in a dissociation solution consisting of 9 mL 0.1% Collagenase II, 1 mL 
2.5 units.ml-1 Dispase, 1 µM Calcium Chloride and 1 μM Magnesium Chloride in 
Hanks Buffer solution per sample. The tissue-dissociation mix was incubated at 
37°C for 45 mins in a MACSMix Tube Rotator (Miltenyi Biotech) to provide 
continuous agitation.  
 
Following enzymatic digestion, the samples were passed through 100 μm and 40 
μm cell strainers to remove any undigested tissue. Cells were washed twice in PEB 
buffer consisting of PBS, EDTA 2 mM and 0.5% BSA pH 7.2. The washed pellets 
were suspended in 200 µL of dead cell removal paramagnetic microbeads per 1 
x107 cells (Miltneyi Biotec) in PEB buffer at room temperature for 15 mins. After 
incubation, the cells were passed through an LS column prepared with 1 x binding 
buffer (Miltenyi Biotec) in a magnetic field (MiniMACS Separator, Miltenyi Biotec). 
The eluates were incubated with 20 mL red blood cell lysis buffer consisting of 
0.206 g Tris base, 0.749 g NH4Cl in 100 mL PBS pH 7.2 for 10 mins and then 
washed a final time in PEB buffer.  
 
IMS was used to select CD146 positive cells. Live cells were incubated with 30 µL 
CD146-conjugated paramagnetic microbeads for 15 mins at 4 ˚C under continuous 
agitation. After incubation, the solution was passed through an MS column 
prepared with PEB buffer. CD146 positive cells were retained in the column and 
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CD146 negative cells passed through as eluate. CD146 positive cells were washed 
through with warm EBM-2 media supplemented with a BulletKitTM and the CD146 
selection process was repeated for a second time to help reduce contamination 
with other cell types. After the second selection cells were plated directly onto 
experimental dishes in a 5% CO2 incubator at 37˚C. Medium was changed at 12 hrs 
and then every 48 hrs until experiments were performed.  
 
2.3 Drugs and Reagents 
2.3.1 Drugs 
2.3.1.1 AZD1775 
AZD1775 (Active Biochem) is a small molecule WEE1 inhibitor, which inhibits 
WEE1-activity in an ATP-competitive manner and has an IC50 of 5.2 nM. It is a 
pyrazolo-pyrimidine derivative and has high specificity for WEE1, inhibiting only 
eight out of 223 other serine/threonine or tyrosine kinases tested (Hirai et al., 2009). 
Of these eight, AZD1775 only had high affinity for Yamaguchi sarcoma virus 
oncogene with an IC50 value of 14 nM. It was reconstituted in dimethyl sulfoxide 
(DMSO) which in experiments is referred to as the vehicle control.  
 
2.3.1.2 RO-3306 
RO-3306 (Sigma) is a quinolinyl thiazolinone derivative and selective ATP-
competitive inhibitor of CDK1. It inhibits cyclin B-CDK1 activity with Ki of 35 nM. It 
has nearly 10-fold selectivity relative to cyclin E-CDK2 and over 50-fold relative to 
cyclin D-CDK4 (Vassilev et al., 2006).  
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2.3.1.3 5-Fluorouracil 
5-FU (Sigma) is a chemotherapeutic agent used clinically for the treatment of 
colorectal cancer. Its primary mechanism of action is as a thymidylate synthase 
(TS) inhibitor, inhibiting the synthesis of the critical pyrimidine thymidine. TS is an 
enzyme that normally catalyzes the reductive methylation of deoxyuridine 
monophosphate to deoxythymidine monophosphate (dTMP). Depletion of dTMP 
results in subsequent depletion of deoxythymidine triphosphate (dTTP), which 
induces perturbations in the levels of the other deoxynucleotides (dATP, dGTP and 
dCTP) through various feedback mechanisms (Longley et al., 2003). 
Deoxynucleotide pool imbalances (in particular, the dATP/dTTP ratio) are thought 
to severely disrupt DNA synthesis and repair, resulting in lethal DNA damage 
(Houghton JA et al., 1995). The chemical structures of all chemotherapeutic agents 
used in this study are shown in Figure 10. 
 
2.3.1.4 Oxaliplatin 
Oxaliplatin (Sigma) is a platinum-based chemotherapy used clinically for the 
treatment of colorectal cancer. It forms inter- and intra-strand cross links in DNA, 
preventing DNA replication and transcription, resulting in cell death (Graham et al., 
2004). 
 
2.3.1.5 Irinotecan 
Irinotecan (Sigma) is used in combination with other chemotherapeutic agents for 
the treatment of colorectal cancer. It is a derivative of camptothecin, which inhibits 
the action of topoisomerase I, a nuclear enzyme that has a critical role in DNA 
replication and transcription. Topoisomerase I normally causes transient breaks in a 
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single strand of DNA that helps release the torsional strain caused by synthesis of a 
new strand of DNA or RNA around the double helix. Irinotecan binds to the 
topoisomerase I-DNA complex stabilising it and preventing the reannealing of the 
parent DNA. Collision of replication forks with the stabilized complex during cell 
division leads to double-stranded DNA breaks and tumour cell death.  
 
2.3.1.6 Yoda1 
Yoda1 is a recently discovered activator of Piezo1 (Syeda et al., 2015). 
Concentrations of up to 10 μM were used for experiments, at which point Yoda1 
becomes insoluble. 
 
2.3.1.7 Ionomycin 
Ionomycin (Sigma) is a selective Ca2+ ionophore produced by the bacterium 
Streptomyces conglobatus. Ionomycin was used at a final concentration of 1 μM for 
experiments. 
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Figure 10 Chemical Structures of Chemotherapeutic Agents 
5-FU is a TS inhibitor that disrupts the synthesis of the pyrimidine thymidine, which is necessary for DNA replication.  It contains a 
fluorine atom on the 5th carbon of a uracil ring. Oxaliplatin is a platinum-based chemotherapy that interferes with DNA cross-
linking. It contains a square central planar platinum, a bidentate ligand, 1,2-diaminocyclohexane and a bidentate oxalate group. 
Irinotecan is a topoisomerase I inhibitor, preventing the co-ordinated unwinding of DNA during replication. It is a semisynthetic 
analogue of camptothecin and is characterised by a bulky piperidino side-chain at the Carbon 10 position.   
 
 
 
5-FU Oxaliplatin Irinotecan
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2.3.2 VEGF 
VEGF (Sigma) was used to mediate increases in cytosolic Ca2+ and stimulate 
endothelial cell migration. VEGF was prepared as a 30 μg.mL-1 stock solution in 
distilled water and was used at a concentration of 30 ng.ml-1 during experiments. 
 
2.3.3 ATP 
ATP (Sigma) is a key signalling molecule that causes Ca2+ entry in endothelial cells 
through a number of mechanisms. ATP was prepared as a 100 mM stock solution 
in distilled water and used at a concentration of 20 μM during experiments.  
 
2.3.4 Matrigel® 
Matrigel® (Corning) is a gelatinous protein mixture secreted by Engelbreth-Holm-
Swarm (EHS) mouse sarcoma cells. It acts as an artificial basement membrane 
upon which endothelial cells form lattice like structures. Matrigel® was diluted with 
EBM-2 media supplemented with a BulletKitTM to a concentration of 10 mg.mL-1 for 
experiments. 
2.3.5 Nucleosides 
Nucleosides (EmbryoMax) were applied exogenously in experiments to rescue 
nucleotide shortage. Their dilution factor is stated in each experiment. 
 
 
 
 
- 66 - 
 
 
2.4 Transfections 
Knockdown of WEE1 was achieved using a transient transfection method. 
Endothelial cells were seeded overnight on a 6-well plate and transfected once 90% 
confluent. For transfection of one well, 100 μL of Optimem containing 3% 
Lipofectamine 2000 was added to 100 μL Optimem containing 250 nM pooled 
WEE1 siRNA (Dharmacon On-Targetplus) and left at room temperature for 20 
mins. The individual siRNA sequences are provided in (Table 5). The 200 μL 
transfection mix was added to 800 μL fresh EBM-2 media supplemented with a 
BulletKitTM and added to the well, giving a final WEE1 siRNA concentration of 50 
nM. This was applied and incubated in a 5% CO2 incubator at 37°C. After 3.5 hrs, 
the transfection mix was removed and replaced with fresh EBM-2 media 
supplemented with a BulletKitTM. Cells were incubated for a further 24 hrs and 
were used in experiments from 48 hrs onwards. WEE1 knockdown was confirmed 
by western blot. Transfection of Thrombospondin-1 was also achieved using pooled 
siRNA (Dharmacon On-Targetplus) using the same method.  
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Table 5 Pooled WEE1 siRNA Sequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
siRNA Target Sequence
WEE1 (J-005050-05) AAUAGAACAUCUCGACUUA
WEE1 (J-005050-06) AAUAUGAAGUCCCGGUAUA
WEE1 (J-005050-07) GAUCAUAUGCUUAUACAGA
WEE1 (J-005050-08) CGACAGACUCCUCAAGUGA
- 68 - 
 
 
2.5 Western Blotting 
2.5.1 Solutions 
Lysis Buffer 
10 mM Tris, pH 7.4, 150 mM NaCl, 0.5 mM EDTA, 0.5 % NP-40, MiniComplete 
protease inhibitors (Roche 1:500), and PhosSTOP phosphatase inhibitors (Roche 
1:500). 
Sample (Loading) Buffer 
200 mM Tris pH 6.8, 8% SDS, 40% glycerol, 8% mercaptoethanol, 0.1% 
bromophenol blue. 
Running (Electrophoresis) Buffer 
25 mM Tris, 192 mM glycine and 0.1% SDS, pH 8.3. 
Semi-dry transfer buffer 
48 mM Tris, 39 mM glycine and 20% methanol, pH 9.2. 
TBS-T 
145 mM NaCl, 20 mM Tris-base, 0.5% Tween 20, pH 7.5.  
 
2.5.2 Cell Lysis 
Cells were grown to confluence in a 6-well culture plate and harvested in lysis 
buffer. Cells were washed with PBS twice before 0.1 mL of lysis buffer was added 
and the cells incubated for 1 min. Cells were then scraped off the dish and collected 
into an eppendorf. The lysate was centrifuged at 13,000 revolutions per minute 
(RPM) at 4 ˚C for 10 mins and the soluble protein-containing layer aspirated.  
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2.5.3 Protein Quantification 
Protein was quantified using the Bio-Rad Protein Assay (Bio-Rad). This is a dye-
binding assay in which a differential colour change occurs in response to various 
concentrations of protein. Absorbance was measured in a microtitre plate reader at 
570 nm wavelength. Comparison was made to a BSA standard curve and the 
protein concentrations were derived from this. 
 
2.5.4 Western Blotting 
Equal quantities of test and control protein samples were mixed with sample buffer 
and heated to 90˚C for 5 mins to ensure complete denaturation. Samples were 
loaded alongside markers (Bio-Rad) into sodium dodecyl sulphate (SDS) 
polyacrylamide gels and electrophoresis was carried out for 90 mins at 160 V. SDS 
is an anionic detergent that disrupts the secondary structures of proteins to create 
linear, negatively charged structures. Application of an electrical charge across the 
gel results in the movement of negatively charged proteins towards the positively 
charged electrode. The distance each protein travels is inversely proportional to its 
size and molecular weight.  
 
Following gel electrophoresis, the protein was transferred to a polyvinylidene 
fluoride membrane using semi-dry transfer buffer and electrophoresis at a constant 
current of 0.05 A for 90 mins. The membrane was then incubated in either 5% non-
fat milk solution or 5% BSA solution (dependent on primary antibody) to reduce 
non-specific background antibody binding. Following this, the membrane was 
incubated with primary antibody at appropriate dilutions at 4 ˚C for 12 hrs (Table 6). 
The membrane was then washed in TBS-T and the secondary HRP-conjugated 
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antibody was added at 1:5,000 dilution in 5% non-fat milk solution. After a 1 hr 
incubation at room temperature, the membrane was washed for a final time in  
TBS-T.  
 
2.5.5 Protein Visualisation 
To detect protein bands, membranes were treated with SuperSignal Femto 
detection reagent (Perbio Science). Membranes were imaged using a G:BOX 
(Syngene). Data were analysed using Image J software.  
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Table 6 Summary of Primary Antibodies used for Western Blotting 
Antibody Host Species Dilution MW
(kDa)
Dilution Supplier
Anti-WEE1 Mouse 1:300 96 5% Non-Fat Milk Santa Cruz Biotechnology (sc-5285)
Anti-ϒH2AX Rabbit 1:1000 15 5% BSA Cell Signalling Technology (#9718)
Anti-pCDK1-Y15 Rabbit 1:1000 34 5% BSA Cell Signalling Technology (#9111)
Anti-CDK1 Mouse 1:1000 34 5% Non-Fat Milk Cell Signalling Technology (#9116)
Anti-β-Actin Mouse 1:2000 42 5% Non-Fat Milk Santa Cruz Biotechnology (sc-47778)
Anti-CD31 Mouse 1:1000 130 5% Non-Fat Milk Dako (M0823)
Anti-VEGFR1 Goat 1:1000 180 5% Non-Fat Milk R&D Systems (AF321)
Anti-VEGFR2 Goat 1:1000 250 5% Non-Fat Milk R&D Systems (AF357)
Anti-eNOS Rabbit 1:1000 133 5% Non-Fat Milk Cell Signalling Technology (#9572)
Anti-peNOS Rabbit 1:1000 133 5% BSA Cell Signalling Technology (#9571)
Anti-TSP-1 Rabbit 1:1000 180 5% Non-Fat Milk GeneTex (GTX130967)
Anti-Fibronectin Rabbit 1:1000 263 5% Non-Fat Milk Abcam (ab2413)
Anti-vWF Mouse 1:1000 250 5% Non-Fat Milk Dako (M0616)
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2.6 WST-1 Proliferation Assay 
WST-1 [(2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium] is 
a tetrazolium salt. It is broken down to formazan by the mitochondrial 
dehydrogenase succinate-tetrazolium reductase, which is present in metabolically 
active cells. Cells were plated onto a 96-well plate at an optimised seeding density 
and grown overnight.  The following morning cells were drugged and allowed to grow 
for the duration of the experiment. Upon completion of the experiment WST-1 was 
added to media in each well in accordance with the manufacturer’s protocol. The 
absorbance of the formazan salt was measured at 440 nm using a microtiter plate 
reader. A second reading at 630 nm was recorded and subtracted from the 440 nm 
reading to control for artefacts. Drug effect on proliferation was quantified by 
measuring the absorbance of treated cells and comparing this to vehicle control 
cells. 
 
2.7 Vybrant® DyeCycleTM Green Proliferation Assay 
Vybrant® DyeCycleTM Green (Molecular Probes, Invitrogen) is an inert, membrane 
permeable, fluorescent, double-stranded DNA dye. It is excited at 488 nm with 
emission ~520 nm. As with the WST-1 assay, cells were plated onto a 96-well plate 
at an optimized seeding density and grown overnight.  The following morning cells 
were drugged and allowed to grow for the duration of the experiment. At the end of the 
experiment, 1 μM Vybrant® DyeCycleTM Green was added to each well as per the 
manufacturer’s instructions and the plate was imaged on an IncucyteTM Kinetic 
Imaging System (Essen Bioscience, Michigan) in phase-contrast and fluorescence 
mode using a x10 objective. The total number of fluorescent cells in each well was 
calculated using inbuilt algorithms.  
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2.8 Migration Assays 
Migration was analysed using the IncucyteTM Kinetic Imaging System (Essen 
Bioscience, Michigan). This consists of a microscope inside an incubator and permits 
long-term live content imaging of cells (Figure 11). For migration assays, cells were 
plated onto a 96-well plate (Essen Imagelock, Essen) and grown overnight to 
confluence. The following morning a linear scratch (wound) was made in every well 
using the Essen WoundmakerTM (Essen). Following the scratch, cells were drugged 
before being placed in the IncucyteTM Kinetic Imaging System. Cells were imaged 
every hour for 24 hrs or until they had fully migrated across the scratch wound.  
 
Migration was measured automatically by the IncucyteTM Kinetic Imaging System, 
which calculates Relative Wound Density (RWD). This measures the spatial density 
in the scratch wound relative to the spatial density of cells outside of the scratch 
wound. It is 0% at 0hrs and reaches 100% once the spatial density inside the 
scratch is the same as outside. This allows data to be self-normalised against 
changes in cell density that occur outside of the wound due to cell proliferation. For 
endothelial cell migration, cells were treated with media that contained a higher 
concentration of VEGF (20 ng.mL-1) and lower concentration of serum (0.2%) 
compared to normal EBM-2 media supplemented with a BulletKitTM. This was to 
stimulate migration and reduce proliferation.  
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Figure 11 IncucyteTM Kinetic Imaging System and Essen WoundmakerTM 
The IncuctyeTM Kinetic Imaging System (left) consists of a microscope inside an 
incubator and permits long-term live content imaging of cells. The Essen 
WoundmakerTM (right upper and lower) is capable of making a linear scratch in each 
well of a 96-well plate. 
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2.9 In vitro Co-Culture Tube Formation Assay 
In vitro tube formation was studied using an endothelial/fibroblast co-culture assay 
(Figure 12). Normal Human Dermal Fibroblasts (NHDF, Lonza) were seeded at 
6,000 cells per well in a 96 well plate (Greiner Bio-one) and allowed to grow to a 
confluent monolayer over 4 days. On day 5, endothelial cells were seeded on top of 
the fibroblast monolayer at 6,000 cells per well and allowed to grow overnight. Over 
the next 5 days endothelial cells reliably grew into tube structures and were treated 
daily with either AZD1775 (1 μM) or vehicle control (days 6-10). On day 11 cells 
were stained for CD31 to assess tube formation.  
 
For staining, cells were fixed in 4% paraformaldehyde and permeabilised with 0.1% 
TritonX-100 at room temperature. After three washes in PBS the cells were blocked 
in donkey serum for 30 mins at 37°C. Cells were then incubated with 1% BSA in 
PBS containing mouse anti-human CD31 (Dako, Clone JCT0A) at 1:300 dilution for 
1 hr at 37°C. Following washing, cells were incubated with Alexa 488-conjugated 
Affinipure Donkey anti-Mouse IgG (Jackson Immuno Research Laboratories) at 
1:300 dilution for 45 mins at 37°C. After this cells were incubated with 100 μL PBS 
and imaged on the IncucyteTM FLR Kinetic Imaging System in phase-contrast and 
fluorescence mode using a x10 objective. Tube length, number of branch points and 
tube surface area were calculated using inbuilt algorithms. 
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Figure 12 In vitro Co-Culture Tube Formation Assay 
1. 6,000 normal human dermal fibroblasts are plated into a well of a 96 well plate 2. After 4 days they reach confluence 3. 6,000 
endothelial cells are plated on top of the confluent normal human dermal fibroblasts 4. Over the next 5 days the endothelial cells grow 
into tube like structures that can be stained with Alexa 488 conjugated CD31 and imaged on the IncucyteTM Kinetic Imaging System. 
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2.10 Matrigel® Tube Formation Assay 
An alternative way to asses tube formation is by the use of Matrigel®. When applied 
to Matrigel®, endothelial cells form tube like structures. Matrigel® (Corning) was 
plated onto each well of a 96-well plate (Nunc) at a concentration of 10 mg.mL-1 and 
incubated at 37°C overnight. The following morning 20,000 endothelial cells were 
plated into each well containing Matrigel®. Over the space of 24 hrs the endothelial 
cells reliably grew into tube-like structures and plates were imaged on the 
IncucyteTM FLR Kinetic Imaging System. To assess tube formation the number of 
complete loops were counted and compared to conditions when Matrigel® was not 
present.  
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2.11 Flow Cytometry 
2.11.1 General Principles 
Flow cytometry is an analytical technique that utilizes light to count and profile cells. 
It can be used to measure multiple parameters of individual cells within a 
heterogeneous population. It performs this analysis by passing thousands of cells 
through a laser beam, capturing the light that emerges from each cell as it passes 
through. There are several components to a flow cytometer, including a fluidics 
system, lasers, optics, detectors and an electronic processing system (Figure 13).  
 
 
Figure 13 Components of a Flow Cytometer 
A fluidics system delivers cells in a single file to a laser. As the cells pass through 
the laser it causes light to scatter which can be registered by detectors. The 
detectors convert light intensity into a voltage pulse which is processed by the 
electronic processing system. Adapted from ThermoFisher Scientific (2016). 
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During flow cytometry, it is important that cells are analysed one at a time, therefore 
an injected cell suspension must be converted into a stream of fluid consisting of 
single cells only. To achieve this, sheath fluid is used to haemodynamically focus 
the cell suspension through a small nozzle. Once in single file, cells progress 
towards the laser. As a cell passes through a laser it will refract (“scatter”) light at all 
angles. There are two important measures of scatter; “forward-scatter” and 
“sideward-scatter” (Figure 14). Forward-scatter is the amount of light that is 
scattered in the forward direction and is approximately proportional to the size of 
the cell. Side-scatter is caused by structural complexity within the cell. It is focused 
through a lens system to a separate detector. Both detectors convert the light 
intensity into a voltage pulse, which is recorded by the electronic processing 
system.  
 
In addition to light scatter detectors, flow cytometers have fluorescence detectors. 
Characteristics of cells can be analysed using fluorophore labelled antibodies 
(Figure 15). Laser light of a specific wavelength excites fluorophores to a higher 
energy level. This is followed by the return of the fluorophore to its ground state with 
the emission of light. The energy in the emitted light is dependent upon the energy 
level to which the fluorophore is excited. The emission light will have a specific 
wavelength and a specific colour. This is directed to the appropriate detector where 
it is also converted into a voltage pulse and recorded by the electronic processing 
system.  
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Figure 14 Forward and Side Scatter 
As a cell passes through the laser beam it will scatter the light. Forward scatter is 
the amount of light scattered in the forward direction and provides a measurement 
of cell size (left). Side scatter reveals structural complexity within the cell (right). 
Adapted from ThermoFisher Scientific (2016). 
 
 
Figure 15 Measurement of Fluorescence 
Fluorophores bound to specific antibodies are excited to a higher energy level by 
laser light of a specific wavelength. As it returns to its ground state it emits light, the 
colour and energy of which can be registered by detectors and converted to voltage 
pulses. Adapted from ThermoFisher Scientific (2016). 
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2.11.2 Sample Preparation 
All experiments were undertaken on 6-well plates. Cells were seeded overnight and 
treated the following morning. At the end of the experiment, cells, media and drugs 
were removed and washed with PBS. Following this, the cells were trypsinised and 
placed in a 15 mL falcon tube with fresh media. The samples were centrifuged at 
1,000 RPM for 5 mins. All medium was then removed and 0.5 mL ice cold 70% 
ethanol was added dropwise to each sample under continuous agitation. Ethanol 
allows permeabilisation of the cells. The samples were immediately frozen at -20ºC 
until analysis was performed.  
 
2.11.3 Cell Cycle Analysis 
Propidium Iodide (PI) is a fluorescent dye that intercalates with DNA and RNA in a 
stoichiometric fashion. As PI binds to both DNA and RNA, the latter must be 
removed by digestion with ribonucleases. Forty-eight hours after freezing samples 
with ethanol they were retrieved and centrifuged at 1,000 RPM for 5 mins. The 
samples were then washed in PBS and re-centrifuged before 0.5 mL PI-RNAse 
Staining Buffer (BD Biosciences) was added per 1x106 cells. Samples were 
incubated at room temperature for 15 mins before being run on the flow cytometer.  
 
DNA histograms can provide information about how cells in a sample are 
distributed throughout the cell cycle. They are generated by plotting the PI 
fluorescence (measured as the voltage pulse area and assigned an arbitrary 
channel number) on the x-axis against the number of cells per channel number on 
the y-axis (Figure 16 upper left). Normal diploid cells in G0 or G1-phase contain 2N 
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DNA. Cells in G2/M phase contain double the amount of DNA (4N). Cells with DNA 
contents between 2N and 4N are in S phase.  
 
Cell clumping was eliminated from the dataset by gating. If 2 cells in the G0 or G1-
Phase were clumped together (“doublet”) and passed through the laser they would 
register as having 4N, incorrectly labelling the cell as being in G2/M phase. 
Doublets were eliminated by gating cells based on the voltage pulse width versus 
the voltage pulse area of the PI signal (Figure 16 upper right). This takes into 
account the fact that it takes longer for a doublet to pass through the laser beam 
than a single cell. This makes the width of the signal larger for doublets than single 
cells, whilst the area is the same (Figure 16 bottom). Only single cell events are 
highlighted in the gate. 
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Figure 16 Eliminating Doublets from Cell Cycle Analysis 
DNA histograms (upper left) are generated by measuring the PI signal against cell 
count and follows that cells in G2/M phase have twice the DNA content (4N) 
compared to G1 Phase (2N). By plotting PI width vs PI area doublets can be 
excluded from analysis (upper right). This is because although singlets and 
doublets have the same area signal, it takes longer for a doublet to pass through 
the laser resulting in a larger width signal (bottom). 
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2.11.4 γH2AX Detection  
Histones are highly basic proteins that complex with DNA to form chromatin. The 
H2AX histone belongs to the H2A histone family. Members of this family are 
components of nucleosomal histone octamers. Double-stranded DNA breaks 
resulting from a magnitude of processes, including replication errors and cytotoxic 
agents, lead to the phosphorylation of H2AX on serine 139. Phosphorylation 
specifically at this site is termed γH2AX. γH2AX recruits and localises proteins to 
repair DNA, maintaining genomic stability and preventing oncogenic transformation. 
Thus, γH2AX can be used as a specific marker to measure double-stranded DNA 
breaks.  
 
To detect γH2AX, samples were defrosted, washed twice with 1 mL PBS and then 
incubated with 5 μL Alexa Fluor 488 Mouse anti-H2AX (BD Biosciences) in 50 μL 
PBS per test for 20 mins at room temperature. Following incubation, samples were 
washed again with 1 mL PBS before adding 0.5 mL PI-RNAse Staining Buffer per 
1x106 cells. Samples were incubated at room temperature for 15 mins before 
analysis on the flow cytometer.  
 
As two fluorophores were used in this experiment compensation needed to be 
made for the spectral overlap of the fluorescence emission profiles. Figure 17 
shows the fluorescence emission profiles for Alexa 488 and PI, showing overlap 
between 560 nm and 600 nm. If this were not compensated for, filters for one 
fluorophore could capture fluorescence emitted by the other fluorophore at these 
wavelengths. To eliminate this, samples were run with a single fluorophore (e.g. 
Alexa 488) and the mean fluorescence values for both the positive (fluorophore 
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present in sample) and negative (no fluorophore in sample) populations were 
corrected to be equal in the other fluorophore channel (e.g. PI).  
 
 
Figure 17 Fluorescence Emission Profiles for Alexa 488 and PI  
Alexa 488 and PI have a small area of fluorescence emission overlap. If not, 
corrected filters for PI could detect fluorescence emitted by Alexa 488 and vice 
versa. Adapted from ThermoFisher Scientific (2016). 
 
To identify the subset of γH2AX positive cells a specific gating strategy was 
employed. Firstly a plot of forward-scatter versus side-scatter was created to 
ensure one population of cells (Figure 18 upper left). Next, a plot of PI width versus 
PI area was created to separate singlet and doublet events (Figure 18 upper right). 
To identify γH2AX positive cells a negative and positive control were used to set the 
threshold fluorescence intensity (Figure 18 bottom left). Finally, PI-area was plotted 
against Alexa 488-area (Figure 18 bottom right) with the gate indicating cells 
positive for γH2AX. 
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Figure 18 Gating Strategy for the Detection of γH2AX Positive Cells 
To ensure one population of cells were studied a plot of forward-scatter versus 
side-scatter was created (upper left). Next doublets were removed by gating PI 
width versus PI area (upper right). The gate highlights singlets only. To identify 
γH2AX positive cells a negative and positive control were used to set the threshold 
fluorescence intensity (bottom left). Finally γH2AX cells were identified by plotting 
PI-area against Alexa 488-area (bottom right). The blue dots in the gate are γH2AX 
positive cells. The red dots outside the gate are γH2AX negative cells 
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2.11.5 pHH3 Detection 
Detection of pHH3 followed broadly the same principles as γH2AX detection. 
Histone H3 is phosphorylated at serine 28 during mammalian cell mitosis and 
meiosis, specifically in the transition from prophase to anaphase. 
 
To detect pHH3 samples were defrosted, washed twice with 1 mL PBS and then 
incubated with 20 μL Alexa Fluor 647 Rat anti-Histone H3 (pS28) (BD Biosciences) 
in 80 μL PBS for 20 mins at room temperature. Following incubation, samples were 
washed again with 1 mL PBS before adding 0.5 mL PI-RNAse Staining Buffer per 
1x106 cells. Samples were incubated at room temperature for 15 mins before 
analysis on the flow cytometer.  
 
2.11.6 Data Analysis 
All flow cytometry work was undertaken on a BD-LSR Fortessa Flow Cytometer. All 
pHH3 and γH2AX analysis was undertaken using BD FACSDiva v6.2 software. Cell 
cycle analysis was performed using ModFit LT software.  
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2.12 Intracellular Ca2+ Measurement 
Fura-2 is a ratiometric Ca2+ indicator dye which permits the measurement of 
intracellular Ca2+.  It is excited at 340 nm and 380 nm and the ratio of emission at 
510 nm calculated. Once bound to Ca2+ there is a spectral shift in Fura-2 absorption 
which is proportional to the intracellular concentration of Ca2+. This causes a 
change in the ratio which can be measured (∆ F Ratio).  
 
To test changes in intracellular Ca2+ concentration, a FlexStation II384 (Molecular 
Devices, California) bench-top fluorometer was used (Figure 19). This can be 
utilised for kinetic fluorescence experiments using a 96-well based assay. 
Endothelial cells were grown to confluence in a 96-well plate overnight. The 
following morning medium was removed and cells in each well were incubated with 
50 μL Fura-2 loading solution for 1 hr at 37 ºC in a 5% CO2 incubator. The Fura-2 
loading solution consisted of 2 µM Fura-2 AM and 0.01% Pluronic Acid in Standard 
Bath Solution (Ca2+-SBS) consisting of 130 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 
1.5 mM CaCl2, 8 mM D-Glucose and 10 mM HEPES. After 1 hr the loading solution 
was removed and 80 μL of Ca2+-SBS was added to each well and left at room 
temperature for 10 mins. A compound plate was prepared containing drugs to be 
tested (VEGF/Yoda1/ATP/Ionomycin) at twice the final concentration in Ca2+-SBS. 
The FlexStation II384 was set to add 80 μL of the compound solution to each well on 
the test plate containing 80 μL of Ca2+-SBS.  Baseline fluorescence ratios were 
recorded before the addition of the compound solution to the cell plate after 60 
seconds, with regular recordings thereafter for a total of 5-10 mins.  
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Figure 19 Flexstation II (Molecular Devices)  
Flexstation II device with areas of interest highlighted. The assay plate consisted of 
a confluent monolayer of endothelial cells loaded with the intracellular Ca2+ indicator 
Fura-2 AM. The tip box area contained pipette tips that transferred drugs from the 
compound plate to the assay plate. The SoftMax Pro program was used to acquire 
data.  
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2.13 Immunocytochemistry 
Endothelial cells were seeded and grown to 80% confluence on glass coverslips in 
a 24 well plate. After removal of media, cells were washed in PBS and fixed in 4% 
paraformaldehyde solution at room temperature for 5 mins. To permeabilise cells, 
0.1% Triton X-100 was applied for 5 mins at room temperature.  To prevent non-
specific antibody binding, cells were blocked with 300 μL 5% donkey serum for 1 hr. 
Primary antibodies were prepared at the appropriate concentrations by diluting in 
1% BSA solution (Table 7). Cells were incubated with primary antibody at room 
temperature for 1 hr. After washing, cells were incubated with the relevant species-
specific secondary antibodies conjugated with appropriate fluorophores at room 
temperature for 30 mins. Following incubation, cells were washed and the 
coverslips were mounted on glass slides using Prolong Gold Antifade Reagent 
(Invitrogen). This contains DAPI which was used to counterstain the nuclei of cells. 
Slides were kept at room temperature overnight and imaged the following day using 
an LSM 880 confocal microscope (Zeiss). 
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Antibody Host Species Dilution Supplier
Anti-WEE1 Mouse 1:50 Santa Cruz Biotechnology (sc-5285)
Anti-SMα Mouse 1:100 Sigma (C6198)
Anti-γH2AX Mouse 1:50 BD Biosciences (560445)
Anti-CD31 Mouse 1:100 Dako (M0823)
Anti-CD31 Rabbit 1:100 abcam (ab28364)
Anti-vWF Mouse 1:100 Dako (M0616)
Anti-VEGFR2 Goat 1:200 R+D Systems (AF357)
Anti-eNOS Rabbit 1:100 Cell Signalling Technology (#9572)
Anti-VE-Cadherin Rabbit 1:200 Invitrogen (36-1900)
Table 7 Summary of Primary Antibodies used for Immunocytochemistry 
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2.14 Caspase-3 Measurement 
Caspases (cysteine-aspartic proteases) are a family of protease enzymes playing 
essential roles in programmed cell death including apoptosis. Caspases are 
generally divided into two distinct classes: “initiator caspases”, which include 
caspase-2, -8, -9 and -10 and “effector caspases”, which include caspases-3, -6 
and -7. All caspases are produced in cells as inactive zymogens and undergo 
proteolytic activation in response to stimuli. Effector caspases cause proteolytic 
cleavage of several cellular targets, leading to cell death. Caspase-3 is activated by 
the extrinsic (death ligand) and intrinsic (mitochondrial) apoptotic pathways. 
NucView™ 488 Caspase-3 substrate is a novel cell membrane-permeable 
fluorogenic caspase substrate designed for detecting caspase-3 activity within live 
cells in real time (Figure 20). It consists of a fluorogenic DNA dye and a DEVD 
(Aspartic Acid - Glutamic Acid - Valine - Aspartic Acid) substrate moiety specific for 
caspase-3.The DEVD substrate is non-fluorescent and non-functional as a DNA 
dye. It is able to cross the cell membrane into the cytoplasm where, in the presence 
of caspase-3 it is cleaved to a high affinity DNA-dye that stains the nucleus green. 
To assess apoptosis, cells were plated onto a 6-well plate and grown overnight. The 
following morning they were treated with the relevant drugs and 5 μM NucView™488 
caspase-3 substrate (Biotium) was added to each well according to the 
manufacturer’s instructions. Cells were placed in the IncucyteTM FLR and imaged 
every hr for 24 hrs in phase contrast and fluorescence mode using a x10 objective. At 
24 hrs, the number of apoptotic cells (fluorescent green) was calculated using inbuilt 
software. Subsequently the total number of cells were calculated by staining with 5 μM 
Vybrant DyeCycle Green® (Molecular Probes, Invitrogen). The Apoptotic Index was 
calculated as the percentage of caspase-3 positive cells divided by the total number 
of cells.  
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Figure 20 NucView™ 488 Caspase-3 Assay 
The NucView™ 488 Caspase-3 substrate consists of a non-functional fluorogenic 
DNA dye and a DEVD substrate moiety specific for caspase-3. In the presence of 
capase-3 it is cleaved to a high affinity DNA-dye. Adapted from Biotium (2016). 
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2.15 Endothelial Cell Alignment 
Endothelial cells align in response to shear stress. To investigate this, endothelial 
cells were grown to 80% confluence in a 6-well plate. Shear stress was achieved by 
placing the cells on an orbital shaker for 48 hrs (180 RPM). The swirling motion of 
the media around the edge of the wells produces tangential shear stress, resulting 
in cell elongation and alignment. After 48 hrs, cells were imaged using the 
IncucyteTM Kinetic Imaging System (Essen Bioscience, Michigan).  Images were 
analysed using ImageJ software to determine the degree of alignment. To do this, 
images were rotated to the direction of applied shear stress and were processed 
using a Difference of Gaussian plugin to define cell edges 
(http://www.sussex.ac.uk/gdsc/intranet/microscopy/imagej/utility). Quantification of 
cell orientation relative to the direction of shear stress was determined using 
OrientationJ software (http://bigwww.epfl.ch/demo/orientation/). OrientationJ 
generates a histogram of all local angles in each image and a Gaussian distribution 
curve was fitted. From this, the baseline-subtracted frequency maximum at the 
mode of the distribution was determined. 
 
2.16 RNA Interference Screening 
RNA Interference screening was performed by Dr Heather Martin (University of 
Leeds) and involves high-throughput imaging combined with siRNA gene silencing. 
Briefly, reverse transfection was undertaken on a 96-well plate using Dharmacon 
siGenome siRNA (50 nM per well), 0.1 µL RNAiMAX and 5,000 HUVECs per well. 
siRNA from ion channel, GPCR, Kinase, Phosphatase and Apoptosis libraries was 
transfected. Cells were incubated for 72hrs before being stained with Hoescht 
(1:1000). Cells were then fixed, imaged and analysed with plate-wise robust Z 
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scores (sample median - plate median / median absolute deviation). In a second 
validation screen reverse transfection was undertaken on a 96-well plate using 
Dharmacon On-Target Plus siRNA (50 nM per well) with other steps remaining 
unchanged. Genes with a robust Z-score of  >2 or <-2 on the RNA interference 
screen corresponded to a p-value of <0.05 and were deemed significant. 
2.17 Proteomic Studies 
2.17.1.Sample Preparation 
Matched human liver endothelial cells and endothelial cells from colorectal cancer 
liver metastases were culture expanded in T25 flasks up to passage 3. Cells were 
lysed in filter-aided sample preparation buffer which consisted of 100 mM Tris-HCl 
(pH 7.6), 4% w/w SDS, MiniComplete protease inhibitors (Roche 1:500), and 
PhosSTOP phosphatase inhibitors (Roche 1:500). The lysate was centrifuged at 
13,000 RPM 4 ˚C for 10 mins and the soluble protein layer aspirated. Samples were 
quantified using the Bio-Rad Protein Assay (Bio-Rad) and immediately frozen at      
-80°C. Once all samples were collected, they were sent on dry ice to Dundee Cell 
Products for proteomic analysis.  
 
2.17.2 TMT-Labelling and High pH reversed-phase 
chromatography 
All proteomic experiments were performed by Dundee Cell Products. Aliquots of 
100 µg of six samples per experiment were digested with trypsin (2.5 µg trypsin per 
100 µg protein; 37°C, overnight), labelled with Tandem Mass Tag (TMT) ten-plex 
reagents according to the manufacturer’s protocol (Thermo Fisher Scientific) and 
the labelled samples pooled. 
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An aliquot of the pooled sample was evaporated to dryness and re-suspended in 
buffer A (20 mM ammonium hydroxide, pH 10) prior to fractionation by high pH 
reversed-phase chromatography using an Ultimate 3000 liquid chromatography 
system (Thermo Fisher Scientific).  In brief, the sample was loaded onto an XBridge 
BEH C18 Column (130Å, 3.5 µm, 2.1 mm X 150 mm, Waters, UK) in buffer A and 
peptides eluted with an increasing gradient of buffer B (20 mM Ammonium 
Hydroxide in acetonitrile, pH 10) from 0-95% over 60 mins.  The resulting fractions 
were evaporated to dryness and re-suspended in 1% formic acid prior to analysis 
by nano-LC MSMS using an Orbitrap Fusion Tribrid mass spectrometer (Thermo 
Scientific). 
 
2.17.3 Nano-LC Mass Spectrometry 
High pH RP fractions were further fractionated using an Ultimate 3000 nanoHPLC 
system in line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo 
Scientific).  In brief, peptides in 1% (vol/vol) formic acid were injected onto an 
Acclaim PepMap C18 nano-trap column (Thermo Scientific). After washing with 
0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were resolved on a 
250 mm × 75 μm Acclaim PepMap C18 reverse phase analytical column (Thermo 
Scientific) over a 150 min organic gradient, using 7 gradient segments (1-6% 
solvent B over 1min., 6-15%B over 58min., 15-32%B over 58min., 32-40%B over 
5min., 40-90%B over 1min., held at 90%B for 6min and then reduced to 1%B over 
1min.) with a flow rate of 300 nL.min−1. Solvent A was 0.1% formic acid and Solvent 
B was aqueous 80% acetonitrile in 0.1% formic acid.  Peptides were ionized by 
nano-electrospray ionization at 2.0 kV using a stainless steel emitter with an 
internal diameter of 30 μm (Thermo Scientific) and a capillary temperature of 
275°C.  
- 97 - 
 
 
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer 
controlled by Xcalibur 1.9 software (Thermo Scientific) and operated in data-
dependent acquisition mode using an SPS-MS3 workflow.  FTMS1 spectra were 
collected at a resolution of 120 000, with an automatic gain control (AGC) target of 
400 000 and a max injection time of 100 ms. The TopN most intense ions were 
selected for MS/MS.  Precursors were filtered according to charge state (to include 
charge states 2-6) and with monoisotopic precursor selection. Previously 
interrogated precursors were excluded using a dynamic window (40s +/-10 ppm). 
The MS2 precursors were isolated with a quadrupole mass filter set to a width of 
1.2m/z. ITMS2 spectra were collected with an AGC target of 5000, max injection 
time of 70 ms and CID collision energy of 35%. 
 
For FTMS3 analysis, the Orbitrap was operated at 30 000 resolution with an AGC 
target of 50 000 and a max injection time of 105 ms.  Precursors were fragmented 
by high energy collision dissociation (HCD) at a normalised collision energy of 55% 
to ensure maximal TMT reporter ion yield.  Synchronous Precursor Selection (SPS) 
was enabled to include up to 10 MS2 fragment ions in the FTMS3 scan. 
 
2.17.4 Data Analysis 
The raw data files were processed and quantified using Proteome Discoverer 
software v1.4 (Thermo Scientific) and searched against the UniProt Human 
database (downloaded 08/11/14: 126385 entries) using the SEQUEST algorithm.  
Peptide precursor mass tolerance was set at 10 ppm, and MS/MS tolerance was 
set at 0.6Da.  Search criteria included oxidation of methionine (+15.9949) as a 
variable modification and carbamidomethylation of cysteine (+57.0214) and the 
addition of the TMT mass tag (+229.163) to peptide N-termini and lysine as fixed 
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modifications. Searches were performed with full tryptic digestion and a maximum 
of 1 missed cleavage was allowed. The reverse database search option was 
enabled and all peptide data was filtered to satisfy false discovery rate (FDR) of 
5%.   
 
2.18  Generation of Endothelial Specific Piezo1 Knockout 
Mice 
All animal work including organ harvesting was performed by Dr Baptiste Rode 
(University of Leeds). All animal work was approved by the University of Leeds 
Animal Ethics Committee and by The Home Office, UK (Ref: 40/3557 and 
P606320FB). All animals were maintained in GM500 individually ventilated cages 
(Animal Care Systems), at 21°C 50–70% humidity, light/dark cycle 12/12 hrs on 
RM1 diet (SpecialDiet Services, Witham,UK) ad libitum and bedding of Pure‘o Cell® 
(Datesand, Manchester, UK). All animal use was authorised by the University of 
Leeds Animal Ethics Committee and The Home Office, UK. Genotypes were 
determined using real-time PCR with specific probes designed for each gene 
(Transnetyx, Cordova, TN). 
 
To generate tamoxifen inducible deletion of the Piezo1 gene in endothelial cells of 
adult mice, C57BL/6 Piezo1flox mice were crossed with C57BL/6 mice expressing 
cre recombinase under the Cadherin5 promoter (Tg(Cdh5-cre/ERT2)1Rha) and 
inbred to obtain C57BL/6 Piezo1flox/flox/Cdh5-cre mice. Tamoxifen (Sigma-Aldrich) 
was dissolved in corn oil (Sigma-Aldrich) at 20 mg.mL-1. Adult male mice (aged 12 
to 16 weeks) were injected intra-peritoneal with 75 mg.kg-1 tamoxifen for 5 
consecutive days and liver tissues was harvested 10 to 14 days following the last 
tamoxifen injection. Piezo1flox/flox/Cdh5-cre mice that received tamoxifen injections 
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and therefore had Piezo1 deleted from their endothelial cells were referred as 
Piezo1ΔEC,  Piezo1flox/flox littermates that received tamoxifen injections and therefore 
retained endothelial cell Piezo1 were referred as Control.  
 
2.19  Data Analysis 
Origin® 8.6 software was used for data analysis and presentation. Data are 
expressed as mean +/- standard error of the mean. Data were checked for 
normality using the Shapiro-Wilk test. If normally distributed, statistical comparisons 
were made using the Student’s T-Test. Data sets with more than two groups were 
compared using a one-way ANOVA test with a post-hoc Bonferroni correction. 
Statistical significance is indicated by * (p<0.05), ** (p<0.01) and *** (p<0.001). No 
significant difference is indicated by NS (p>0.05). The number of independent 
experiments is indicated by ‘n’. For multiwell assays, the number of replicate wells 
is indicated by ‘N’.  
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Chapter 3: Characterisation of Colorectal Cancer Liver 
Metastases Endothelial Cells  
Much of our understanding about the biology of tumour angiogenesis is based upon 
experiments undertaken in HUVECs. Although easy to culture and study, it is 
important to note that tumour angiogenesis most commonly involves the 
microvasculature rather than the macrovasculature. Furthermore, there is 
increasing evidence that TECs are genetically and phenotypically distinct from 
normal endothelial cells (Dudley, 2012). Therefore,  conclusions derived from in 
vitro studies using HUVECs may lead to inaccurate assumptions about true tumour 
angiogenesis. 
Anti-angiogenic agents have been utilised in the treatment of metastatic colorectal 
cancer for over a decade. However, promising pre-clinical studies have not really 
translated into radical improvements in patient outcomes. The majority of licensed 
therapeutics target the VEGF-VEGFR-2 signalling pathway, which has been 
established as the main regulator of angiogenesis, but it appears that tumours can 
resort to other mechanisms to result in treatment resistance. These pathways are 
not fully understood, in part, due to a lack of specific knowledge about the 
properties and molecular mechanisms of CLM endothelial cells. Another approach 
to inhibiting CLM angiogenesis would be to directly target mechanisms essential to 
TEC survival. Identification of these critical mechanisms would involve the isolation 
and detailed study of CLM endothelial cells, a feat which has not yet been 
achieved.  
The aim of this chapter was to successfully isolate and characterise CLM 
endothelial cells and identify a new anti-angiogenic target relevant for their survival. 
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3.1 Endothelial Cells Isolated from Colorectal Cancer Liver 
Metastases Express Recognised Endothelial Markers 
Endothelial cells were isolated and cultured from CLM and surrounding 
macroscopically normal liver in patients undergoing curative hepatic resection. 
Immunofluorescent staining of CLM endothelial cells (CLMECs) confirmed 
expression of the endothelial intercellular-junction protein CD31 (Figure 21a).  
Western blotting also confirmed the presence of CD31 in healthy liver endothelial 
cells (LECs) as well as CLMECs, but not in the colorectal cancer cell line HT29 
(Figure 21b). Quantification of the CD31 band intensity relative to the β-actin 
loading control in matched samples revealed the expression of CD31 to be 64% 
lower in CLMECs (Figure 21c). To further validate the endothelial nature of 
CLMECs, immunofluorescent staining of additional endothelial markers was 
performed. CLMECs stained positively for VE-Cadherin, VEGFR-2, von Willebrand 
Factor (vWF) and endothelial Nitric Oxide Synthase (eNOS) (Figure 22). 
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Figure 21 Isolated LECs and CLMECs Express CD31 
a. Immunofluorescence images of CLMECs stained with anti-CD31 antibody 
(green) and DAPI to label nuclei (blue). Scale bars 20 μm b. Example western blot 
labelled with anti-CD31 and anti--actin antibodies for matched LECs and CLMECs 
and a human colorectal adenocarcinoma cell line (HT29) c. Quantification of the 
CLMEC CD31 band intensity relative to -actin and normalised to LEC (n=3 each). 
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Figure 22 CLMECs Express Recognised Endothelial Markers 
Immunofluorescence images of CLMECs stained with anti-VE-Cadherin (turquoise), 
anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2, red), anti-von 
Willebrand Factor (vWF, green) and anti-endothelial Nitric Oxide Synthase (eNOS, 
orange). In each image nuclei were labelled with DAPI (blue). Control images in the 
absence of the primary antibodies are shown on the right. Scale bars 20 μm. 
 
 
 
 
 
 
 
 
 
 
 
VE-Cadherin VEGFR-2
vWF eNOS DAPI (no 1 Ab) (Mouse) 
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3.2 VEGF Evokes Ca2+ Entry in LECs and CLMECs 
The VEGF-VEGFR-2 signalling pathway has been established as the main 
regulator of angiogenesis. To establish the presence of this pathway, firstly, 
western blotting was performed to confirm VEGFR-2 expression in matched LECs 
and CLMECs (Figure 23a). Quantification of the VEGFR-2 band intensity relative to 
the β-actin loading control revealed the expression of VEGFR-2 to be 55% lower in 
CLMECs (Figure 23b).  
 
Intracellular Ca2+ elevation is an early event in the action of VEGF acting through 
VEGFR-2 in endothelial cells (Li et al., 2015). To elicit this response, matched LECs 
and CLMECs were stimulated with a physiological concentration of VEGF                    
(30 ng.mL-1) in the presence of extracellular Ca2+ and intracellular Ca2+ 
concentrations were recorded. In both LECs and CLMECs, application of VEGF 
resulted in an increase in intracellular Ca2+ that reached a peak after 220 seconds 
followed by a sustained phase that remained above the baseline for at least 600 
seconds (Figure 23c). The peak intracellular Ca2+ response in CLMECs was 53% 
lower than in matched LECs (Figure 23d). There was less difference in the 
sustained response, which was 31% lower in CLMECs (Figure 23d). 
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Figure 23 CLMEC VEGF-Evoked Ca2+ Entry is Decreased Compared to Matched LECs  
a. Example western blot labelled with anti-VEGFR-2 and anti--actin antibodies for matched LECs and CLMECs b. Quantification of the CLMEC 
VEGFR-2 band intensity relative to -actin and normalised to LEC (n=3 each) c. Intracellular Ca2+ measurement data from matched LECs (left) 
and CLMECs (right). Traces show averaged responses to 30 ng.mL-1 VEGF across multiple wells of a 96-well plate compared to control (N=5 
wells each) d. Mean data for the peak (200 s) and sustained (600 s) responses to VEGF of the type exemplified in c (n=3, N=15 each). 
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3.3 CLMECs Have Endothelial Specific Functional Properties 
To determine if CLMECs behaved functionally like endothelial cells, alignment in 
response to shear stress and tube formation in the presence of Matrigel® was 
investigated.  
 
Endothelial cells align in response to shear stress, a process occurring 
physiologically in blood vessels as a result of blood flow (Li et al., 2014). In static 
conditions, CLMECs grew into a “cobblestone” monolayer, typical for endothelial 
cell growth in vitro. In contrast, after 48 hrs of shear stress, CLMECs appeared to 
align to the direction of flow (Figure 24a). Analysis of CLMECs exposed to shear 
stress revealed a peak in the number of cells orientated to the direction of flow (0°) 
confirming alignment (Figure 24b,c).  
 
The formation of capillary-like structures on the artificial basement membrane 
extracellular matrix Matrigel® is a behaviour specific to endothelial cells (Arnaoutova 
et al., 2009). In the presence of Matrigel®, CLMECs rapidly formed capillary-like 
structures in less than 12 hrs (Figure 25a). The number of capillary-like structures 
were quantified by counting the number of complete loops. With Matrigel®, 25 
complete loops were observed, whereas in the absence of Matrigel®, CLMECs grew 
into a confluent monolayer and no capillary-like structures were observed (Figure 
25b).  
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Figure 24 CLMECs Align in Response to Shear Stress 
a. Images of CLMECs in static condition and after shear stress. Scale bars 80 μm 
b. Example orientation analysis for the images shown in a c. Mean data for the 
analysis shown in b (n=3, N=18). 
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Figure 25 CLMECs Form Tubular Structures when Grown on Matrigel® 
a. Images of CLMECs in the absence and presence of Matrigel®. Scale bars 250 
μm b. Quantification of the number of complete loops seen in images of the type 
shown in a (n=4, N=12). 
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3.4 RNA Interference Screen Reveals WEE1 to have Critical 
Role in Regulating Endothelial Cell Proliferation 
To help determine which proteins are important for CLMEC proliferation, results of 
an unbiased RNA interference screen in HUVECS performed by Dr Heather Martin 
(University of Leeds) were analysed. The screen was performed prior to the 
commencement of this research project and consisted of an initial screen followed 
by a validation screen with different siRNA chemistry. To identify potential anti-
angiogenic targets, plate wide robust Z-scores were calculated for each gene with a 
robust Z-score of -2 or less indicating a significant inhibition of proliferation. In total, 
12 genes were identified to significantly inhibit HUVEC proliferation (Figure 26a). A 
review of the literature indicated two related proteins involved in cell cycle 
regulation, WEE1 and CDK1.  
 
WEE1 is a tyrosine kinase that forms a crucial component of the G2/M checkpoint, 
preventing cells from entering mitosis with unrepaired DNA damage by regulating 
the phosphorylation of cyclin B bound cyclin dependent kinase 1 (CDK1) at Tyr15. 
As WEE1 regulates CDK1 activity and had a clear anti-proliferative effect (Figure 
26b) that was greater than CDK1 (mean robust Z-score -4.05 vs -2.52) it was 
selected for further investigation.  
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Figure 26 RNA Interference Screen Identifies WEE1 as a Regulator of 
HUVEC Proliferation 
a. Table of results for the RNA interference screen in HUVECs performed by Dr 
Heather Martin (University of Leeds). All proteins that significantly inhibited 
proliferation are displayed. Plate wise robust Z-scores are provided for the initial 
and validation screens. A Z-score of less than -2 suggests the protein significantly 
inhibits HUVEC proliferation (p<0.05) b. Example images of Hoechst staining of 
HUVECs 72 hrs after transfection with scrambled siRNA (Scr) or with siGENOME 
WEE1 siRNA (siWEE1) as part of the initial RNA interference screen. Scale bars 50 
μm. 
Gene Initial Screen Z Score Validation Screen Z Score
PLK1 -2.85 -9.43
PPP1R12B -2.75 -5.73
WEE1 -2.72 -5.37
KCNS2 -3.36 -4.77
TNFRSF1B -2.37 -3.92
PIK3C2A -2.99 -3.82
FN3KRP -3.03 -3.58
MAPK1 -3.10 -3.42
ALPP -2.08 -3.26
NT5E -2.96 -3.06
CDK1 -2.34 -2.70
PPP5C -2.42 -2.09
Scr siWEE1
a
b
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3.5 Genetic and Chemical Inhibition of WEE1 Inhibits HUVEC 
Proliferation 
To validate the RNA interference results, transfection of HUVECs was performed 
with pooled WEE1 siRNA and its effects on proliferation were measured using a 
Vybrant® DyeCycleTM Green proliferation assay. In non-transfected HUVECs, 
western blotting confirmed a single band the expected size for WEE1 (96 kDa) 
(Figure 27a). Knockdown of WEE1 by siRNA decreased the single band intensity 
(Figure 27a). Quantification of the WEE1 band intensity relative to the β-actin 
loading control revealed the expression of WEE1 to be 66% lower in HUVECs 
transfected with WEE1 siRNA compared to scrambled siRNA (Figure 27b). 
Proliferation was measured 48 hrs after transfection using the nuclear dye Vybrant® 
Green (Figure 27c). Transfection with siRNA against WEE1 inhibited proliferation 
by 53% compared to scrambled siRNA (Figure 27d). 
 
AZD1775, a small molecule WEE1 inhibitor, was used to achieve chemical 
inhibition of WEE1 and its effects on proliferation were measured using a WST-1 
proliferation assay. After 48 hrs of treatment AZD1775 (1 μM) inhibited HUVEC 
proliferation by 83% compared to vehicle control (Figure 28a). A concentration-
response curve was constructed for the effect of AZD1775 on HUVEC proliferation. 
The derived IC50 for AZD1775 against HUVEC proliferation was 365 nM (Figure 
28b). 
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Figure 27 Genetic Inhibition of WEE1 Decreases Proliferation in 
HUVECs 
a. Example western blot labelled with anti-WEE1 and anti--actin antibodies for 
non-transfected (NT) HUVECs and HUVECs transfected with scrambled siRNA 
(Scr) or ON-TARGETplus WEE1 siRNA (siWEE1) b. Quantification of the siWEE1 
group WEE1 band intensity relative to -actin and normalised to the Scr group (n=3 
each) c. Fluorescence images of HUVECs 48 hrs after transfection with scrambled 
siRNA (Scr) or ON-TARGETplus WEE1 siRNA (siWEE1). Fluorescence was from 
cell nuclei stained with Vybrant® Dye Cycle™ (green). Scale bars 400 μm d. 
Quantification of the number of HUVECs seen in the images of the type shown in c. 
The siWEE1 group has been normalised to the Scr group (n=3, N=18). 
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Figure 28 Chemical Inhibition of WEE1 Decreases Proliferation in 
HUVECs 
a. Mean data for HUVEC viability measured using WST-1 reagent after treatment 
with AZD1775 (1 μM) or vehicle control (Control) for 48 hrs (n=3, N=9) b. AZD1775 
dose response curve in HUVECs. HUVECs were treated with AZD1775 at the 
indicated concentrations for 48 hrs and plotted as percentages of the vehicle control 
(n=3, N=9). 
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3.6 Genetic and Chemical Inhibition of WEE1 Regulates 
Phosphorylation of CDK1 
WEE1 regulates phosphorylation of cyclin B bound CDK1 at Tyr15. Therefore, 
western blotting was performed to check target modulation following genetic or 
chemical inhibition of WEE1. In non-transfected HUVECs, western blotting for 
pCDK1-Y15 confirmed a single band 34 kDa in size. As expected, knockdown of 
WEE1 by pooled WEE1 siRNA decreased the single band intensity (Figure 29a). 
Total CDK1 content was unchanged. Quantification of the pCDK1-Y15 to CDK1 
ratio revealed pCDK1-Y15 expression to be reduced in the siWEE1 group 
compared to scrambled group by 72% (Figure 29b). A similar effect was observed 
when treating HUVECs with AZD1775. AZD1775 reduced pCDK1-Y15 but not 
overall CDK1 (Figure 29c). Quantification of the pCDK1-Y15 to CDK1 ratio showed 
pCDK1-Y15 expression to be reduced with AZD1775 treatment by 78% compared 
to vehicle control (Figure 29d). 
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Figure 29 Genetic and Chemical Inhibition of WEE1 Decreases    
pCDK1-Y15 in HUVECs 
a. Example western blot labelled with anti-pCDK1-Y15, anti-CDK1 and anti--actin 
antibodies for non-transfected (NT) HUVECs and HUVECs transfected with 
scrambled siRNA (Scr) or ON-TARGETplus WEE1 siRNA (siWEE1) b. 
Quantification of the pCDK1-Y15 band intensity divided by the CDK1 band intensity. 
siWEE1 has been normalised to Scr (n=3 each) c. Example western blot labelled 
with anti-pCDK1-Y15, anti-CDK1 and anti--actin antibodies for HUVECs treated 
with AZD1775 (1 μM) or vehicle control (Control) for 24 hrs d. Quantification of the 
pCDK1-Y15 band intensity divided by the CDK1 band intensity. AZD1775 has been 
normalised to Control (n=3 each). 
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3.7 WEE1 is Upregulated in CLMECs 
After identifying WEE1 as a potential anti-angiogenic target in HUVECs, western 
blotting was performed in matched LECs and CLMECs to confirm the presence of 
WEE1 and compare its expression between the two cell types. As with HUVECs, a 
single band 96 kDa in size was detected in both LECs and CLMECs (Figure 30a). 
Interestingly, quantification of the WEE1 band intensity relative to the β-actin band 
intensity revealed WEE1 to be significantly upregulated in CLMECs compared to 
matched LECs (Figure 30b). In contrast, the target protein of WEE1, CDK1, was not 
upregulated in CLMECs (Figure 30c,d).  
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Figure 30 WEE1 is Upregulated in CLMECs Compared to Matched LECs 
a. Example western blot labelled with anti-WEE1 and anti--actin antibodies for 
matched LECs and CLMECs b. Quantification of the CLMEC WEE1 band intensity 
relative to -actin and normalised to LEC (n=3 each) c. Example western blot 
labelled with anti-CDK1 and anti--actin antibodies for matched LECs and CLMECs 
d. Quantification of the CLMEC CDK1 band intensity relative to -actin and 
normalised to LEC (n=3 each) 
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3.8 Summary of Findings 
 Endothelial cells isolated from colorectal cancer liver metastases behave 
superficially like other endothelial cells: 
 
1) They express CD31, vWF, VE-Cadherin, eNOS and VEGFR-2 
2) They elevate intracellular Ca2+ in response to VEGF stimulation 
3) They have a “cobblestone” appearance when grown in vitro 
4) They align in response to shear stress 
5) They form tube-like structures on Matrigel® 
 
 CLMECs have reduced CD31 and VEGFR-2 protein expression compared to 
matched LECs.  
 
 The VEGF-induced increase in intracellular Ca2+ is relatively smaller in 
CLMECs compared to matched LECs. 
 
 CLMECs have increased WEE1 protein expression compared to matched 
LECs 
 
 siRNA knockdown of WEE1 inhibits HUVEC proliferation 
 
 AZD1775 inhibits HUVEC proliferation with an IC50 of 365 nM. 
 
 WEE1 phosphorylates CDK1 at Tyr15 in HUVECs 
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3.9 Discussion 
The aim of this chapter was to successfully isolate and characterise CLMECs and 
find a new anti-angiogenic target for the treatment of CLM. CLMECs have been 
shown to be superficially similar to other types of endothelial cells, including LECs, 
exhibiting expected markers and functional characteristics. Nevertheless, 
differences in protein expression have been identified between matched LECs and 
CLMECs, including the upregulation of WEE1 and downregulation of CD31 and 
VEGFR-2. 
 
3.9.1 Characterisation of CLMECs 
To isolate CLMECs an IMS technique was used with anti-CD31 coated magnetic 
beads. The liver has a number of endothelial subtypes including those within the 
conventional vasculature (hepatic artery, arterioles, capillaries, venules, portal vein 
and hepatic veins) as well as specialised sinusoidal endothelial cells contained 
within hepatic lobules. These different subtypes have different endothelial marker 
profiles. CD31 was chosen as it is considered a pan-endothelial marker and would 
result in the highest yield of endothelial cells (Vermeulen et al., 2002). CD31 
expression was found to be lower in CLMECs than matched LECs. CD31 is a cell 
adhesion protein found at inter-cellular junctions of endothelial cells. It has a critical 
role in leucocyte trafficking across the endothelial monolayer (Muller, 2014). One 
possible explanation for downregulation of CD31 in CLMECs could be a tumour 
defence mechanism. Decreased CD31 expression could abrogate leucocyte 
extravasation, meaning tumours escape immunological attack. Although there are 
no previous reports of CD31 down-regulation in tumour endothelial cells, other 
adhesion molecules, such as ICAM-1 and VCAM-1, have been reported to be 
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down-regulated in the tumour endothelium (Griffioen et al., 1996, Alessandri et al., 
1999).  
 
A range of other endothelial markers have been used to isolate tumour endothelial 
cells previously including CD146 (St Croix et al., 2000), Endoglin (Xiong et al., 
2009) and ICAM2 (Dudley et al., 2008). However, no 100% specific marker exists 
for normal endothelial cells or tumour endothelial cells. Therefore, to further validate 
the endothelial nature of CLMECs, other endothelial markers were investigated. 
CLMECs positively expressed vWF, VE-Cadherin, eNOS and VEGFR-2, strongly 
suggesting that the isolated cells were endothelial in nature. 
 
Although endothelial cells from primary colorectal cancer have previously been 
isolated and characterised (van Beijnum et al., 2006, Schellerer et al., 2007, 
Jayasinghe et al., 2009, Mesri et al., 2013), this is the first time that endothelial cells 
from CLM have been studied in detail. The formation of tube like structures on the 
artificial membrane Matrigel® has long been used as a method of investigating 
angiogenesis. Matrigel® is a gelatinous protein mixture secreted by Engelbreth-
Holm-Swarm (EHS) mouse sarcoma cells. In vivo, the basement membrane 
regulates endothelial behaviour maintaining endothelial cells in a differentiated 
state. Rather than grow in a classical cobblestone appearance, the presence of 
Matrigel® resulted in CLMECs migrating across the Matrigel®, aligning and forming 
tube like structures within 12 hrs. This complex behaviour is specific to endothelial 
cells and does not occur with cancer cells or connective tissue cells such as 
fibroblasts. Tumour derived endothelial cells have previously been reported to be 
capable of forming chord-like structures on Matrigel® within 24 hrs of culture 
(Alessandri et al., 1999). 
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The ability of cells to align in response to shear stress is another endothelial 
specific characteristic and the way in which physical forces, such as blood flow, 
regulate endothelial vascular structure are complex. The ability of tumour 
endothelial cells to align in response to shear stress has not been reported. Our 
laboratory has recently published work on the mechanosensitive Ca2+ permeable 
ion channel Piezo1 (Fam38), which has a critical role in sensing frictional force 
(shear stress) and determining vascular structure in both development and adult 
physiology (Li et al., 2014). The role of Piezo1 in the tumour endothelium will be 
discussed in subsequent chapters of this thesis.  
 
3.9.2 The VEGF-VEGFR-2 Signalling Pathway in CLMECs 
VEGFR-2 stimulation by VEGF is thought to be the major regulator of tumour 
angiogenesis. VEGFR-2 is expressed in CLMECs and was significantly down-
regulated compared to matched LECs. The finding of decreased VEGFR-2 
expression in CLMECs disagrees with other studies which have reported increased 
VEGFR-2 expression in tumour derived endothelial cells (Alessandri et al., 1999, 
Hida et al., 2013).  
 
To examine the VEGF-VEGFR-2 signalling pathway, CLMEC Ca2+ entry was 
investigated in response to VEGF application. Intracellular Ca2+ entry is an early 
consequence of VEGF stimulation in endothelial cells (Li et al., 2015). Upon 
activation by VEGF, VEGFR-2 dimerization occurs which facilitates auto-
phosphorylation of multiple tyrosine residues along the cytoplasmic domains of 
each monomer (Schlessinger, 2000). This activates binding sites for proteins with 
Src-homology 2. One such protein is phospholipase C-γ, which upon activation 
hydrolyses its substrate phosphatidylinositol 4,5-biphosphate (PIP2) into two 
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secondary messengers, inositol triphosphate (IP3) and diacyl glycerol (DAG). IP3 
diffuses into the endoplasmic reticulum (ER) and binds to the IP3 receptor. The IP3 
receptor serves as a Ca2+ channel, and releases Ca2+ from the ER. The reduction in 
ER [Ca2+] is sensed and stimulates the influx of extracellular Ca2+ via store-
operated channels into the cell cytoplasm (Li et al., 2015). In tumour endothelial 
cells Ca2+ is important in regulating angiogenic processes including proliferation, 
migration and tube formation (Fiorio Pla and Munaron, 2014). The peak intracellular 
response (caused by Ca2+ release from intracellular stores) was significantly lower 
in CLMECs compared to matched LECs. Similarly the sustained response (caused 
by extracellular Ca2+ entry) was also significantly lower in CLMECs, although the 
magnitude of difference was not the same compared to the peak response. 
 
The decreased expression of VEGFR-2 and reduced Ca2+ signalling in CLMECs is 
an unexpected finding. As the main regulatory pathway of tumour angiogenesis, it 
may be hypothesised that VEGFR-2 would be upregulated. However, down-
regulation of VEGFR-2 may be a consequence of prolonged exposure to high 
concentrations of VEGF, which is known to be secreted by tumour cells and cells 
within the tumour microenvironment such as fibroblasts and macrophages (Goel 
and Mercurio, 2013). Downregulation of VEGFR-2 is maintained through passage 
of the cells and although the media that CLMECs were cultured in contained VEGF, 
this is not thought to be responsible for the downregulation of VEFGR-2, as 
matched LECs were also cultured in the same media. The downregulation of the 
VEGF-VEGFR2 signalling pathway in CLMECs could have significant implications 
upon the efficacy of anti-angiogenic treatments in patients. Tumours are known to 
be able to develop resistance to anti-VEGF therapy by upregulating alternative pro-
angiogenic pathways, however, some patients fail to respond to anti-VEGF therapy 
from the initiation of treatment. CLM are heterogenous and one possibility is that 
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VEGF-VEGFR-2 signalling is not as important in the growth of these tumours. This 
means that agents which target the VEGF-VEGFR-2 axis, such as bevacizumab, 
ramucirumab and regorafenib will have little benefit.  
 
3.9.3 WEE1 Inhibition as an Anti-Angiogenic Target 
The RNA interference screen revealed WEE1 to have a role in HUVEC 
proliferation. This was validated with separate pooled siRNA and with the small 
molecule WEE1 inhibitor AZD1775. Furthermore, WEE1 expression was 
upregulated in CLMECs compared to matched LECs making it a potentially 
attractive target that could be essential for CLMEC viability. 
 
3.9.3.1 WEE1 Function and Regulation 
WEE1 is a tyrosine kinase which forms part of the G2/M cell cycle checkpoint. In 
response to DNA damage, WEE1 causes phosphorylation of cyclin B bound CDK1 
on its Tyr15 residue (Watanabe et al., 1995). CDK1 regulates cell entry into mitosis 
and phosphorylation by WEE1 negatively regulates mitotic entry, allowing damaged 
DNA damage to be repaired before the cell divides. Transcriptional synthesis of 
WEE1 increases during S (DNA synthesis) phase and G2 (Growth 2) phase of the 
cell cycle and decreases during M (Mitosis) phase (Chow et al., 2011). Once a cell 
enters mitosis, the exact mechanism by which WEE1 is inactivated is not fully 
understood, however it appears to occur as a result of hyper-phosphorylation (Perry 
and Kornbluth, 2007). At the onset of mitosis, WEE1 is phosphorylated by CDK1 at 
Ser123, which generates a binding motif allowing polio-like kinase 1 (PLK1) to 
phosphorylate WEE1 at Ser53. Further phosphorylation of WEE1 by Casein Kinase 
2 at Ser121 coupled with the phosphorylated Ser123 and Ser53 residues serve as 
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phosphodegrons that target WEE1 for degradation by the ubiquitin ligase SCFβ-TrCP 
complex (Chow et al., 2011).  
Whilst WEE1 has been known historically as a key component of the G2/M 
checkpoint, more recently it has been reported to have a critical role in DNA 
synthesis during S phase (Beck et al., 2010). During replication, DNA is replicated 
exactly once and it is achieved by thousands of replication forks, which are initiated 
from replication origins spaced throughout the genome. The number of origins 
exceeds what is actually needed for replication. Other dormant origins can be fired 
as a result of replication fork stalling (Alver et al., 2014). Regulation of origin firing 
by CDKs is important to prevent excessive origin firing and replication stress. 
Therefore, regulation of CDK1 activity, by WEE1, is critical in regulating DNA 
synthesis. Recently it has been reported that WEE1 inhibition results in increased 
CDK1 activity causing increased origin firing (Beck et al., 2012). The increased 
origin firing results in increased DNA synthesis which exhausts nucleotide stores 
leading to replication fork stalling and double stranded DNA breaks (Beck et al., 
2012). 
 
3.9.3.2 WEE1 Inhibition as an Anti-Cancer Therapy 
Due to its functions as a regulator of mitosis and DNA synthesis, WEE1 has been 
targeted as an anti-cancer agent. Conventional medical therapies for cancer, such 
as chemotherapy and radiotherapy, cause cell death by inducing lethal DNA 
damage in cells. In health, DNA damage activates cell cycle checkpoints (G1, S 
and G2/M) that arrest the cell cycle allowing DNA to be repaired. Understandably 
this is an essential process in healthy cells in order to preserve genomic integrity, 
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but in cancerous cells this can limit the efficacy of DNA-damaging treatments. The 
combination of WEE1 inhibition with DNA damaging agents has emerged as an 
attractive anti-cancer treatment strategy, whereby cancer cells with lethal DNA 
damage are forced into premature mitosis with unrepaired DNA damage, resulting 
in cell death (Medema and Macurek, 2012). This is thought to be particularly 
effective in cancers with non-functioning p53 as they have a defective G1 cell cycle 
checkpoint and cannot maintain G1 arrest in response to DNA damage. Therefore, 
these cancer cells are more reliant on the G2/M checkpoint for DNA repair. 
Mutation of the tumour suppressor gene p53 is a frequent event in cancer (Rivlin et 
al., 2011) and therefore this treatment strategy is potentially applicable to a diverse 
range of cancers. Preclinical studies in several cancer lines, including colorectal 
cancer, support this treatment strategy (Wang et al., 2001, Hirai et al., 2009, Hirai et 
al., 2010, Rajeshkumar et al., 2011). At present there are over 25 clinical trials 
assessing the small molecule WEE1 inhibitor, AZD1775, in combination with DNA 
damaging agents in a range of cancers (ClinicalTrials.gov Accessed July 2016). 
 
The importance of p53 status in combination therapy has however been questioned 
after several studies demonstrated that AZD1775 sensitises cancer cells to DNA-
damaging agents independent of p53 function (Kreahling et al., 2013, Van Linden et 
al., 2013, Guertin et al., 2013, Mueller et al., 2014). At the same time, the discovery 
of the importance of WEE1 in the regulation of DNA synthesis was being made 
(Beck et al., 2012) and it was hypothesised that WEE1 inhibition in the absence of 
DNA damaging agents could be a viable anti-cancer strategy. Indeed, a number of 
studies have shown that AZD1775 is able to induce double-stranded DNA (DS-DNA) 
breaks in S phase and that cancer cell proliferation could be limited without the need for 
premature mitosis (Kreahling et al., 2012, Guertin et al., 2013, Pfister et al., 2015). The 
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first Phase I clinical trial of AZD1775 monotherapy in solid tumours has recently 
been reported confirming target modulation, safety and efficacy (Do et al., 2015).  
 
Based on the known functions of WEE1, it could be hypothesised that the reduction 
in HUVEC viability observed with WEE inhibition in this chapter is more likely a 
consequence of DS-DNA breaks rather than mitosis. This is because WEE1 
inhibition was tested in the absence of any DNA-damaging agents and therefore the 
mechanism of premature mitosis/mitotic catastrophe is not possible.  
 
3.9.3.3 The Role of WEE1 in the Endothelium 
The mechanism for WEE1 upregulation in CLMECs is unknown, but whatever the 
mechanism is it is sustained despite culturing of CLMECs under physiological 
conditions. One potential stimulus for upregulation is tumour hypoxia. In the only 
previous piece of research on WEE1 in endothelial cells, hypoxia increased WEE1 
mRNA and CDK1 phosphorylation in the MS-1 endothelial cell line (Hong et al., 
2011). However, CLMECs were cultured in the same conditions as LECs and this 
did not revert WEE1 expression in CLMECs back to the levels observed in LECs. 
 
WEE1 has been shown to be upregulated in a number of different cancers including 
colorectal cancer (Egeland et al., 2016), hepatocellular carcinoma (Masaki et al., 
2003), breast cancer (Iorns et al., 2009) and osteosarcoma (PosthumaDeBoer et 
al., 2011). Expression is shown to increase during carcinogenesis and is highest in 
metastatic disease (Magnussen et al., 2012). High WEE1 expression has been 
found to be negatively correlated with disease free survival and primary tumour 
burden (Magnussen et al., 2012). It is hypothesised that tumour cells have 
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increased expression of WEE1 to protect themselves from DNA-damage and cell 
death (Magnussen et al., 2012). This is not only because of its role in controlling 
mitotic entry, but in ensuring DNA is synthesised in a controlled and co-ordinated 
manner. In complete contrast, WEE1 has been shown to be down-regulated in non-
small cell lung cancer, and loss of WEE was associated with a poorer prognosis 
(Yoshida et al., 2004).  Here investigators hypothesised that decreased WEE1 
expression conferred an advantage to neoplastic cells by allowing faster 
progression through the cell cycle. If this were to be true one could argue that 
increased WEE1 expression would result in a slower cell cycle in CLMECs 
compared to LECs. Although proliferation was not formally compared between the 
two groups, there was no obvious difference in proliferation rate observed during 
cell culture.    
 
Preliminary work in HUVECs has shown that WEE1 has functional importance in 
endothelial cells. Pooled WEE1 siRNA generated a good knockdown of WEE1 in 
HUVECs that had clear effects on HUVEC proliferation. Reassuringly, similar 
results were observed with the small molecule WEE1 inhibitor, AZD1775. As 
expected both WEE1 siRNA and AZD1775 inhibited CDK1 phosphorylation at 
Tyr15 in HUVECs confirming that CDK1 is that target of WEE1 in HUVECs. 
Therefore, it is likely that the effects on HUVEC proliferation by WEE1 inhibition are 
mediated through the increased activity of cyclin B-CDK1 complexes. 
 
3.9.4 RNA interference Screening Results 
Over the last decade RNA interference screening has become a powerful tool 
whereby the effects of gene silencing on biological properties, such as cell 
proliferation, can be systematically explored. RNA interference provided an 
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unbiased approach in identifying proteins critical to endothelial cell proliferation. The 
RNA interference screen was performed in HUVECs. Although this means the 
results of the screen may not directly apply to CLMECs, it does provide a starting 
point for identifying which genes are important in normal endothelial cell 
proliferation in vitro. By using two independent sets of RNA interference chemistry, 
hits in the initial screen were able to be validated in a confirmation screen, 
suggesting that their effect on HUVEC proliferation is genuine.  
 
The screen identified twelve genes important in inhibiting HUVEC proliferation. The 
majority of these have not been reported as critical regulators of cellular 
proliferation, including a potassium voltage-gated ion channel, fructosamine 3 
kinase related protein and a myosin phopsphatase subunit. However, two hits were 
noted to be key regulators of the cell cycle (WEE1 and CDK1) and were selected 
for further investigation. Small molecule inhibitors of both WEE1 (AZD1775) and 
CDK1 (R0-3306) have been shown to inhibit tumour cell proliferation (Vassilev et 
al., 2006, Guertin et al., 2013). 
 
WEE1 was not the most significant hit in the RNA interference screen. It was 
chosen because its target protein CDK1 also significantly inhibited HUVEC 
proliferation when knocked down, suggesting this signalling pathway has significant 
importance. The top hit in the screen was Polio-like kinase 1 (PLK1), which is also 
implicated in the regulation of cyclin B-CDK1 activity and mitotic entry. PLK1 
promotes mitotic entry in two ways. Firstly it is able to phosphorylate CDC25C 
which activates phosphatases capable of de-phosphorylating (and thereby 
activating) the cyclin B-CDK1 complex, promoting mitosis (Roshak et al., 2000). 
Secondly, as previously discussed, it is able to phosphorylate and deactivate 
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WEE1, which normally keeps cyclin B-CDK1 complexes in an inhibited state by 
phosphorylation of the Tyr15 residue on CDK1. Although PLK1 promotes mitotic 
entry, its primary role in mammalian cells is the control of mitotic progression, 
particularly the regulation of proteins that are involved in the metaphase-anaphase 
transition and mitotic exit. Inhibition of PLK1 with a small molecule PLK1 inhibitor 
results in mitotic arrest and apoptosis in tumour cells (Steegmaier et al., 2007). As a 
result, Volasertib (also known as BI 6727), is currently being investigated in clinical 
trials as an anti-cancer agent. Therefore, in the RNA interference screen it is not 
surprising that knockdown of PLK1 inhibited the proliferation in HUVECs. 
 
3.9.5 Conclusion 
For the first time, CLMECs have successfully been isolated and characterised in 
vitro. Although they share functional properties with LECs, differences in protein 
expression are apparent. Both CD31 and VEGFR-2 are down-regulated in 
CLMECs, the latter significantly impacting upon VEGF-VEGFR-2 induced Ca2+ 
signalling. This may, in part, explain the lack of clinical efficacy observed with 
current anti-VEGF therapy. WEE1 has been identified as a potential anti-angiogenic 
target which is up-regulated in CLMECs. It has functional importance in HUVECs, 
with genetic and chemical inhibition significantly inhibiting proliferation. Targeting 
mechanisms critical to tumour endothelial cell survival represents an alternative 
approach to anti-angiogenesis therapy, which may help overcome the current 
problems associated with VEGF-signalling resistance. 
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Chapter 4: WEE1 Inhibition has Anti-Angiogenic Effects in 
Endothelial Cells of Colorectal Cancer Liver Metastases  
In the previous chapter, WEE1 was identified as a possible anti-angiogenic target 
that was found to be upregulated in CLMECs. In HUVECs, both genetic inhibition of 
WEE1 with pooled WEE1 siRNA and chemical inhibition of WEE1 with the small 
molecule inhibitor AZD1775 inhibited phosphorylation of CDK1 at its Tyr15 residue. 
In both cases this resulted in a reduction in HUVEC proliferation.  
 
AZD1775, a small molecule WEE1 inhibitor is currently being investigated in a 
number of oncological clinical trials as both a DNA-damaging sensitiser and as an 
outright monotherapeutic agent (ClinicalTrials.gov Accessed July 2016). This 
reflects the ability of WEE1 to regulate CDK1, which has dual functions as a 
regulator of mitosis and DNA synthesis. As a monotherapy, AZD1775 has been 
shown to increase CDK1 activity resulting in increased origin firing in cancer cells. 
This is followed by nucleotide exhaustion, replication fork stalling and DS-DNA 
breaks (Beck et al., 2012). However, the effects of WEE1 inhibition on endothelial 
cells, including tumour endothelial cells remain unknown. 
 
Tumour angiogenesis is a complex process involving much more than endothelial 
cell proliferation. The importance of WEE1 on CLMEC properties such as migration 
and tube formation are unknown. The aim of this chapter was to determine if WEE1 
inhibition has anti-angiogenic activity in CLMECs and identify the mechanism 
underlying these effects.  
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4.1 Genetic and Chemical Inhibition of WEE1 Inhibits 
Proliferation in CLMECs 
Although WEE1 had been shown to be important in HUVEC proliferation as a first 
step it was crucial to determine the importance of WEE1 in CLMEC proliferation. 
CLMECs were transfected with pooled WEE1 siRNA and its effects on proliferation 
were measured with the Vybrant® DyeCycleTM Green proliferation assay. 
Knockdown of WEE1 by siRNA decreased WEE1 band intensity compared to non-
transfected CLMECs and CLMECs transfected with scrambled siRNA (Figure 31a). 
Quantification of the WEE1 band intensity relative to the β-actin loading control 
revealed the expression of WEE1 to be 85% lower in CLMECs transfected with 
WEE1 siRNA compared to scrambled siRNA (Figure 31b). Proliferation was 
measured 48 hrs after transfection using the nuclear dye Vybrant® Green (Figure 
31c). Knockdown of WEE1 inhibited proliferation by 41% compared to scrambled 
siRNA (Figure 31d).  
 
The small molecule WEE1 inhibitor AZD1775 was tested against CLMECs for 48 
hrs and cell proliferation was measured using a WST-1 assay. At 1 μM, AZD1775 
inhibited proliferation by 63% compared to vehicle control (Figure 32a). 
Concentration-response curves were created for AZD1775 in pooled LECs and 
CLMECs (Figure 32b). The calculated IC50 in CLMECs was 267 nM and this was 
significantly less than the IC50 in LECs, which was 414 nM (Figure 32c).  
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Figure 31 Genetic Inhibition of WEE1 Decreases Proliferation in 
CLMECs 
a. Example western blot labelled with anti-WEE1 and anti--actin antibodies for 
non-transfected (NT) CLMECs and CLMECs transfected with scrambled siRNA 
(Scr) or ON-TARGETplus WEE1 siRNA (siWEE1) b. Quantification of the siWEE1 
group WEE1 band intensity relative to -actin and normalised to the Scr group (n=3 
each) c. Fluorescence images of CLMECs 48 hrs after transfection with scrambled 
siRNA (Scr) or ON-TARGETplus WEE1 siRNA (siWEE1). Fluorescence was from 
cell nuclei stained with Vybrant® Dye Cycle™ (green). Scale bars 400 μm d. 
Quantification of the number of CLMECs seen in the images of the type shown in c. 
The siWEE1 group has been normalised to the Scr group (n=3, N=18). 
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Figure 32 AZD1775 Inhibits CLMEC Proliferation 
a. Mean data for CLMEC viability measured using WST-1 reagent after treatment 
with AZD1775 (1 μM) or vehicle control (Control) for 48 hrs (n=3, N=9) b. AZD1775 
dose response curve in pooled LECs and CLMECs. LECs and CLMECs were 
treated with AZD1775 at the indicated concentrations for 48 hrs and plotted as 
percentages of the vehicle control (n=6, N=18 each) c. Mean data for the derived 
IC50 values of AZD1775 against LECs and CLMECs.  
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4.2 AZD1775 Inhibits Angiogenic Processes in CLMECs 
The process of angiogenesis is not only reliant upon the proliferation of endothelial 
cells, but also the ability of endothelial cells to migrate and form tube-like structures 
which will eventually become blood vessels. 
 
To investigate the effects of AZD1775 on CLMEC migration a scratch wound was 
made in a confluent layer of CLMECs and the cells were subsequently imaged for 
24 hrs as they migrated to close the wound (Figure 33a). Media contained low 
serum (0.2%) and high VEGF concentrations (20 ng.mL-1) to simulate the tumour 
microenvironment, limit proliferation and ensure migration was the dominant 
process. The effects of AZD1775 (1 μM) upon CLMEC migration were evident from 
4 hrs onwards (Figure 33b). At 24 hrs AZD1775 inhibited migration by 20% 
compared to vehicle control (Figure 33c). 
 
To assess tube formation a fibroblast/CLMEC co-culture assay was developed. In 
this, CLMECs were plated onto a confluent layer of fibroblasts and after 5 days 
reliably grew into tube structures that could be detected with anti-CD31 staining 
(Figure 34a see Control). Treatment with AZD1775 (1 μM) profoundly inhibited tube 
formation compared to vehicle control (Figure 34a). Specifically, it inhibited the 
number of branch points, tube length and tube surface area (Figure 34b). The 
fibroblast bed appeared unaffected by the AZD1775 treatment (Figure 35a). In the 
absence of CLMECs, AZD1775 (1 μM) did not alter the number of fibroblasts after 5 
days of treatment (Figure 35b). 
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Figure 33 AZD1775 Inhibits CLMEC Migration 
a. Example linear wound mask images after 24 hr CLMEC migration in vehicle 
control (Control) or 1 µM AZD1775 treated cells. Black represents cells outside the 
linear wound, grey represents cells which have migrated into the wound, and white 
represents no cells. Scale bars 200 μm b. Mean RWD at the indicated time points 
after AZD1775 (1 µM) or vehicle control (Control) treatment (n=3 each) c. Relative 
wound density at 24 hrs in CLMECs treated with AZD1775 presented as a 
percentage of Control (n=3, N=9).  
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Figure 34 AZD1775 Inhibits CLMEC Tube Formation 
a. Fluorescence images of anti-CD31-labelled CLMECs (green) in tube formation on a bed of fibroblasts (the fibroblasts are not visible 
in the images). The co-cultures were treated daily for 5 days with 1 µM AZD1775 or its vehicle control (Control). Scale bars 800 μm b. 
For experiments of the type exemplified in a, mean data for tube length, number of branch points and tube surface area (n=3, N=9) 
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Figure 35 AZD1775 Does Not Affect Fibroblast Bed Integrity 
a. Fluorescence images of NHDF cells after 5 days treatment with AZD1775 (1 μM) 
or its vehicle control (Control). Fluorescence was from cell nuclei stained with 
Vybrant® Dye Cycle™ (green). Scale bars 400 μm b. Quantification of the number 
of NHDF cells seen in the images of the type shown in a.  
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4.3 AZD1775 Changes the Cell Cycle Distribution in CLMECs 
as a Result of Altered CDK1 Phosphorylation 
WEE1 (through CDK1) is known to regulate cell entry into mitosis and also regulate 
DNA synthesis. To determine what effect AZD1775 had on the cell cycle, CLMECs 
were treated for 24 hrs with AZD1775 or vehicle control and CLMEC DNA content 
was analysed by flow cytometry. CLMECs treated with vehicle control had a large 
peak at G0/G1 with relatively few cells in S phase and G2/M phase (Figure 36a). In 
contrast, treatment with AZD1775 (1 μM) resulted in significantly more cells in S 
phase (40% vs 18.6%)  and G2/M phase (30.6% vs 25.6%) (Figure 36b). 
To confirm WEE1 inhibition was preventing CDK1 phosphorylation at Tyr15, 
western blotting was performed. Firstly an siRNA knockdown approach was used. 
In non-transfected CLMECs, western blotting for pCDK1-Y15 confirmed a single 
band 34 kDa in size. As expected, knockdown of WEE1 by pooled WEE1 siRNA 
decreased the single band intensity (Figure 37a). Total CDK1 content was 
unchanged. Quantification of the pCDK1-Y15 to CDK1 ratio revealed pCDK1-Y15 
expression to be reduced in the siWEE1 group compared to scrambled group by 
89% (Figure 37b). A similar effect was observed when treating CLMECs with 
AZD1775. AZD1775 reduced pCDK1-Y15 but not overall CDK1 band intensity 
(Figure 37c). Quantification of the pCDK1-Y15 to CDK1 ratio showed pCDK1-Y15 
expression to be reduced with AZD1775 treatment by 89% compared to vehicle 
control (Figure 37d). 
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Figure 36 AZD1775 Increases the Number of CLMECs in S Phase and 
G2/M Phase 
a. Example flow cytometry recording for CLMECs 24 hr after treatment with 1 µM 
AZD1775 or its vehicle control (Control). The vertical dotted lines separate different 
phases of the cell cycle b. Mean percentage of cells in G0/G1, S and G2/M phases 
(n=3 each). AZD1775 data are statistically compared with Control data for each 
phase. * (p<0.05), ** (p<0.01) and *** (p<0.001).  
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Figure 37 Genetic and Chemical Inhibition of WEE1 Decreases    
pCDK1-Y15 in CLMECs 
a. Example western blot labelled with anti-pCDK1-Y15, anti-CDK1 and anti-β-actin 
antibodies for non-transfected (NT) CLMECs and CLMECs transfected with 
scrambled siRNA (Scr) or ON-TARGETplus WEE1 siRNA (siWEE1) b. 
Quantification of the pCDK1-Y15 band intensity divided by the CDK1 band intensity. 
siWEE1 has been normalised to Scr (n=3 each) c. Example western blot labelled 
with anti-pCDK1-Y15, anti-CDK1 and anti-β-actin antibodies for CLMECs treated 
with AZD1775 (1 μM) or its vehicle control (Control) for 24 hrs d. Quantification of 
the pCDK1-Y15 band intensity divided by the CDK1 band intensity. AZD1775 has 
been normalised to Control (n=3 each). 
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4.4 AZD1775 Induces DS-DNA Breaks in CLMECs 
Studies in cancer cell lines have shown that AZD1775 monotherapy is able to 
induce DS-DNA breaks. To investigate if the same mechanism of action was 
occurring in CLMECs, cells were treated with AZD1775 (1 μM) or its vehicle control 
for 24 hrs and levels of γH2AX were measured by western blot and flow cytometry.  
In AZD1775 treated CLMECs, western blotting revealed a single band 15 kDa in 
size consistent with γH2AX expression (Figure 38a). In contrast, vehicle control 
treated CLMECs expressed minimal γH2AX. Quantification of the γH2AX band 
intensity relative to the β-actin band intensity revealed γH2AX expression to be 
increased 14-fold in the AZD1775 treated cells compared to the vehicle control 
treated cells (Figure 38b). 
To further validate these findings, flow cytometry was performed to measure the 
percentage of cells that expressed γH2AX (Figure 38c). As with the western blotting 
data, relatively few vehicle control treated cells were positive for γH2AX (0.2%). 
However, AZD1775 treatment resulted in significantly more CLMECs expressing 
γH2AX (14%). Quantification of the flow cytometry data indicated a 70-fold increase 
in the amount of DS-DNA breaks with AZD1775 treatment (Figure 38d). 
WEE1 also negatively regulates mitotic entry, therefore levels of mitosis were 
analysed after 24 hrs of AZD1775 treatment using the specific mitotic marker pHH3 
(Figure 39a). Surprisingly, levels of mitosis were lower in the treatment group after 
24 hrs treatment. In the control group relatively few cells were positive for pHH3 
(0.6%) and with AZD1775 treatment even fewer were positive (0.05%) (Figure 39b).  
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Figure 38 AZD1775 Induces DS-DNA Breaks in CLMECs 
a. Example western blot labelled with anti-γH2AX and anti-β-actin antibodies for CLMECs treated with AZD1775 (1 μM) or its vehicle control 
(Control) for 24 hrs b. Quantification of the γH2AX band intensity divided by the β-actin band intensity. AZD1775 has been normalised to Control 
(n=3 each) c. Example flow cytometry dot plots for unlabelled CLMECs (red) and CLMECs labelled with anti-γH2AX antibody (blue) after 24 hrs 
treatment with AZD1775 (1 μM) or its vehicle control (Control) d. Mean data for the groups in c (n=3 each). 
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Figure 39 AZD1775 Does Not Increase Mitosis in CLMECs 
a. Example flow cytometry dot plots for unlabelled CLMECs (blue) and CLMECs 
labelled with anti-pHH3 antibody (purple) after 24 hrs treatment with AZD1775 (1 μM) 
or its vehicle control (Control) b. Mean data for the groups in a (n=3 each). 
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4.5 AZD1775 Induced DS-DNA Breaks in CLMECs can be 
Prevented if Co-Treated with RO-3306 or Exogenous 
Nucleosides 
CDK1 regulates origin firing, allowing DNA to be synthesised in a co-ordinated 
fashion. WEE1 inhibition results in increased CDK1 activity, causing excessive 
origin firing and ultimately leading to DS-DNA breaks due to nucleotide depletion. 
To confirm this was occurring in CLMECs treated with AZD1775, the pathway was 
manipulated at two separate points in an attempt to prevent AZD1775 induced DS-
DNA breaks. Firstly RO-3306, a CDK1 inhibitor, was tested in combination with 
AZD1775 (Figure 40a). After 24 hrs of AZD1775 monotherapy (1 μM) 12.7% of 
CLMECs expressed γH2AX, whereas with RO-3306 monotherapy (10 μM) only 
0.1% of CLMECs expressed γH2AX. When the treatments were combined, the 
AZD1775 induced DS-DNA breaks were prevented with only 0.3% of CLMECs 
expressing γH2AX (Figure 40b). Combination treatment with a lower dose of RO-
3306 (1 μM) did not fully prevent AZD1775 induced DS-DNA breaks with 8.4% of 
CLMECs expressing γH2AX. 
In an attempt to prevent AZD1775 induced nucleotide depletion CLMECs treated 
with AZD1775 were supplemented with exogenous nucleosides (Figure 41a). 
Nucleosides were used as charged nucleotides cannot readily cross the plasma 
membrane. Addition of nucleosides to AZD1775 reduced the number of CLMECs 
expressing γH2AX from 14.6% to 0.4% (Figure 41b). 
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Figure 40 AZD1775 Induced DS-DNA Breaks in CLMECs Can be Prevented if Co-treated with RO-3306 
a. Five example flow cytometry dot plots for unlabelled CLMECs (red) and CLMECs labelled with anti-γH2AX antibody (blue). The five 
conditions were vehicle control (Control), 10 µM RO-3306, 1 µM AZD1775, 1 µM AZD1775 + 1 µM RO-3306, and 1 µM AZD1775 + 10 
µM RO-3306 b. Mean data for the five groups in a (n=3 each). 
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Figure 41 AZD1775 Induced DS-DNA Breaks in CLMECs Can be Prevented if Co-treated with Exogenous 
Nucleoside Addition 
a. Four example flow cytometry dot plots for unlabelled CLMECs (red) and CLMECs labelled with anti-γH2AX antibody (blue). The 
four conditions were vehicle control (Control), exogenous nucleosides (Nucleoside) (EmbryoMax®, 1:5 dilution), 1 µM AZD1775 
and 1 µM AZD1775 + exogenous nucleosides (Nuc) (EmbryoMax®, 1:5 dilution) b. Mean data for the four groups in a (n=3 each). 
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4.6 AZD1775 Causes Caspase-3 Dependent Apoptosis in 
CLMECs which can be Rescued with Exogenous Nucleoside 
Supplementation 
A potential consequence of DS-DNA breaks is increased apoptosis, therefore levels 
of caspase-3-dependent apoptosis were investigated using a NucView™ 488 
Caspase-3 assay. At 24 hrs, levels of apoptosis were very low (0.4%) in vehicle 
control treated CLMECs (Figure 42a). Treatment with AZD1775 resulted in 10.4% 
of cells undergoing apoptosis, a 20-fold increase compared to vehicle control 
treated cells. An increase in apoptosis was evident from 8hrs after treatment and 
continued to increase up to the end of the experiment at 24 hrs (Figure 42b). As 
exogenous nucleoside supplementation was able to prevent AZD1775-induced DS-
DNA breaks, they were also tested to see if they could prevent apoptotic cell death. 
Co-treatment with exogenous nucleosides significantly reduced the percentage of 
Caspase-3 positive cells from 10.4% to 2.6% (Figure 42c).  
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Figure 42 AZD1775 Causes Caspase-3 Dependent Apoptosis in 
CLMECs 
a. Images of fluorescence from caspase-3 activity indicator in CLMECs 24 hrs after 
treatment with AZD1775 (1 µM) or its vehicle control (Control). Scale bar 200 μm b. 
Mean number of caspase-3 positive CLMECs per mm2 at the indicated time points 
after AZD1775 treatment or vehicle control (Control) (n=3 each) c. Mean data for 
experiments of the type shown in a after 24 hr treatment and including a 1 μM 
AZD1775 + exogenous nucleoside group (AZD/N) (EmbryoMax®, 1:5 dilution) (n=3 
each). 
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4.7 Summary of Findings 
 Genetic and chemical inhibition of WEE1 inhibits proliferation in CLMECs 
 
 AZD1775 inhibits proliferation in CLMECs with an IC50 of 267 nM, significantly 
less than in LECs  
 
 AZD1775 inhibits CLMEC migration 
 
 AZD1775 inhibits CLMEC tube formation, specifically, tube length, tube surface 
area and number of branching points. 
 
 WEE1 inhibition decreases pCDK1-Y15 and causes an increase in cells in S 
Phase and G2/M phase  
 
 AZD1775 induces a 70-fold increase in DS-DNA breaks in CLMECs, which can 
be rescued if co-treated with RO-3306 or exogenous nucelosides 
 
 AZD1775-induced DS-DNA breaks lead to a 20-fold increase in caspase-3 
dependent apoptosis in CLMECs 
 
 AZD1775-induced apoptosis can be rescued if co-treated with exogenous 
nucleosides 
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4.8 Discussion 
The aim of this chapter was to determine if WEE1 inhibition has anti-angiogenic 
activity in CLMECs and identify the mechanism underlying these effects. Both 
AZD1775 and pooled WEE1 siRNA decreased CDK1 phosphorylation at Tyr15 and 
inhibited CLMEC proliferation. AZD1775 also inhibited other angiogenic processes 
including CLMEC migration and tube formation. Investigation of the underlying 
mechanism revealed that AZD1775 was able to induce DS-DNA breaks that lead to 
caspase-3 dependent apoptosis. Supplementation of CLMECs with exogenous 
nucleosides rescued DS-DNA breaks and caspase-3 dependent apoptosis induced 
by AZD1775.  
 
4.8.1  Functional Importance of WEE1 in CLMECs 
Tumour angiogenesis is a complex process. For over thirty years sprouting 
angiogenesis was thought to be the exclusive method of tumour vascularisation. 
However, the last decade has revealed a number of other important mechanisms 
including intussusceptive angiogenesis, vessel co-option and vasculogenic mimicry, 
all of which have made anti-angiogenic treatment strategies more complex than 
initially thought. Nevertheless, sprouting angiogenesis and VEGF signalling has 
formed the basis for most tumour angiogenesis research. This has led to the first 
set of licensed anti-angiogenic therapies which attempt to disrupt VEGF-VEGFR-2 
signalling. Sprouting angiogenesis is a complex process that requires endothelial 
cells to proliferate, migrate and form vessels. AZD1775 was able to inhibit all of 
these processes and had a particularly striking effect on the ability of tubes to 
branch, which was reduced by 83% compared to vehicle control. This reduced 
ability to form branching vessels would restrict the ability of CLM to recruit blood 
vessels required for growth and survival. 
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WEE1 protein expression was upregulated in CLMECs compared to LECs. This in 
itself suggests WEE1 may be important for CLMEC survival. As previously 
discussed, increased expression of WEE1 may protect CLMECs from DNA-damage 
and cell death, not only because of its role in controlling DNA repair and mitotic 
entry, but in ensuring DNA is synthesised in a controlled and co-ordinated manner. 
Further evidence of the functional importance of WEE1 in CLMECs is illustrated by 
the lower IC50 value for AZD1775 compared to LECs. Increased sensitivity to 
AZD1775 infers that CLMECs are more reliant on WEE1 for normal proliferation 
and survival. Being cancerous in nature, CLMECs may already harbour more DNA 
damage than LECs and are therefore already more reliant on DNA repair 
mechanisms. This means a relatively smaller disruption to these DNA repair 
mechanisms (such as WEE1 inhibition) will result in a relatively greater amount of 
DNA damage and cell death.  
 
4.8.2 In Vitro Angiogenesis Assays 
Assays that stimulate the formation of capillary-like tubules represent the latter 
stages of angiogenesis and are used extensively to assess novel compounds for 
pro- or anti-angiogenic activity (Staton et al., 2009). A number of in vitro assays 
exist and the most basic form involves plating endothelial cells onto a gel matrix 
such as collagen, fibrin or Matrigel®. Matrigel® causes endothelial cells to 
differentiate and form capillary-like tubules, although researchers debate as to 
whether these structures possess lumens or not (Bikfalvi et al., 1991, Grant et al., 
1991).  
 
Another method, which was used in this chapter, involves the co-culture of 
endothelial cells with fibroblasts. The fibroblasts secrete matrix components which 
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act as a scaffold enabling tube formation. These tubes contain lumens and are 
heterogeneous in length, more closely resembling capillary beds in vivo (Donovan 
et al., 2001). Excellent results were achieved using this technique and it is believed 
that this is the first time this technique has been performed using isolated human 
tumour endothelial cells. A number of computed modalities were measured (tube 
length, tube surface area, number of branching points) which eliminated any 
possibility of human error or bias. AZD1775 significantly inhibited all of these 
parameters providing strong evidence that it can work as an anti-angiogenic agent. 
The technique is not without its limitations however. Firstly it is very time 
consuming, with each assay taking two weeks to perform. Secondly it is not clear 
what the fibroblasts secrete in their matrix as this has yet to be characterised. 
Finally, for this assay, normal human dermal fibroblasts were used (non-cancerous 
cell line) which may not truly reflect what is occurring in tumour angiogenesis. The 
assay was attempted with tumour fibroblasts also isolated from the patient samples, 
however these failed to grow into a confluent monolayer, which is necessary for the 
endothelial cells to form tubes. One potential concern was that AZD1775 could 
cause cell death in the fibroblast monolayer which is in turn affecting the ability of 
tubes to form. However, this was ruled out, as five-days treatment of the confluent 
fibroblast monolayer with AZD1775 resulted in no change in fibroblast cell number.    
 
The next step would be to evaluate AZD1775 in in vivo angiogenesis assays. A 
number of these exists, each with its own inherent advantages and disadvantages. 
Commonly used assays include the corneal angiogenesis assay and the chick 
chorioallantoic membrane assay. Although the anti-angiogenic effects of AZD1775 
were not tested in vivo, the in vitro assay worked well and provided strong evidence 
that WEE1 is necessary for successful tube formation.  
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4.8.3  Mechanism of Action of WEE1 Inhibition 
Work in this chapter has proposed a mechanism by which up-regulated WEE1 in 
CLMECs could facilitate CLM progression by protecting CLMECs against caspase-
3 dependent apoptosis which would otherwise restrict tube formation.  
 
Single agent AZD1775 significantly inhibited CLMEC proliferation and to 
understand its mechanism of action, WEE1 inhibition in cancer cell studies were 
reviewed. A number of studies have shown that single agent AZD1775 can inhibit 
cancer cell proliferation (Kreahling et al., 2012, Guertin et al., 2013, Do et al., 2015, 
Pfister et al., 2015). In these studies, the activity of AZD1775 has been attributed to 
its ability to increase CDK1 activity, which is critical for DNA synthesis. WEE1 
normally causes an inhibitory phosphorylation of CDK1 at Tyr15. Both AZD1775 
and pooled siRNA targeted against WEE1 were able to abolish this inhibitory 
phosphorylation of CDK1, a finding which is supported in multiple other cell lines 
(PosthumaDeBoer et al., 2011, Rajeshkumar et al., 2011, Sarcar et al., 2011). 
CDK1 has two key roles, regulation of origin firing during DNA synthesis and 
regulation of mitotic entry. The former has been shown to be the key mechanism of 
action for single agent activity (Beck et al., 2012, Pfister et al., 2015). Excess origin 
firing culminates in DS-DNA breaks as replication forks stall due to a critical 
nucleotide shortage. DS-DNA breaks were detectable in CLMECs by measuring 
levels of γH2AX through western blotting and flow cytometry. After 24 hrs treatment 
14% of CLMECs were positive for γH2AX compared to 0.2% in the control group 
with flow cytometry. Although 14% seems like a relatively small amount, it is a 70-
fold increase compared to the control group. By comparison, at IC90 concentrations, 
AZD1775 reportedly caused a 28-fold, 53-fold and 77-fold increase in γH2AX 
expression in A2058 lung cancer cells, LoVo colorectal cancer cells and HT29 
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colorectal cancer cells respectively (Guertin et al., 2013). AZD1775 treatment 
resulted in apoptotic cell death as determined by measuring levels of caspase-3. 
With AZD1775 treatment 10.4% of CLMECs were positive for caspase 3, compared 
to 0.4% in the control group. This suggests that not all CLMECs that sustain DS-
DNA breaks undergo apoptosis and that CLMECs may be able to repair some of 
the DNA damage. Alternatively, the 3.6% difference may indicate the delay 
between the cell sustaining DS-DNA breaks and the initiation of apoptosis.  
 
Several experiments in this chapter support the hypothesis that the dominant 
mechanism of action for AZD1775 is through its ability to induce DS-DNA breaks 
and not premature mitosis. Firstly, when levels of mitosis were measured at 24 hrs 
they were significantly lower in the AZD1775 treatment group. It may well be that 
AZD1775 forces cells into mitosis relatively quickly (eg. after 8 hrs) and that by 24 
hrs most cells have actually completed mitosis, meaning pHH3 levels are low. 
However, the CLMEC apoptosis time course showed a linear increase. If early 
premature mitosis was the dominant mechanism of action an early peak in 
apoptotic cell death would be expected. The linear increase in apoptotic cell death 
better reflects accumulating DNA-damage as stalling replication forks lead to DS-
DNA breaks. Secondly, supplementation of CLMECs with exogenous nucleosides 
reversed the AZD1775-induced DS-DNA break levels nearly back to those of the 
control group. Nucleosides were used because charged nucleotides cannot cross 
the cell membrane easily. The dose used was based upon reports from previous 
studies (Beck et al., 2012, Cuneo et al., 2016). Exogenous nucleoside addition also 
reversed the AZD1775-induced apoptosis levels nearly back to those of the control 
group. The rescue was not 100%, for either the DS-DNA breaks or capase-3 
dependent apoptosis and may reflect the fact that not enough nucleosides were 
added. This was difficult to gauge as the measurement of nucleotides is extremely 
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challenging, with limited techniques available. Other studies have reported difficulty 
in obtaining a 100% rescue with nucleoside addition (Beck et al., 2012). The 
supplementation of nucleosides should have no impact upon the toxicity of 
premature mitosis and therefore by observing a rescue effect this provides further 
evidence that DS-DNA breaks are the dominant mechanism of action.  
 
RO-3306, a CDK1 inhibitor, was also able to reverse the AZD1775-induced DS-
DNA breaks when used at 10 μM. This dose was used based upon reports from 
previous studies (Beck et al., 2012). RO-3306 was not used to rescue apoptosis, 
because CDK1 is relevant to both mechanisms of action and therefore if it did 
rescue apoptosis it would be unclear if this was because of CDK1 causing DS-DNA 
breaks or CDK1 causing premature mitosis.  
 
Another possibility is that AZD1775 could be causing both mechanisms of action to 
work together synergistically. For instance, it could induce DS-DNA breaks in cells 
and force them into mitosis prematurely resulting in mitotic catastrophe. This could 
explain why a 100% rescue with exogenous nucleoside addition was not fully 
possible. However, providing evidence that both these mechanisms were working 
synergistically would be extremely difficult.    
 
4.8.4  Implications of AZD1775 as an Anti-Angiogenic Drug 
WEE1 inhibition has clear anti-angiogenic effects, but what are the potential 
consequences of using AZD1775 as an anti-angiogenic agent for CLM clinically? 
Endothelial cells line vessels throughout the body and are pivotal both in health and 
disease. The relative functional importance of WEE1 inhibition in these contexts is 
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unknown. Substantial impact upon physiological blood vessels does however seem 
unlikely because these endothelial cells are normally quiescent. AZD1775 causes 
DS-DNA breaks in cells that are in the cell cycle and actively replicating (S phase). 
Results from Phase I clinical trials report no serious vascular complications (Do et 
al., 2015), however this does not mean that such complications are lacking. 
Furthermore, not all endothelial cells are quiescent. Physiological angiogenesis 
occurs in adult life, for instance in the cycling ovary and pregnancy (Carmeliet, 
2005). Very relevant to the surgical patient would be the impact of AZD1775 upon 
angiogenesis required for wound healing after surgery. Designers of future clinical 
trials involving AZD1775 should include assessments of wound-healing and 
cardiovascular parameters including those relating to the risk of atherosclerotic 
disease. However, it is important to note that these concerns will be common 
amongst any anti-angiogenic agent and current anti-angiogenic agents such as 
bevacizumab have been used safely in patients. If AZD1775 were to cause 
systemic problems, techniques to deliver therapy locally, such as HIA infusion could 
always be considered.  
 
Sustained angiogenesis is one of the six hallmarks of cancer (Hanahan and 
Weinberg, 2000). It is generally accepted that once tumours grow beyond 1-2 mm3 
in size they are reliant upon angiogenesis to provide oxygen and nutrients to meet 
their increased metabolic demand. Therefore, AZD1775 could be used to treat not 
only CLM, but all vascularised tumours. The significance of WEE1 in specific 
vascular tumours such as hemangiomas, hemangioendotheliomas, Kaposi 
sarcoma, or angiosarcomas is unknown. Anti-angiogenic agents have been used 
for cancers other than metastatic colorectal cancer. For instance in the US, 
bevacizumab is also licensed for the treatment of glioblastoma, non-small cell lung 
cancer and metastatic renal cancer. Sorafenib (Nexvar®) is a multi-targeted VEGF 
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receptor tyrosine kinase inhibitor and is licensed for the treatment of hepatocellular 
carcinoma and renal cancer. The results from this chapter could mean that 
AZD1775  could be used as an anti-angiogenic treatment for other types of cancer.  
 
One key question is when exactly would AZD1775 be used in the colorectal cancer 
patient. It has previously been shown to have direct single agent anti-cancer activity 
in colorectal cancer cells in vivo (Guertin et al., 2013). It has been reported to 
improve the efficacy of DNA-damaging agents through premature mitosis (Hirai et 
al., 2009, Hirai et al., 2010) and in this chapter AZD1775 has also been shown to 
have anti-angiogenic activity in CLMECs. Therefore AZD1775 has at least three 
anti-cancer effects and the optimal time and duration to use the drug is difficult to 
predict. In an anti-angiogenic context, the logical conclusion would be to use 
AZD1775 in patients diagnosed with CLM to prevent their further growth. However, 
it could be argued that AZD1775 could be given after the resection of the patient’s 
primary colorectal cancer to prevent metastatic spread.  
 
Clinical trials using AZD1775 have not observed any anti-angiogenic efficacy, but 
equally they have not been designed to look for one. In current clinical trials, 
AZD1775 is used for short durations, usually 2-3 days with weekly intervals 
between each treatment cycle. For instance, in the Phase I single agent trial, 
AZD1775 was administered orally twice per day (225 mg) over 2.5 days per week 
for up to 2 weeks per 21-day cycle (Do et al., 2015). This dosing pattern may not be 
the most appropriate to observe anti-angiogenic activity. An excellent piece of 
research highlighting “anti-angiogenic scheduling” was published in 2000 and co-
authored by Judith Folkmann (Browder et al., 2000). Historically, chemotherapy 
regimens have been scheduled on a maximum tolerated dose principle. This 
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schedule, which consists of the highest survivable (minimum lethal) dose, yielded a 
higher percentage cure rate in in vivo studies, however, such high doses require an 
extended treatment-free period to allow recovery of normal host cells, such as 
hematopoietic progenitor cells. Similar to hematopoietic progenitor cells, the tumour 
endothelial cells may also resume growth during this treatment-free period. Bowder 
et al., developed an anti-angiogenic schedule for cyclophosphamide dosed at 
shorter intervals without interruption. This schedule increased apoptosis of tumour 
endothelial cells and demonstrated long-term suppression of the growth of 
cyclophosphamide-resistant lung carcinoma and breast carcinoma models in vivo, 
significantly better than conventional scheduling. Other studies have also confirmed 
that extended low dose chemotherapy can target cycling endothelial cells (Bocci et 
al., 2002, Drevs et al., 2004). In this chapter, 5 days uninterrupted AZD1775 
significantly inhibited CLMEC tube formation. Therefore, it could be hypothesised 
that to derive anti-angiogenic benefit clinically, AZD1775 should be dosed for 
prolonged intervals to prevent tumour endothelial cell recovery. Dosing of AZD1775 
in current clinical trials therefore is likely not optimal for anti-angiogenic activity.     
 
Assessing the anti-angiogenic activity of AZD1775 in patients would be difficult as it 
has direct anti-tumour activity also. It would be difficult to ascertain if any effect on 
tumour growth was direct, anti-angiogenic or a combination of both. One possible 
way to determine this could be the generation of an in vivo murine model with an 
inducible, endothelial specific, WEE1 knockout. After the endothelial WEE1 
knockout is induced, tumours could be implanted subcutaneously and allowed to 
grow. Any deficiency in tumour growth could then be attributed to the genetic 
inhibition of WEE1 in the endothelial cells. Although it does not specifically involve 
AZD1775 it would give important information about WEE1 inhibition.  
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4.8.5  Conclusion 
WEE1 has been identified to be both upregulated in CLMECs and critical for their 
survival. Targeted inhibition of WEE1, with AZD1775, inhibits CLMEC proliferation, 
migration and tube formation, three processes which are essential for tumour 
angiogenesis. Treatment with AZD1775 causes a 70-fold increase in DS-DNA 
breaks in CLMECs which leads to caspase-3 dependent apoptosis because of a 
critical nucleotide shortage. As AZD1775 is currently under investigation in a 
number of oncological clinical trials, it is important to investigate its anti-angiogenic 
efficacy and possible complications that may consequently arise from this.  
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Chapter 5: AZD1775 Induces Toxicity Through DS-DNA 
Breaks Independently of Chemotherapeutic Agents in p53 
Mutated Colorectal Cancer Cells 
In Chapters 3 and 4 WEE1 has been identified as an anti-angiogenic target and the 
small molecule WEE1 inhibitor AZD1775 has been shown to have clear anti-
angiogenic effects in CLMECs. This makes AZD1775 a promising anti-cancer agent 
which can target both cancer cells and the tumour vasculature. When administered 
as a monotherapy AZD1775 causes cytotoxicity by causing DS-DNA breaks as a 
result of excess origin firing and nucleotide shortage. This has been shown here in 
CLMECs and has also been reported in cancer cells (Guertin et al., 2013, Pfister et 
al., 2015, Do et al., 2015). However, in the majority of ongoing clinical trials using 
AZD1775 in combination with DNA-damaging agents, AZD1775 is thought to act by 
causing premature mitosis in cells with unrepaired DNA damage and not by its 
ability to induce DS-DNA breaks. 
 
The lack of clarity regarding the dominant mechanism of action for AZD1775 when 
used in conjunction with DNA-damaging agents is the underlying rationale for this 
chapter. It is important to determine the main mechanism of action of AZD1775 to 
ensure an optimal, effective dosing strategy in humans, especially when trying to 
derive anti-angiogenic benefit. Another factor to consider is the p53 status of cancer 
cells as some studies have shown that AZD1775 in combination with DNA-
damaging agents is only effective in p53-mutated cancer cells (Hirai et al., 2009, 
Hirai et al., 2010, Rajeshkumar et al., 2011), whereas other studies have shown 
efficacy independent of p53 status (Kreahling et al., 2012, Van Linden et al., 2013, 
Mueller et al., 2014). Whether or not AZD1775 increases the sensitivity of p53 
deficient/mutant and wildtype cancer cells to DNA-damaging therapies remains one 
of the outstanding questions regarding AZD1775 therapy (Matheson et al., 2016). 
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Previous research assessing the mechanism of action of WEE1 inhibition as a 
treatment for colorectal cancer is conflicting. Evidence of WEE1 inhibition as a 
radio-sensitising treatment for colorectal cancer was first reported in 2001 (Wang et 
al., 2001). Irradiation of HT29 (p53 mutant) colorectal cancer cells with 7.5 Gy 
resulted in an increase in cells arrested at the G2/M checkpoint from 19% to 69%. 
After a subsequent 4 hrs of treatment with PD0166285 (a less specific WEE1 
inhibitor) this was reduced to 37% and resulted in increased cell death. In 2009 
Hirai et al., reported that AZD1775 enhanced the cytotoxicity of gemcitabine to treat 
p53 mutated WiDr colorectal cancer cells in vitro (Hirai et al., 2009). In vivo, 
AZD1775 (20 mg/kg) given orally 24 hrs following a bolus of gemcitabine (50 
mg/kg) in nude rats bearing WiDr colorectal xenografts resulted in significantly 
reduced tumour growth compared to gemcitabine alone. Also, combination 
treatment allowed a lower dose of gemcitabine to be administered to obtain 
similar/improved anti-tumour effects. The following year the same group of authors 
investigated the ability of AZD1775 to sensitise colorectal cancer cell lines to 
different types of DNA damaging agents (Hirai et al., 2010). In vitro, AZD1775 
enhanced cytotoxic killing of 5-FU in four p53-mutated colorectal cancer cell lines 
(WiDr, SW948, COLO205 and LS411N), but did not enhance 5-FU cytotoxicity in 
three p53 wildtype colorectal cancer cell lines (HCT116, COLO678, LS513). Also 
AZD1775 monotherapy up to 300 nM had no effect. 
 
However, in 2013 evidence first emerged for AZD1775 having monotherapy 
efficacy against colorectal cancer cell lines (Guertin et al., 2013). In contrast to 
previous studies this was found to be independent of p53 status. AZD1775 was 
shown to inhibit proliferation in 66 different colorectal cancer cell lines, irrespective 
of p53 status, with IC50 values ranging from 0.17 µM to 16.26 µM. In the LoVo and 
HT29 cell lines, 24 hr AZD1775 treatment induced significant DS-DNA breaks 
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compared to vehicle control. Only the HT29 cell population showed a significant 
increase in mitosis as well. In vivo, LoVo bearing xenograft CD-1 nu/nu mice 
treated with 60 mg/kg AZD1775 twice daily for 13 days had a 13% tumour growth 
inhibition compared to vehicle control. These results contradicted earlier studies 
where authors reported no monotherapeutic efficacy of AZD1775 in vivo (Hirai et 
al., 2009). 
 
The aim of this chapter therefore was to determine the dominant mechanism of 
action of AZD1775 when used in combination with DNA-damaging agents. To study 
this, the HT29 colorectal cancer cell line was used which has a mutated non-
functional p53 (Arg-273 to His). This meant that both premature mitosis and DS-
DNA breaks were possible mechanisms of action.  
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5.1 AZD1775 Enhances 5-FU Toxicity in HT29 cells, but only 
Enhances Other Colorectal Cancer Chemotherapeutic 
Agents at Low Concentrations 
In the majority of clinical trials AZD1775 is administered following DNA-damaging 
therapy in p53-mutated cells to cause mitotic catastrophe and cell death. To 
investigate the ability of AZD1775 to sensitise p53-mutated colorectal cancer cells 
to common chemotherapeutic agents (5-FU, irinotecan, oxaliplatin) the HT29 cell 
line was studied. Concentration-response curves were created by treating cells for 
24 hrs with chemotherapy at a range of doses followed by either AZD1775 (300 
nM) or vehicle control for a further 24 hrs. An AZD1775 dose of 300 nM was used 
based on the reports of previous studies (Hirai et al., 2009, Hirai et al., 2010).  
 
5-FU alone had limited effects on HT29 cell viability (Figure 43a), but combination 
treatment with 300 nM AZD1775 significantly reduced the IC50 from 9.3 μM to 3.5 
μM (Figure 43b). When used in combination with oxaliplatin, AZD1775 decreased 
cell viability at lower doses of oxaliplatin, but not higher doses (Figure 43c). The 
IC50 was significantly higher in combination treatment than oxaliplatin alone (Figure 
43d). Similarly, with irinotecan and AZD1775 combination therapy cell viability was 
decreased at lower doses of irinotecan but not higher doses (Figure 43e). There 
was no significant difference in the IC50 values (Figure 43f). Overall, these data 
suggest that 5-FU cytotoxicity is enhanced with AZD1775 treatment and both 
oxaliplatin and irinotecan treatments are only enhanced at lower doses.  
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Figure 43 AZD1775 Enhances the Cytotoxicity of 5-FU 
a. Dose response curves in HT29 cells for 5-FU with AZD1775 (300 nM) or vehicle control (Control) b. Mean data for the derived IC50 values for 
the experiments exemplified in a (n=3, N=9 each condition) c. Dose response curves in HT29 cells for oxaliplatin with AZD1775 (300 nM) or 
vehicle control (Control) d. Mean data for the derived IC50 values for the experiments exemplified in c (n=3, N=9 each condition) e. Dose response 
curves in HT29 cells for irinotecan with AZD1775 (300 nM) or vehicle control (Control) d. Mean data for the derived IC50 values for the experiments 
exemplified in e (n=3, N=9 each condition) 
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5.2 AZD1775 Decreases pCKD1-Y15 in 5-FU Treated HT29 
Cells and Increases the Number of Cells in S Phase and 
G2/M Phase 
To further investigate if a true chemo-sensitisation effect existed subsequent 
experiments were focused on 5-FU and AZD1775 combination treatment. A dose of 
1 μM 5-FU and 300 nM AZD1775 was studied as this resulted in a large reduction 
in HT29 viability compared to 5-FU alone. Initially western blotting was performed to 
ensure AZD1775 was modulating its target, pCDK1-Y15. Combination treatment 
significantly reduced the pCDK1-Y15 band intensity compared to 5-FU alone 
(Figure 44a). Quantification of the pCDK1-Y15 band intensity relative to the CDK1 
band intensity revealed the expression of pCDK1-Y15 to be 89% lower with 
combination treatment (Figure 44b). Combination therapy also grossly altered the 
cell cycle distribution (Figure 45a). The addition of AZD1775 (300 nM) significantly 
increased the percentage of cells in S phase (40.8% vs 55.7%) and G2/M phase 
(19.4 vs 35.2%) (Figure 45b). 
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Figure 44 Combination Therapy Decreases pCDK1-Y15 compared to 5-
FU Treatment Alone 
a. Example western blot labelled with anti-pCDK1-Y15, anti-CDK1 and anti-β-actin 
antibodies for HT29 cells treated for 24 hrs with 5-FU (1 μM) and then an additional 
24 hrs AZD1775 (300 nM) or vehicle control (Control) b. Quantification of the 
pCDK1-Y15 band intensity divided by the CDK1 band intensity. 5-FU + AZD1775 
has been normalised to 5-FU + Control (n=3 each). 
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Figure 45 5-FU and AZD1775 Combination Therapy Increases the 
Number of HT29 Cells in S Phase and G2/M Phase 
a. Example flow cytometry recording for HT29 cells after 24 hrs treatment with 5-FU 
(1 µM) followed by either AZD1775 (300 nM) or vehicle control (Control). The 
vertical dotted lines separate different phases of the cell cycle b. Mean percentage 
of cells in G0/G1, S and G2/M phases (n=3 each). 5-FU+AZD1775 data are 
statistically compared with 5-FU+Control data for each phase. 
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5.3 5-FU and AZD1775 Combination Therapy Causes 
Increased Mitosis and DS-DNA Breaks in HT29 Cells 
As the HT29 cell line has a mutated p53, both premature mitosis and DS-DNA 
breaks could be a potential mechanism of action for AZD1775. To investigate this 
further, a flow cytometry time course assessing levels of DS-DNA breaks (γH2AX) 
and mitosis (pHH3) in HT29 cells receiving combination therapy was generated 
(Figure 46a, Figure 47a). With combination therapy, levels of DS-DNA breaks 
increased over time to 50.7% 24 hrs after AZD1775 addition, compared to 3.5% in 
the 5-FU + Control group (Figure 46b). Levels of mitosis followed a slightly different 
pattern. With combination therapy, the percentage of cells expressing pHH3 peaked 
8hrs after the addition of AZD1775 and was significantly higher than in the 5-FU + 
Control group (55% vs. 3.4%) (Figure 47b). After 8hrs, levels of mitosis in the 
combination therapy group began to return back to levels in the 5-FU + Control 
group and 24 hrs after the addition of AZD1775 the two groups were much closer 
(10.8% vs 2.6%).  
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Figure 46 AZD1775 Causes Progressive DS-DNA Breaks Over 24 hrs in HT29 Cells Pre-Treated with 5-FU 
a. Example flow cytometry dot plots for unlabelled HT29 cells (red) and HT29 cells labelled with anti-γH2AX antibody (blue) after 24 hrs 
treatment with 5-FU (1 μM) and the addition of AZD1775 (300 nM) for the times indicated b. Mean data for the groups in a including a 
control group (5-FU + Control) where cells were treated for 24 hrs with 5-FU (1 μM) and vehicle control for the times indicated (n=3 each). 
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Figure 47 AZD1775 Causes An Early Peak in Mitosis in HT29 Cells Pre-Treated with 5-FU 
a. Example flow cytometry dot plots for unlabelled HT29 cells (blue) and HT29 cells labelled with anti-pHH3 antibody (purple) after 24 hrs 
treatment with 5-FU (1 μM) and the addition of AZD1775 (300 nM) for the times indicated b. Mean data for the groups in a including a control 
group (5-FU + Control) where cells were treated for 24 hrs with 5-FU (1 μM) and vehicle control for the times indicated (n=3 each). 
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5.4 AZD1775 Causes DS-DNA Breaks in HT29 Cells when 
used as a Monotherapy  
To further understand the dominant mechanism of action in HT29 cells the effects 
of AZD1775 monotherapy were investigated. AZD1775 was tested against HT29 
cells for 48 hrs and cell proliferation was measured using a WST-1 assay. At 1 μM, 
AZD1775 inhibited proliferation by 69% compared to its vehicle control (Figure 
48a). A concentration-response curve was created for AZD1775 in HT29 cells 
(Figure 48b) and the IC50 value was calculated at 183 nM. To see if AZD1775 
monotherapy was able to induce DS-DNA breaks, flow cytometry was used to 
measure γH2AX expression (Figure 48c). After 24 hrs treatment AZD1775 (1 μM) 
caused 43% of cells to express γH2AX compared to 0.2% in vehicle control 
(Control) (Figure 48d). 
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Figure 48 AZD1775 Monotherapy Inhibits Proliferation of HT29 Cells and Causes DS-DNA Breaks 
a. Mean data for HT29 viability measured using WST-1 reagent after treatment with AZD1775 (1 μM) or its vehicle control (Control) for 48 hrs (n=3, N=9) 
b. AZD1775 dose response curve in HT29 cells. Cells were treated with AZD1775 at the indicated concentrations for 48 hrs and plotted as percentages 
of the vehicle control (n=3, N=9) c. Example flow cytometry dot plots for unlabelled HT29 cells (red) and HT29 cells labelled with anti-γH2AX antibody 
(blue) after 24 hrs treatment with AZD1775 (1 μM) or its vehicle control (Control) d. Mean data for the groups in c (n=3 each). 
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5.5 AZD1775 and 5-FU Combination Therapy Causes DS-DNA 
Breaks and Caspase-3 Dependent Apoptosis that can be 
Rescued by Exogenous Nucleoside Addition 
AZD1775 and 5-FU combination therapy cytotoxicity has previously been attributed 
to premature mitosis in the presence of unrepaired DNA damage. As AZD1775 
monotherapy causes DS-DNA breaks in HT29 cells it was hypothesised that this 
may actually be the dominant mechanism of action for combination therapy also. 
Critical to investigating this was the fact that nucleotide shortage is a consequence 
of excess origin firing and not premature mitosis, both regulated by CDK1, which 
itself is regulated by WEE1. 
 
Flow cytometry was used to see if exogenous nucleoside addition could reverse 
DS-DNA breaks induced by combination therapy (Figure 49a). AZD1775 (300 nM) 
and 5-FU (1 μM) combination therapy resulted in 44.2% of cells being positive for 
γH2AX, whereas 5-FU and vehicle control only caused 4.5% of cells to express 
γH2AX. When exogenous nucleosides were added to AZD1775 and 5-FU 
combination therapy the number of HT29 cells expressing γH2AX was significantly 
reduced to 8.7% (Figure 49b). 
 
As DS-DNA breaks can lead to apoptosis, caspase-3 dependent apoptosis was 
investigated. 5-FU (1 μM) and vehicle control alone resulted in low levels of 
apoptosis (4%), whereas 5-FU (1 μM)  and AZD1775 (300 nM) combination therapy 
significantly increased the apoptotic index up to 13% (Figure 50a,b). The addition of 
exogenous nucleosides reduced the apoptotic index to 4.7%, which was very 
similar to levels observed with 5-FU and vehicle control treatment (Figure 50b).   
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Figure 49 DS-DNA Breaks Caused by AZD1775 and 5-FU Combination Therapy can be Prevented by Adding Exogenous 
Nucelosides 
a. Four example flow cytometry dot plots for unlabelled HT29 cells (red) and HT29 cells labelled with anti-γH2AX antibody (blue). All cells 
received 24 hrs 5-FU (1 μM) followed by either vehicle control (Control), exogenous nucleosides (Nuc, EmbryoMax®, 1:5 dilution), AZD1775 
(300 nM) or AZD1775 (300 nM) + exogenous nucleosides (EmbryoMax®, 1:5 dilution) b. Mean data for the four groups in a (n=3 each). 
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Figure 50 AZD1775 and 5-FU Combination Therapy Induces Caspase-3 Dependent Apoptosis, which can be Prevented 
with Exogenous Nucleoside Addition 
a. Images of fluorescence from caspase-3 activity indicator in HT29 cells. All cells received 24 hrs 5-FU (1 μM) followed by 24 hrs of either 
vehicle control, exogenous nucleosides (EmbryoMax®, 1:5 dilution), AZD1775 (300 nM) or AD1775 (300 nM) + exogenous nucleosides 
(EmbryoMax®, 1:5 dilution) b. Mean data for experiments of the type shown in a (n=3 each). 
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5.6 Summary of Findings 
 AZD1775 decreases HT29 cell viability when used in combination with 5-FU   
 
 AZD1775 only sensitises p53 mutated HT29 colorectal cancer cells to 
irinotecan or oxaliplatin at low concentrations. 
 
 AZD1775 monotherapy  causes DS-DNA breaks and inhibits HT29 proliferation 
with an IC50 of 183 nM 
 
 5-FU and AZD1775 combination therapy causes an early increase in mitosis 
and progressive DS-DNA breaks in HT29 cells compared to 5-FU and vehicle 
control 
 
 5-FU and AZD1775 combination therapy causes increased Caspase-3 
dependent apoptosis compared to 5-FU and vehicle control, which can be 
rescued with exogenous nucleoside supplementation 
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5.7 Discussion 
The aim of this chapter was to determine the dominant mechanism of action of 
AZD1775 when used in combination with DNA-damaging agents. The rationale for 
this chapter stems from the lack of clarity within the literature about the dominant 
mechanism of action of AZD1775 and the importance of p53 status. In the majority 
of clinical trials AZD1775 is used as a DNA-damaging sensitiser, where cells with 
DNA damage (e.g. from chemotherapy) are forced into mitosis prematurely with 
lethal unrepaired DNA damage. However, AZD1775 can also have 
monotherapeutic activity by inducing DS-DNA breaks. In this chapter, AZD1775 did 
not fully sensitise HT29 cells (p53 mutated) to Irinotecan or Oxaliplatin. It did 
however improve the IC50 of 5-FU. In combination with 5-FU, AZD1775 increased 
mitosis, DS-DNA breaks and apoptosis compared to 5-FU alone. Supplementation 
of 5-FU and AZD1775 treated HT29 cells with exogenous nucleosides reversed the 
increased capase-3 dependent apoptosis, suggesting that DS-DNA breaks and 
nucleotide shortage are the dominant mechanism of action of AZD1775 when used 
in conjunction with DNA-damaging agents. 
 
5.7.1  Dosing Strategies 
The vast majority of ongoing clinical trials assessing AZD1775 efficacy are 
investigating it as a DNA-damage sensitising agent through its ability to cause 
premature mitosis. In general, the DNA-damaging agent is given on day 1, followed 
by several doses of AZD1775. Treatment is then repeated in a cycle every couple 
of weeks depending on the individual trial endpoints. For instance, in one clinical 
trial for relapsed or recurrent brain tumours, irinotecan hydrochloride is 
administered on day 1 and AZD1775 on days 1-5, with treatment repeating every 
21 days (ClinicalTrials.gov Identifier: NCT02095132). In another clinical trial for 
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recurrent ovarian, primary peritoneal, or fallopian tube cancer, patients receive 
gemcitabine hydrochloride on days 1, 8, and 15 and AZD1775 on days 1, 2, 8, 9, 
15, and 16. The cycle is then repeated every 28 days (ClinicalTrials.gov Identifier 
NCT02101775). The proliferation assays were designed to replicate this dosing 
pattern, with HT29 cells receiving 5-FU, irinotecan or oxaliplatin on day 1 and 
AZD1775 or vehicle control on day 2.  
 
The dosing strategies used in this chapter are also based upon a previous study 
using colorectal cancer cell lines (Hirai et al., 2010). Hirai et al., tested a range of 
chemotherapies on colorectal cancer cell lines for 24 hrs and then treated with 
AZD1775 100 nM, AZD1775 300 nM or vehicle control for a further 24 hrs. As a 
sensitising effect had been seen using 300 nM AZD1775 this dose was used in the 
present studies.  
 
5.7.2  AZD1775 Mechanism of Action 
Work in this chapter shows that when AZD1775 is used in combination with 5-FU 
against a p53 mutated colorectal cancer cell line the enhanced cytotoxicity is due to 
AZD1775 causing increased DS-DNA breaks, not premature mitosis. AZD1775 
appears to exert its own cytotoxic effects independent of chemotherapeutic agents. 
 
In this chapter, the HT29 colorectal cancer cell line was studied specifically 
because it has a mutated p53 (Arg-273 to His). This means that both mechanisms 
of action (premature mitosis and DS-DNA breaks) were possible explanations for 
cytotoxicity seen with combination therapy. Three chemotherapeutic agents 
commonly used to treat colorectal cancer, 5-FU, oxaliplatin and irinotecan were 
investigated as it is clinically relevant to see if AZD1775 could improve their 
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sensitivity. In the proliferation assays AZD1775 significantly improved the IC50 of 5-
FU but not irinotecan or oxaliplatin. In all three cases AZD1775 greatly improved 
chemotherapy efficacy at lower doses, but had less effect at higher doses. This 
does not indicate increased sensitisation at lower chemotherapeutic doses, but 
likely reflects AZD1775 having independent cytotoxicity. AZD1775 has potent 
monotherapeutic action against HT29 cells and has been found to have more 
potent effects on cell viability than some DNA-damaging agents in other cancer cell 
lines (Kreahling et al., 2013). AZD1775 monotherapy was capable of inhibiting 
HT29 cell proliferation by causing DS-DNA breaks with an IC50 of 183 nM. 
Therefore, a single dose of 300 nM AZD1775 is likely to cause some cytotoxicity 
independent of its interaction with chemotherapeutic agents.  
 
5-FU was chosen for further investigation because AZD1775 addition significantly 
improved its IC50. However, 5-FU monotherapy had limited effects on HT29 viability. 
Even at doses of 100 μM it only inhibited proliferation by 30% compared to vehicle 
control. Therefore the big improvement with AZD1775 addition likely reflected the 
independent cytotoxicity of AZD1775 and not a sensitisation effect. Hirai et al., 
previously reported that AZD1775 had a sensitisation effect with 5-FU against p53 
deficient colorectal cancer cell lines (Hirai et al., 2010). Although they did not test 
HT29 cells, the IC50 for 5-FU was improved with 100 nM and 300 nM AZD1775 
addition in WiDr, S498, COLO205, and LS411N p53 deficient colorectal cancer cell 
lines. However, a review of their data shows similar concentration-response curves 
to those generated in this chapter, with AZD1775 addition greatly improving 5-FU 
toxicity at low concentrations (3 μM) and having much smaller improvements at 
higher concentrations of 5-FU (100 μM).  
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To clarify if AZD1775 could sensitise HT29 cells to 5-FU at low concentrations 
experiments investigating the mechanism of action for AZD1775 were performed. 
Doses of 1 μM 5-FU and 300 nM AZD1775 were chosen because in the 
concentration-response curves this combination caused a big reduction in HT29 
viability compared to 1 μM 5-FU alone.  As expected, both mitosis and DS-DNA 
breaks increased with AZD1775 addition. The increase in mitosis was quick, with a 
peak at 8hrs before almost returning back to control levels at 24 hrs. In contrast the 
increase in DS-DNA breaks occurred in a linear fashion and peaked at 24 hrs.  
 
Both premature mitosis and DS-DNA breaks occur with AZD1775 treatment 
because of an increase in active CDK1 (reduction in pCDK1-Y15). However, only 
DS-DNA breaks occur as a consequence of critical nucleotide shortage. The 
addition of exogenous nucleosides to combination therapy could rescue the amount 
of DS-DNA breaks almost to the levels seen with 5-FU treatment alone. In chapter 
4, it was shown that AZD1775 could cause apoptosis in CLMECs as a 
consequence of DS-DNA breaks. Therefore, caspase-3 dependent apoptosis was 
measured for 5-FU and AZD1775 combination therapy. As expected, there was a 3-
fold increase in apoptosis when AZD1775 was added to 5-FU compared to 5-FU 
treatment alone.  Importantly, this increased apoptosis could be rescued with 
exogenous nucleoside addition. This suggests that DS-DNA breaks are the cause 
of the increased apoptosis and although there is an increase in mitosis levels, it is 
not the cause of cytotoxicity. Obviously these findings contradict  a number of 
previous studies in colorectal cancer cell lines that suggest WEE1 inhibition 
sensitises cells to DNA damaging agents through premature mitosis (Wang et al., 
2001, Hirai et al., 2009, Hirai et al., 2010). However, these studies were published 
before the role of WEE1 in regulating DNA synthesis was discovered and so DS-
DNA breaks were not investigated. 
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One interesting point to consider as a result of work in this chapter is whether 5-FU 
could actually sensitise HT29 cells to AZD1775. The mechanism of action of 5-FU 
is attributed to the inhibition of thymidine synthesis, which results in 
deoxynucleotide pool imbalances (Longley et al., 2003). As AZD1775 causes a 
critical nucleotide shortage the addition of 5-FU may further exacerbate the critical 
shortage of nucleotides. Further work on this hypothesis is necessary, initially in the 
form of in vitro studies.  
 
5.7.3  Importance of p53 Status 
The p53 status of a cancer has previously been reported to be important for the 
success of AZD1775 combination therapy. Numerous studies have reported that 
AZD1775 only sensitises DNA-damaging agents in p53 mutated cancer cells (Wang 
et al., 2001, Hirai et al., 2009, Hirai et al., 2010, Rajeshkumar et al., 2011). This is 
because p53 has an important role in maintaining G1/S phase arrest in response to 
DNA damage. ATM, ATR, CHK1 and CHK2 can phosphorylate p53 in response to 
DNA damage, which prevents its nuclear export and degradation (Sancar et al., 
2004). Increased p53 targets the p21CIP/WAF1 gene, which encodes the p21 
protein. p21 is capable of binding to and inhibiting the cyclin E/CDK2 and cyclin 
D/CDK4 complexes, preventing cell cycle progression into S phase and allowing 
DNA to be repaired (Sancar et al., 2004). It is thought that cancer cells that have a 
mutated non-functional p53 have a non-functional G1/S cell cycle checkpoint and 
therefore are much more reliant on the G2/M cell cycle checkpoint for DNA repair. If 
a cancer cell has a functioning p53 its G1/S checkpoint is intact and DNA damage 
can be repaired here, meaning that induced DNA damage is repaired before the 
cell enters mitosis. In 2012, evidence first emerged that AZD1775 can sensitise 
DNA-damaging agents independent of p53 status although the exact mechanism of 
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action was not clear (Kreahling et al., 2012, Van Linden et al., 2013, Guertin et al., 
2013, Muller, 2014). 
 
As the main mechanism of action of AZD1775 in combination therapy is the 
generation of DS-DNA breaks and critical nucleotide shortage, p53 status should 
have no impact upon efficacy. In agreement with this, AZD1775 has been shown to 
have single agent activity in 66 different colorectal cancer cell lines with varying p53 
status (Guertin et al., 2013). If that is the case, then why have previous studies not 
seen a “sensitisation” effect in wildtype p53 cancer cell lines? One possibility is the 
dose of AD1775 necessary to induce DS-DNA breaks may be greater. Of the 
studies performed in cell lines, the maximum dose that has been used with 
combination therapy is 300 nM, often less (Wang et al., 2001, Hirai et al., 2009, 
Hirai et al., 2010, Mueller et al., 2014). This would also indicate why no 
monotherapy effects of AZD1775 are reported in these studies.  
 
5.7.4  Implications for Ongoing Clinical Trials 
As previously discussed, the vast majority of ongoing clinical trials investigating 
AZD1775 are doing so in the context of a DNA-damaging sensitiser. This usually 
involves a maximum tolerated dose of a DNA damaging agent (eg. chemotherapy) 
followed by several doses of AZD1775 to cause premature mitosis before DNA-
damage is repaired. This is followed by a period of no treatment before the cycle is 
repeated. However, work in this chapter has demonstrated that AZD1775 exerts its 
own cytotoxic effects through DS-DNA breaks, independent of chemotherapeutic 
agents. Therefore, current dosing regimens may not be the most effective in terms 
of causing cytotoxicity. Further work is needed to calculate the optimum duration of 
AZD1775 treatment, but results from current clinical trials may be improved if 
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AZD1775 is used as an outright DNA-damaging agent alongside other DNA-
damaging agents. 
 
5.7.5  Conclusion 
Despite the discovery of AZD1775 over seven years ago, its dominant mechanism 
of action has yet to be determined. In this chapter it has been shown that when 
AZD1775 is used in combination with 5-FU against a p53 mutated colorectal cancer 
cell line the enhanced cytotoxicity is due to AZD1775 causing increased DS-DNA 
breaks, not premature mitosis. AZD1775 exerts its own cytotoxic effects 
independent of chemotherapeutic agents by causing DS-DNA breaks and caspase-
3 dependent apoptosis due to a critical nucleotide shortage. This has important 
implications in ongoing clinical trials investigating AZD1775, where current dosing 
strategies may not be optimised to derive maximal oncological benefit from WEE1 
inhibition.  
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Chapter 6: Identifying New Anti-Angiogenic Targets in 
Colorectal Cancer Liver Metastases using a Proteomics 
Screen 
Tumour endothelial cells are distinct from normal endothelial cells. For instance, in 
Chapter 3 it was shown that CLMECs have reduced expression of CD31 and 
VEGFR-2 compared with matched LECs. Identifying proteins that are up- or down-
regulated in tumour endothelial cells and ascertaining their importance in tumour 
angiogenesis would be of great value for the development of future anti-angiogenic 
agents. However, a number of issues have prevented this from being a 
straightforward process. As eluded to in Chapter 3, the isolation and culture of 
human endothelial cells can be technically challenging. Pure endothelial cell 
cultures can be difficult to obtain and may become contaminated with other cell 
types, such as fibroblasts. The lack of a specific endothelial marker also makes 
culture confirmation difficult. Furthermore, identifying important differences in 
protein expression can be a prolonged process, not least because investigators are 
“hunting in the dark”.  
 
Quantitative proteomics is a powerful technique used to analyse global protein 
expression within a cell. It involves the isotopic labelling of proteins or peptides, 
which can then be separated and identified by mass spectrometry. Comparisons of 
protein or peptide abundance can be made between matched samples and 
therefore can be used to identify differentially expressed proteins between groups. 
 
The aim of this chapter was to identify differentially expressed proteins in matched 
LECs and CLMECs using proteomic studies. 
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6.1 LECs and CLMECs Express Numerous Endothelial Cell 
Markers 
Matched LECs and CLMECs from five patients were expanded in culture and 
submitted for proteomic analysis to identify any differences in protein expression. 
The patient characteristics are summarised in Table 8. There were two male 
patients and three female patients ranging in age from 63 to 81 years old. There 
were a range of co-morbidities, but four of the five patients had cardiovascular 
disease. This included three patients with hypertension (receiving medication), one 
patient with Type II diabetes mellitus (tablet-controlled) and one patient with Type I 
diabetes mellitus. There was one current smoker. Only one patient had no co-
morbidities and took no medication. 
 
The specific details of each patient’s primary colorectal cancer, diagnosis of CLM, 
subsequent surgery and pathological outcomes are summarised in Table 9. Three 
patients had primary rectal adenocarcinoma and two patients had primary colonic 
adenocarcinoma. Four patients had metachronous liver metastases and one patient 
had synchronous metastases who had the primary colorectal cancer and liver 
metastases resected at separate surgeries. The number, size and location of the 
metastases were variable. Four of the five CLM resections showed moderately 
differentiated adenocarcinoma, with one being well differentiated adenocarcinoma. 
Unfortunately three resections had positive margins (R1). At the time of writing (26 th 
October 2016) two patients are alive with no recurrent disease, two patients are 
alive with recurrent disease not amenable to surgical intervention and one patient 
has died.  
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As endothelial cells display heterogeneity in different organs and endothelial cells of 
CLM have never been characterised before, a panel of 23 endothelial cell markers 
was generated to assess LECs and CLMECs against (Garlanda and Dejana, 1997). 
Proteomics detected 16 out of the 23 markers, including the well-recognised 
endothelial cell markers CD31, vWF, VE-Cadherin, eNOS and endoglin (Figure 51). 
Three endothelial markers had significant differences in expression levels between 
LECs and CLMECs. Both VEGFR-1 and fibronectin (isoform 17) were significantly 
up-regulated in CLMECs and vWF was significantly down-regulated in CLMECs. 
Despite western blotting showing a significant reduction in CD31 expression in 
CLMECs (Figure 21), this was not confirmed with the proteomics data. There was 
an obvious reduction in CD31 intensity in CLMECs, however, the p-value was 0.06. 
Likewise, western blotting clearly showed VEGFR-2 to be significantly down-
regulated in CLMECs (Figure 23), however it wasn’t detected in either the LECs or 
CLMECs with proteomics. To distinguish vascular endothelial cells from lymphatic 
endothelial cells a panel of 3 markers was generated, podoplanin (PDPN), prospero 
homeobox protein 1 (PROX1) and lymphatic vessel endothelial hyaluronan receptor 
1 (LYVE-1) (Podgrabinska et al., 2002) . None of the lymphatic endothelial cell 
markers were identified in LECs or CLMECs.  
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Unique ID Sex (M/F) Age Co-Morbidities Medications
74 M 66 Nil Nil
75 M 67 Type II Diabetes Mellitus Metformin, Simvastatin
78 F 80
Transient Ischaemic Attack, Atrial 
Fibrillation, Anorexia, Smoker, 
Hypertension, Bladder Cancer
Atorvastatin, Clopidogrel, Codeine, 
Folic Acid, Loperamide, Morphine
Sulphate, Ramipril,  Lactulose
79 F 81
Type I Diabetes Mellitus, Hypertension, 
Cholecystectomy, Appendectomy
Clopidogrel, Creon, Enalapril, 
Loperamide, Insulin, Omeprazole,
Simvastatin, Prednisolone
80 F 63
Hypertension, Idiopathic 
Thrombocytopenic Purpura
Amlodipine
Table 8 Patient Characteristics of the Matched LEC and CLMEC Samples Submitted for Proteomic Studies 
Patient age, sex, co-morbidities and current medication are listed for each patient analysed in the LEC vs. CLMEC proteomic studies.  
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Unique ID Primary Colorectal Cancer Colorectal Liver Metastases Date of Operation Nature of Operation
Histology of Colorectal Liver Metastases
74
Caecal Adenocarcinoma
pT3, N0, M0, R0
Metachronous
1 large lesion spanning 
segments 8/5/6/4/1
16/06/2015
Right hepatic trisectionectomy
with caudate lobectomy
Moderately differentiated adenocarcinoma
R1
75
Rectal Adenocarcinoma
pT3, N1, M1, R0
Synchronous
1 lesion in segment 2, 
1 lesion in segment 5
14/07/2015
Laparoscopic Right
hemi-hepatectomy
Moderately differentiated adenocarcinoma
R0
78
Rectal Adenocarcinoma
pT3, N0, M0, R0
Metachronous
1 lesion in segment 2/3
06/10/2015 Laparoscopic left lateral 
sectionectomy
Well differentiated adenocarcinoma
R0
79
Rectal Adenocarcinoma
pT1, N1, M0, R0
Metachronous
1 lesion in segment 4
20/10/2015
Laparoscopic segment 2/3/4 
metastasectomy
Moderately differentiated adenocarcinoma
R1
80
Colonic Adenocarcinoma
pT3 N0 M0, R0
Metachronous (3rd recurrence) 
1 lesion in segment 7, 
1 lesion in segment 8
03/11/2015
Re-do (third) liver resection -
segment 7 and 8 
metastasectomies
Moderately differentiated adenocarcinoma
R1
Table 9 Colorectal Cancer History for Each Patient Investigated with Proteomic Studies 
Pathological data for each patient analysed in the LEC vs. CLMEC proteomic studies. Primary colorectal cancer has been staged according to the 
TNM classification system. The nature, surgical treatment and pathological details for the CLM are also stated.    
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Figure 51 LECs and CLMECs Express a Range of Endothelial Markers 
A comparison of relative protein intensity for 23 endothelial cell markers in LECs and CLMECs. For each endothelial marker the mean 
protein intensity for LECs has been statistically compared with CLMECs (n=5 each), * (p<0.05) and ** (p<0.01)   
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6.2 Quantitative Proteomics Reveals Differentially Expressed 
Proteins in CLMECs and LECs 
The total proteome for each patient is displayed in the heat map in Figure 52. 
Within each matched patient sample, protein abundance in CLMECs has been 
compared to LECs and assigned a colour based on its Z-score. For the majority of 
proteins there was no difference in expression between LECs and CLMECs, 
indicated by a yellow band, reflecting a Z-score of ~ 0. In total, 4,767 proteins were 
detected in both LECs and CLMECs and 157 proteins had a significantly different 
expression level between the two groups (Appendix I). The top 15 differentially 
expressed proteins (ranked according to their p-value) are displayed in Table 10. 
The most significantly up-regulated protein was thrombospondin-1 (TSP-1), a 
known endogenous inhibitor of angiogenesis (Lawler, 2002). The mean expression 
of TSP-1 was 2.8 times higher in CLMECs compared to LECs. VEGFR-1, another 
endogenous inhibitor of angiogenesis was also significantly upregulated in 
CLMECs, expressed 2.5 times higher compared to LECs. Unsurprisingly, for the 
vast majority of the 157 proteins that had a significant difference in expression 
between LECs and CLMECs, little is known about their role in endothelial cells, 
angiogenesis or cancer.  
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Figure 52 Heat Map of the Total LEC and CLMEC Proteome Determined 
by Proteomic Studies 
Z-scores are plotted for the relative protein expression determined by proteomic 
studies. For each patient, CLMEC protein intensity has been compared to LEC 
protein intensity and assigned a colour based on its Z-score. 
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Table 10 Differentially Expressed Proteins in LECs and CLMECs 
The top 15 differentially expressed proteins in LECs and CLMECs in proteomic studies ranked according to their p-value 
Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Thrombospondin-1
47508.6 134408 0.356179697 0.00025449
cAMP-Dependent Protein 
Kinase Type I-Beta Regulatory 
Subunit
1234.5 392.45 3.368114727 0.000697796
Rho GTPase-Activating Protein 
7 664.164 2519.78 0.267445423 0.001026153
Vascular Endothelial Growth 
Factor Receptor 1
3265.7 8222.44 0.403526385 0.001088631
60S Ribosomal Protein L37
2103.42 4174.36 0.480491872 0.001879499
Tubulin Alpha-4A Chain
9472.1 4342.2 2.781709713 0.001927656
LIM Domain Only Protein 7
1345.32 5934.74 0.231716048 0.002053259
Solute Carrier Family 2, 
Facilitated Glucose Transporter 
Member 1
1141.878 2887.7 0.397928842 0.002208671
E3 Ubiquitin-Protein Ligase 
RBBP6 210.436 803.504 0.253763778 0.002245187
Transforming Growth Factor 
Beta-2 1313.032 12818.66 0.116912767 0.00273289
Neuronal Growth Regulator 1
305.332 770.166 0.400242361 0.002752091
Lysosome-Associated 
Membrane Glycoprotein 2 2604.78 3397.5 0.740762045 0.003172724
LIM and Cysteine-Rich Domains 
Protein 1 320.98 1872.46 0.186101686 0.003259361
Cyclin-Dependent Kinase 
Inhibitor 1 587.758 1255.236 0.455710266 0.003761478
Fibronectin Isoform 17
56968.2 192440 0.308406416 0.003766208
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6.3 Validation of Proteomic Results 
To validate the proteomic study results, western blotting was performed on the 
same samples for all endothelial cell markers that showed statistically different 
levels of expression between LECs and CLMECs. In the proteomic studies, vWF 
expression was reduced in all CLMEC samples compared to LECs, although the 
difference was much less in patient sample 75 (Figure 53a,b). Western blotting also 
confirmed vWF to be down-regulated in CLMECs (Figure 53c). Quantification of the 
vWF band intensity relative to the β-actin loading control in matched samples 
revealed the expression of vWF to be 64% lower in CLMECs (Figure 53d).  
 
VEGFR-1 expression was significantly increased in CLMECs in all patient samples 
analysed with proteomics (Figure 54a,b). Western blotting for VEGFR-1 revealed 
two bands, one at ~180 kDa and a separate band at ~110 kDa that were both 
visibly more intense in CLMECs (Figure 54c). The band ~180kDa in size 
corresponds to the full length VEGFR-1. The band ~110 kDa in size corresponds to 
the shorter soluble VEGFR-1 (sVEGFR-1). Both the VEGFR-1 and sVEGFR-1 band 
intensity were increased in CLMECs relative to the β-actin control. VEGFR-1 was 
found to be up-regulated by 52% and s-VEGFR-1 by 65% (Figure 54d). 
 
Fibronectin isoform 17 was significantly up-regulated in CLMECs in all patient 
samples analysed in the proteomic studies (Figure 55a,b). However, western 
blotting showed fibronectin to be down-regulated in CLMECs (Figure 55c). 
Quantification of the fibronectin band intensity relative to the β-actin loading control 
in matched samples revealed the expression of fibronectin to be 53% lower in 
CLMECs (Figure 55d). 
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Figure 53 vWF is Down-Regulated in CLMECs 
a. vWF protein intensity in LECs and CLMECs determined by proteomic studies in 
five matched patient samples (n=5) b. Mean vWF intensity in all matched LEC and 
CLMEC samples shown in a c. Example western blot labelled with anti-vWF and 
anti--actin antibodies for LECs and CLMECs d. Quantification of the CLMEC vWF 
band intensity relative to -actin and normalised to LEC (n=3 each). 
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Figure 54 VEGFR-1 and sVEGFR-1 are Up-Regulated in CLMECs 
a. VEGFR-1 protein intensity in LECs and CLMECs determined by proteomic studies in five matched patient samples (n=5) b. Mean 
VEGFR-1 intensity in all matched LEC and CLMEC samples shown in a c. Example western blot labelled with anti-VEFGR-1 and anti--
actin antibodies for LECs and CLMECs d. Quantification of the CLMEC sVEGFR-1 band intensity relative to -actin and normalised to LEC 
(n=3 each) d. Quantification of the CLMEC VEGFR-1 band intensity relative to -actin and normalised to LEC (n=3 each). 
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Figure 55 Fibronectin is Down-Regulated in CLMECs 
a. Fibronectin isoform 17 protein intensity in LECs and CLMECs determined by 
proteomic studies in five matched patient samples (n=5) b. Mean fibronectin 
isoform 17 intensity in all matched LEC and CLMEC samples shown in a c. 
Example western blot labelled with anti-fibronectin and anti--actin antibodies for 
LECs and CLMECs d. Quantification of the CLMEC fibronectin band intensity 
relative to -actin and normalised to LEC (n=3 each).  
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6.4 Thrombospondin-1 as an Anti-Angiogenic Target 
TSP-1 is a known endogenous inhibitor of angiogenesis and was the most 
significantly upregulated protein in CLMECs (Table 10). In the proteomic studies, 
TSP-1 expression was increased in all CLMEC samples compared to LECs (Figure 
56a,b). Western blotting also confirmed TSP-1 to be up-regulated in CLMECs 
(Figure 56c). Quantification of the TSP-1 band intensity relative to the β-actin 
loading control in matched samples revealed the expression of TSP-1 to be 2.4 fold 
higher in CLMECs (Figure 56d).  
 
TSP-1 inhibits endothelial cell proliferation and migration in HUVECs (Lawler, 
2002). To assess the functional relevance of TSP-1 in CLMECs, pooled siRNA 
targeted against TSP-1 was used to knockdown TSP-1 (Figure 57a). Quantification 
of the TSP-1 band intensity relative to the β-actin loading control revealed the 
expression of TSP-1 to be 51% lower in CLMECs transfected with TSP-1 siRNA 
compared to scrambled siRNA (Figure 57b). Proliferation was measured 48 hrs 
after transfection using the nuclear dye Vybrant® Green (Figure 57c). Knockdown of 
TSP-1 increased CLMEC proliferation by 24% compared to scrambled siRNA 
(Figure 57d). To investigate the effect of TSP-1 knockdown on CLMEC migration a 
scratch wound assay was performed (Figure 58a). At 20 hrs the RWD in CLMECs 
transfected with TSP-1 siRNA was 95%, whereas in CLMECs transfected with 
scrambled siRNA the RWD was 78% (Figure 58b), indicating that knockdown of 
TSP-1 increased migration in CLMECs.  
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Figure 56 Thrombospondin-1 is Up-Regulated in CLMECs 
a. TSP-1 protein intensity in LECs and CLMECs determined by proteomic studies in 
five matched patient samples (n=5) b. Mean TSP-1 intensity in all matched LEC 
and CLMEC samples shown in a c. Example western blot labelled with anti-TSP-1 
and anti--actin antibodies for LECs and CLMECs d. Quantification of the CLMEC 
TSP-1 band intensity relative to -actin and normalised to LEC (n=3 each). 
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Figure 57 TSP-1 Knockdown Increases Proliferation in CLMECs 
a. Example western blot labelled with anti-TSP-1 and anti--actin antibodies for 
CLMECs transfected with scrambled siRNA (Scr) or ON-TARGETplus TSP-1 
siRNA (siTSP-1) b. Quantification of the siTSP-1 group TSP-1 band intensity 
relative to -actin and normalised to the Scr group (n=3 each) c. Fluorescence 
images of CLMECs 48 hrs after transfection with scrambled siRNA (Scr) or ON-
TARGETplus TSP-1 siRNA (siTSP-1). Fluorescence was from cell nuclei stained 
with Vybrant® Dye Cycle™ (green). Scale bars 400 μm d. Quantification of the 
number of CLMECs seen in the images of the type shown in c. The siTSP-1 group 
has been normalised to the Scr group (n=3, N=9). 
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Figure 58 TSP-1 Knockdown Increases Migration in CLMECs 
a. Example linear wound mask images after 20 hr migration in CLMECs transfected 
with scrambled siRNA (Scr) or ON-TARGETplus TSP-1 siRNA (siTSP-1). Black 
represents cells outside the linear wound, grey represents cells which have 
migrated into the wound, and white represents no cells. Scale bars 200 μm b. 
Relative wound density at 20 hrs in CLMECs transfected with ON-TARGETplus 
TSP-1 siRNA (siTSP-1) or scrambled siRNA (Scr) (n=3, N=9).  
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6.5 Piezo1 as an Anti-Angiogenic Target 
Analysis of the proteomics data revealed that Piezo1 was present in both LECs and 
CLMECs (Figure 59a). Our laboratory has a special interest in Piezo1 which is a 
Ca2+ permeable mechanosensitive ion channel. In endothelial cells it serves as a 
sensor of frictional force (shear stress) and determinant of vascular structure in both 
developmental and adult physiology (Li et al., 2014). There was no difference in 
Piezo1 expression between LECs and CLMECs (Figure 59b).  
 
Validation of the proteomic results proved difficult with western blotting due, in part, 
to the lack of a specific antibody against Piezo1. Therefore, an alternative approach 
was adopted to prove the presence of Piezo1. Although physiologically activated by 
shear stress, the first chemical activator of Piezo1, Yoda1, was discovered in 2015 
(Syeda et al., 2015). Activation of Piezo1 by shear stress causes intracellular Ca2+ 
entry (Li et al., 2014), therefore, intracellular concentrations of Ca2+ were measured 
in response to a range of Yoda1 concentrations in matched LECs and CLMECs. In 
LECs, Yoda1 could activate Ca2+ entry between a range of concentrations (0.05 - 
10 μM) (Figure 60a). A concentration-response curve was created for Yoda1 in 
LECs (Figure 60b) and the calculated EC50 was 1.85 μM. Yoda1 could also evoke 
Ca2+ entry in CLMECs at concentrations between 0.05 and 10 μM (Figure 60c). A 
concentration-response curve for Yoda1 was also created for CLMECs and the 
EC50 was calculated to be 2.47 μM (Figure 60d). Although this mean value was 
higher than in LECs, there was no statistically significant difference between the 
two groups (Figure 60e). 
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Figure 59 Piezo1 Expression is not Altered in CLMECs 
a. Piezo1 protein intensity in LECs and CLMECs determined by proteomic studies 
in five matched patient samples (n=5) b. Mean Piezo1 intensity in all matched LEC 
and CLMEC samples shown in a  
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Figure 60 Yoda1 evokes Ca2+ Entry in LECs and CLMECs 
a. Example Intracellular Ca2+ measurement data in LECs in response to a range of Yoda1 concentrations. Traces show averaged responses 
to a range of Yoda1 concentrations across multiple wells of a 96-well plate compared to control (N=3 wells each)  b. Yoda1 concentration 
response curve in LECs measuring intracellular [Ca2+] at 150 secs (n=3) c. Example Intracellular Ca2+ measurement data in CLMECs in 
response to a range of Yoda1 concentrations. Traces show averaged responses to a range of Yoda1 concentrations across multiple wells of 
a 96-well plate compared to control (N=3 wells each)  d. Yoda1 concentration response curve in CLMECs measuring intracellular [Ca2+] at 
150 secs (n=3) e. Mean data for the derived EC50 values for Yoda1 in matched LECs and CLMECs (n=3 each).  
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6.5.1 Yoda1 Causes Ca2+ Entry Specifically Through Piezo1 
The specificity of Yoda1 to cause Ca2+ entry through the Piezo1 channel is 
unknown and therefore Yoda1 could be causing Ca2+ entry through other Ca2+ 
permeable ion channels. To answer this question, use was made of the tamoxifen-
inducible endothelial-specific Piezo1 knockout mouse model we have in our 
laboratory. Generation of the murine model is described in chapter 2.  
 
Mice livers were harvested by Dr Baptiste Rode (University of Leeds) and mouse 
liver endothelial cells (mLECs) were isolated using an IMS technique similar to that 
used for the human studies except the CD146 rather than CD31 antibody was 
used. Immunofluorescent staining of the isolated mLECs confirmed expression of 
CD31 (Figure 61a). PCR, performed by Dr Baptiste Rode (University of Leeds), 
confirmed an 88% knockdown of Piezo1 at the mRNA level in mLECs with deleted 
Piezo1 (Piezo1ΔEC) compared to Control mLECs (Figure 61b). Application of 2 μM 
Yoda1 caused an increase in intracellular Ca2+ that peaked at 150 seconds and 
was maintained until at least 300 seconds in Control mLECs (Figure 61c). In stark 
contrast Yoda1 failed to cause any Ca2+ entry in Piezo1ΔEC mLECs (Figure 61c,d).  
 
To ensure other mechanisms of Ca2+ entry were still functional in the Piezo1ΔEC 
mLECs, Ca2+ entry in response to the physiological agonist ATP and the drug 
ionomycin was tested. In both Control and Piezo1ΔEC mLECs, 20 μM ATP caused 
Ca2+ entry that peaked at 70 seconds before gradually returning back to baseline 
levels by 300 seconds (Figure 62a). There was no significant difference in the peak 
Ca2+ entry values between the two groups (Figure 62b). Ionomycin (1 μM) caused 
Ca2+ entry in both Control and Piezo1ΔEC mLECs that peaked at 80 seconds 
followed by a sustained phase that stayed above the baseline for at least 300 
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seconds (Figure 62c). Although the mean peak Ca2+ entry was lower in the 
Piezo1ΔEC mLECs, there was no significant difference between the two groups 
(Figure 62d). 
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Figure 61 Yoda1 does not Evoke Ca2+ Entry in Mouse Liver Endothelial Cells with Piezo1 Knockout 
a. Immunofluorescence images of mLECs stained with anti-CD31 antibody (green) and DAPI to label nuclei (blue). Scale bars 20 μm b. 
Piezo1 mRNA expression relative to β-actin in Piezo1 endothelial knockout (Piezo1ΔEC) and Control (Control) mLECs (n=3 each performed 
by Dr Baptiste Rode, University of Leeds) c. Intracellular Ca2+ measurement data from Piezo1ΔEC and Control mLECs. Traces show 
averaged responses to 2 μM Yoda1 across multiple wells of a 96-well plate d. Mean data for the peak (200 s) responses to Yoda1 of the 
type exemplified in c (n=6, N=20 each). 
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Figure 62 Endothelial Piezo1 Knockout Does Not Effect ATP and 
Ionomycin Evoked Ca2+ Entry in Mouse Liver Endothelial Cells 
a. Intracellular Ca2+ measurement data from Piezo1ΔEC (blue) and Control (black) 
mLECs. Traces show averaged responses to 20 μM ATP across multiple wells of a 
96-well plate b. Mean data for the peak (70 s) responses to ATP of the type 
exemplified in a (Piezo1ΔEC: n=6, N=16 , Control: n=4, N=10) c. Intracellular Ca2+ 
measurement data from Piezo1ΔEC (blue) and Control (black) mLECs. Traces show 
averaged responses to 1 μM Ionomycin across multiple wells of a 96-well plate d. 
Mean data for the peak (80 s) responses to Ionomycin of the type exemplified in c 
(Piezo1ΔEC: n=6, N=16, Control: n=4, N=10).  
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6.5.2 Yoda1 Causes eNOS Phosphorylation in CLMECs  
Shear stress causes intracellular Ca2+ entry through Piezo1 and is able to induce 
phosphorylation of eNOS at Ser-1177 (Li et al., 2014). eNOS is responsible for 
nitric oxide (NO) synthesis, which is able to regulate angiogenesis (Cooke and 
Losordo, 2002). To see if Yoda1 was also capable of inducing phosphorylation of 
eNOS at Ser-1177, CLMECs were treated with Yoda1 (2 μM) or vehicle control for 
1 minute and levels of eNOS and peNOS-S1177 were measured using western 
blotting. Yoda1 clearly induced phosphorylation of eNOS at Ser-1177, whereas its 
vehicle control did not (Figure 63a). Quantification of the peNOS-S1177 band 
intensity relative to the eNOS band intensity revealed peNOS-S1177 to be up-
regulated 2.2 fold with Yoda1 treatment (Figure 63b). 
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Figure 63 Yoda1 Induces Phosphorylation of eNOS at Ser-1177 in 
CLMECs 
a. Example western blot labelled with anti-peNOS-S1177, anti-eNOS and anti--
actin antibodies for CLMECs treated with Yoda1 (2 μM) or vehicle control b. 
Quantification of the Yoda1 peNOS-S1177 band intensity relative to eNOS and 
normalised to vehicle control (n=3 each). 
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6.6 Summary of Findings 
 Proteomics studies have identified 157 proteins that are differentially 
expressed in LECs and CLMECs 
 
 LECs and CLMECs express a wide range of endothelial cell markers 
 
 CLMECs up-regulate VEGFR-1 and down-regulate vWF  
 
 TSP-1, an endogenous inhibitor of angiogenesis, is the most significantly 
up-regulated protein in CLMECs 
 
 siRNA mediated knockdown of TSP-1 increases CLMEC proliferation and 
migration 
 
 LECs and CLMECs both express Piezo1 
 
 Yoda1 evokes intracellular Ca2+ entry in LECs and CLMECs 
 
 Yoda1 causes Ca2+ entry specifically through Piezo1 in endothelial cells 
 
 Yoda1 causes eNOS phosphorylation in CLMECs 
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6.7 Discussion 
The aim of this chapter was to identify differentially expressed proteins in matched 
LECs and CLMECs using proteomic studies. In total, 157 proteins were found to be 
differentially expressed between the two groups. Both LECs and CLMECs positively 
expressed a broad range of endothelial markers with significant down-regulation of 
vWF and up-regulation of VEGFR-1 in CLMECs. CLMECs also significantly up-
regulated TSP-1, a known endogenous anti-angiogenic substance. Genetic 
knockdown of TSP-1 with pooled siRNA significantly increased proliferation and 
migration in CLMECs. For the first time, Piezo1 was shown to be expressed in 
LECs and CLMECs. Modulation of the Piezo1 channel with Yoda1 lead to Ca2+ 
entry and phosphorylation of eNOS.  
 
6.7.1 Validation of LECs and CLMECs 
Proteomic studies of matched LECs and CLMECs provided a further opportunity to 
validate the endothelial nature of the cells that were being isolated. As previously 
discussed, no specific endothelial marker exists that is expressed by all types of 
endothelial cells.  Therefore, in chapter 3, CLMECs were characterised by testing 
for the expression of several well established endothelial markers (CD31, vWF, 
VEGFR-2, eNOS, VE-Cadherin) and for functional properties of endothelial cells 
(alignment, tube formation). In this chapter, a list of 23 endothelial markers was 
generated based upon a previous study (Garlanda 1997). Proteomics revealed that 
LECS and CLMECs expressed 16 out of the 23 markers. VEGFR-2, Tie-2, CD34, 
ACE, E-Selectin, CD141 and VCAM-1 were not detected. This could be because 
the isolated endothelial cells truly do not express these markers, or it could be 
because of the proteomics methodology. A case for the latter point is VEGFR-2, 
which was easily detectable by western blot in LECs and CLMECs, but was not 
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detected in the proteomics study. This could be for a number of reasons including 
the digestion method used to break up the protein into peptides which are then 
detected by mass spectrometry. Failure of the digestion process to break up the 
protein or digestion that results in unrecognisable peptide sequences will mean 
peptides are not detected by mass spectrometry. For this reason, all potential “hits” 
were confirmed by performing western blots. For the remaining six endothelial 
markers that were not detected by proteomics, it would be important to confirm their 
absence with western blot. 
 
6.7.2 Results of The Proteomics Study 
The proteomics study revealed 157 proteins that were differentially expressed 
between LECs and CLMECs (Appendix I). A small number of these proteins are 
known to have roles in angiogenesis, however the vast majority are not.  
 
Several endothelial markers showed different expression levels in LECs and 
CLMECs. There was up-regulation of VEGFR-1 and Fibronectin (isoform 17) and 
down-regulation of vWF in CLMECs. vWF is a blood glycoprotein that has a role in 
haemostasis and is synthesised in endothelial cells and stored in Wiebel-Palade 
bodies. The presence of vWF in CLMECs was confirmed in Chapter 3, with 
immunofluorescent staining clearly revealing the presence of Wiebel-Palade bodies 
that could be seen as peri-nuclear rod-shaped granules. Western blotting also 
confirmed the proteomics result. The reason for vWF down-regulation is unclear, 
however, several studies support this finding. Firstly, vWF has been reported to be 
significantly down-regulated in primary colorectal cancer endothelial cells compared 
to matched healthy colon endothelial cells (Schellerer et al., 2007). Therefore, this 
could be an important mechanism for both primary and metastatic colorectal cancer 
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angiogenesis. Secondly, apart from its major role as a platelet adhesion molecule, 
endothelial vWF also has a role in leucocyte adhesion and the regulation of 
inflammation (Pendu et al., 2006). Therefore, down-regulation may be a form of 
tumour defence against the host immune system. Furthermore, angiogenesis 
increases in HUVECs depleted of vWF by siRNA in vitro and it is also increased in 
vWF deficient mice in vivo (Starke et al., 2011). This is thought to be due to the 
essential role of vWF in forming Wiebel-Palade bodies, which also store Ang-2. 
With vWF deficiency and reduced Wiebel-Palade bodies Ang-2 cannot be stored, 
resulting in its dysregulated release. Ang-2 is known to promote VEGF-dependent 
stimulation of endothelial cells to migrate and sprout. 
 
Isofrom 17 of fibronectin was upregulated in all CLMEC patient samples in the 
proteomics study, however, western blotting for fibronectin found the opposite 
result, that it was down-regulated in CLMECs. This may mean that the specific 
isoform 17 of fibronectin has importance in CLMEC angiogenesis. Unfortunately 
there is no commercial antibody available against isoform 17 of fibronectin so the 
proteomics result could not be validated. Fibronectin is an extracellular matrix 
protein and known endogenous inhibitor of angiogenesis that acts through integrin 
signalling (Avraamides et al., 2008). Unlike other endogenous inhibitors of 
angiogenesis identified in the proteomics (VEGFR-1, TSP-1), fibronectin was down-
regulated in CLMECs. Targeted down-regulation of fibronectin maybe an 
angiogenesis promoting mechanism in CLMECs. Further work will be needed to 
determine the significance of this result. 
 
In chapter 3, CD31 was found to be down-regulated in CLMECs with western 
blotting. This was not confirmed in the proteomics study. Although it was clearly 
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down-regulated in four out of five samples, it was up-regulated in one sample 
resulting in an overall p-value of 0.06. Interestingly, when the patient characteristics 
of each sample are reviewed, CD31 is down-regulated in all patients with 
metachronous CLM but up-regulated in the only patient with synchronous 
metastases. Similarly, ICAM-1, another adhesion molecule, is clearly down-
regulated in four out of five samples with an overall p-value of 0.06. The only 
sample it was up-regulated in was again the patient with synchronous CLM. 
Adhesion molecules such as ICAM-1 and VCAM-1, have previously been reported 
to be down-regulated in the tumour endothelium (Griffioen et al., 1996, Alessandri 
et al., 1999). This is thought to be a form of tumour defence because leucocytes are 
less able to bind to these adhesion molecules and leave the circulation to attack the 
tumour. Although impossible to determine based upon one synchronous tumour, 
these results may suggest a difference in biology between synchronous and 
metachronous CLM, specifically in terms of ability to evade the host’s immune 
system.  
 
A number of studies have been performed comparing the proteome of TECs with 
that of healthy endothelial cells. To date, four studies have analysed protein 
expression in matched culture-expanded endothelial cells from colorectal cancer 
and healthy colon tissue (van Beijnum et al., 2006, Schellerer et al., 2007, 
Jayasinghe et al., 2009, Mesri et al., 2013) and no study has looked at differences 
in endothelial cell protein expression in CLM. As previously mentioned, work in this 
chapter supports that of Schellerer et al., in that vWF is down-regulated in 
CLMECs. Jayasinghe et al., reported VEGFR-1 and s-VEGFR-1 to be non-
significantly reduced in colorectal cancer endothelial cells compared to healthy 
colon endothelial cells. Although not significant, this is the opposite effect to what 
has been observed in LECs and CLMECs. van Beijnum et al., identified seventeen 
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genes up-regulated in colorectal cancer endothelial cells. Nine of these proteins 
were detected in the proteomics study and one was significantly up-regulated in 
CLMECs, insulin-like growth factor binding protein 7. This is also in agreement with 
other studies (St Croix et al., 2000). Mesri et al., identified 56 proteins 
overexpressed in colorectal cancer endothelial cells. Thirty-three of these were 
detected in the current proteomic study and one of these proteins was significantly 
up-regulated in CLMECs, lysosomal-associated membrane protein 2.  
 
In 2000 St Croix et al., reported nine transcripts thought to be specific markers for 
tumour endothelial cells. Termed Tumour Endothelial Markers (TEM 1-9), these 
genes showed a 10-fold up-regulation compared to healthy endothelial cells (St 
Croix et al., 2000). None of the TEMs were detected in the current proteomic study. 
However, it is important to note that the validity of these markers has been 
questioned, as they are also expressed in a number of different cell types 
(MacFadyen et al., 2007, Halder et al., 2009). Only two proteins were exclusively 
expressed in CLMECs, Tumour necrosis factor receptor superfamily member 10D 
and Mediator of RNA polymerase II transcription subunit 6. Unfortunately 
expression levels in CLMECs were low and both proteins are widely expressed in a 
range of other cell types.  
 
Unfortunately the proteomic study did not detect WEE1. This is most likely due to 
the digestion process used to prepare the sample as in chapters 3 and 4 WEE1 
could be clearly detected with western blotting in LECs and CLMECs. Furthermore, 
the target protein of WEE1, CDK1, was detected in the proteomics study and its 
expression was unchanged. 
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6.7.3 Identification of Further Anti-Angiogenic Targets in CLM 
6.7.3.1 Thrombospondin-1 
Thrombospondins are a family of five multidomain, Ca2+-binding extracellular 
glycoproteins found in a wide variety of cell types. TSP-1 was the first family 
member identified and has been studied the most intensively. TSP-1 was the first 
protein to be shown to play a critical role as a naturally occurring inhibitor of 
angiogenesis (Zhang and Lawler, 2007). TSPs interact with a wide range of other 
proteins and as such, their functions are dynamic and diverse. 
 
TSP-1 antagonizes VEGF in several ways, via inhibition of VEGF release from the 
extracellular matrix, direct interaction, and inhibition of VEGF signal transduction 
(Lawler and Lawler, 2012). Critical to the anti-angiogenic function of TSP-1 is a 
central domain containing three type 1 repeats (TSRs). Via its TSRs, TSP-1 is able 
to bind matrix metalloproteinases, suppressing their activity. This results in 
decreased release of VEGF from the extracellular matrix and suppression of 
angiogenesis (Rodriguez-Manzaneque et al., 2001). TSP-1 can bind directly to 
VEGF, which mediates its uptake and removal from the extracellular space 
(Greenaway et al., 2007). Finally TSRs can interfere with VEGF signal transduction 
through their interaction with CD36. The interaction of CD36 with TSP-1 down 
regulates the VEGFR-2 phosphorylation normally invoked by VEGF-A, the main 
regulator of angiogenesis (Primo et al., 2005). An association of CD36 with β1 
integrins also appears necessary for the inhibition of VEGFR-2 phosphorylation by 
TSP-1 (Primo et al., 2005). TSP-1 is an important antagonist of the VEGF-Nitric 
Oxide (NO) signalling pathway and powerfully counteracts the proangiogenic 
signals generated. Normally VEGF induces phosphorylation of Ser1177 on eNOS 
via both PI3K-AKT and PLCγ-AMPK pathways, which drives the production of NO. 
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NO then binds to the prosthetic heme on soluble guanylate cyclase to stimulate 
cyclic guanosine monophosphate synthesis, which acts to promote endothelial cell 
migration, proliferation, and survival, as well as vascular permeability (Isenberg et 
al., 2009). 
 
In the proteomics study, TSP-1 was upregulated 2.8 times in CLMECs compared to 
LECs and this was validated with western blotting. This could be a consequence of 
prolonged exposure to high concentrations of VEGF found in the tumour 
microenvironment. Up-regulation of TSP-1 may therefore be an attempt to balance 
pro-angiogenic and anti-angiogenic factors. TSP-1 was shown to have a functional 
role in CLMEC proliferation and migration, with knockdown of TSP-1 increasing 
both these processes. However, synthetic analogues of TSP-1 have been 
unsuccessful in clinical trials (Markovic et al., 2007). This may be because TSP-1 is 
already significantly up-regulated and the addition of more TSP-1 is unable to inhibit 
angiogenesis any further. Alternatively, tumours may resort to angiogenic pathways 
independent of VEGF, meaning TSP-1 will have less effect. Promising results with 
TSP-1 in vitro have not translated to patient success. Further work is needed to 
determine why tumours appear to be resistant to TSP-1 targeted therapy.  
 
 
6.7.3.2 VEGFR-1/sVEGFR-1 
Proteomic studies demonstrated a 2.5 times increase in VEGFR-1 expression in 
CLMECs, with all five individual patient samples showing a higher expression in 
CLMECs compared to LECs. VEGFR-1 binds VEGF-A, VEGF-B and PGF and is 
thought to be a negative regulator of angiogenesis, either by acting as a decoy 
receptor for VEGF or by supressing VEGF signalling through VEGFR-2 (Yang et 
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al., 2011). Homozygous deletion of VEGFR-1 in mice results in embryonic lethality 
due to the overgrowth of endothelial cells, resulting in disorganised and 
dysfunctional vasculature (Fong et al., 1995). VEGFR-1 expresses two types of 
mRNA, one which encodes the full length receptor and one which encodes a short 
soluble protein known as soluble (s)VEGFR-1. sVEGFR-1 has been shown to bind 
VEGF with high affinity and inhibit its mitogenic activity in endothelial cells (Kendall 
and Thomas, 1993). Expression of VEGF and sVEGFR-1 is induced by hypoxia, for 
instance, in the tumour microenvironment (Wu et al., 2010). A plethora of in vivo 
studies have demonstrated that gene transfer of sVEGFR-1 can inhibit tumour 
angiogenesis (Yang et al., 2011). In one such study, bone-marrow derived stromal 
cells were used to deliver sVEGFR-1 gene therapy to metastatic colon cancers. 
sVEGFR-1 gene therapy was shown to decrease metastatic disease and prolong 
survival time through inhibition of angiogenesis (Hu et al., 2008) 
 
Targeting VEGFR-1 and sVEGFR-1 for the development of anti-angiogenic therapy 
has had promising results, but nevertheless research is in its infancy. Much work 
needs to be done to understand the exact anti-angiogenic mechanism of VEGFR-
1/sVEGFR-1, consequences of anti-VEGF therapy for VEGFR-1/sVEGFR-1 
expression and the role of VEGFR-1/sVEGFR-1 as prognostic markers. The data in 
this study encourage further investigation of VEGFR-1/sVEGFR1. Both VEGFR-1 
and sVEGFR-1 were up-regulated in CLMECs which may be a consequence of 
prolonged exposure to high concentrations of VEGF in the tumour 
microenvironment. To combat the high expression of VEGF, the up-regulation of 
VEGFR-1 and sVEGFR-1 could serve to prevent excessive VEGFR-2 signalling 
and decrease angiogenesis.  
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6.7.3.3 Piezo1 
Endothelial cells have pronounced sensitivity to the frictional force of shear stress. 
Physiologically, shear stress is generated by blood flow. The detection of shear 
stress by endothelial cells enables vascular development, however, the 
mechanisms that underlie this process have been unclear. Initially, important 
studies showed that shear stress evoked Ca2+ entry in endothelial cells (Schwarz et 
al., 1992). Although a number of ion channels have been reported to be important 
in shear stress sensing, recent work in our laboratory showed the 
mechanosensitive ion channel Piezo1 to be critical for shear-stress evoked Ca2+ 
signalling and non-selective cationic channel current activity in endothelial cells (Li 
et al., 2014). Piezo1 knockout was embryonic lethal in mice at E9.6-11.5, shortly 
after the time when the murine heart starts to beat and when important vascular 
structures should first emerge. Analysis of the embryonic yolk sacs revealed 
disrupted vascular structures. There were even disturbances in the vasculature of 
haploinsufficient mice, where endothelial cells failed to align in the direction of flow 
compared to wildtype animals. The critical role of Piezo1 in vascular development is 
of potential oncological interest, as tumours must develop their own blood supply 
for growth and metastatic spread. Could inhibition of Piezo1 be a potential anti-
angiogenic treatment strategy? Genetic knockdown of Piezo1 in HUVECs inhibits 
tube formation in vitro and in vivo (Li et al., 2014). However, at present there are no 
specific inhibitors of Piezo1. Non-specific blockers of Piezo1 include ruthenium red 
and the spider toxin Grammostola spatulata (Coste et al., 2010, Bae et al., 2011). 
 
Proteomic studies showed no difference in expression of Piezo1 between LECs and 
CLMECs. Western blotting to detect Piezo1 was unsuccessful due to the lack of a 
specific antibody. Fortunately the first chemical activator of Piezo1, Yoda1, was 
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discovered in 2015 (Syeda et al., 2015) and this was used to indirectly confirm 
Piezo1 expression through measurements of intracellular Ca2+ entry. Yoda1 was 
able to induce Ca2+ entry in both LECs and CLMECs and although the mean EC50 
for Yoda1 was higher in CLMECs, it was not statistically significant, suggesting no 
difference in channel expression. To prove that Yoda1 caused Ca2+ entry 
specifically through Piezo1 and not through another ion channel, experiments were 
performed on liver endothelial cells isolated from mice with a tamoxifen-inducible 
endothelial specific Piezo1 knockout. Phenotypically there was no difference in 
culture between Piezo1ΔEC and Control mLECs. Strikingly, Yoda1-evoked Ca2+ 
entry was completely abolished in the Piezo1 knockout endothelial cells. This 
suggests that Yoda1-evoked Ca2+ entry is specifically through Piezo1 and indirectly 
confirms the presence of Piezo1 channels in LECs and CLMECs. Ca2+ entry in 
response to ionomycin and ATP were unaffected with Piezo1 knockout.  
 
The tumour vasculature is highly abnormal and is functionally and morphologically 
distinct from healthy blood vessels. Tumour blood vessels are chaotic in nature. 
They are tortuous, dilated, elongated and leaky with many vessels ending blindly 
(Dudley, 2012). There is also considerable variability in vessel diameter. This 
results in a heterogeneous rate of blood flow throughout the tumour, with areas of 
high and low shear stress. The effects of shear stress on tumour vessel 
angiogenesis are not fully understood. At low levels of shear stress, indicative of a 
poorly-perfused vessel, endothelial cells sprout to seek new sources of blood flow 
(Jain et al., 2014). At the other end of the spectrum, high shear stress is capable of 
inducing vessel branching through intussusceptive angiogenesis (Djonov et al., 
2002). Shear stress induces Ca2+ entry through Piezo1 leading to calpain activation, 
proteolytic cleavage of actin cytoskeletal and focal adhesion proteins and 
endothelial cell reorganisation (Li et al., 2014). Piezo1 channels could represent a 
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therapeutic target whereby chemical inhibition of Piezo1 abolishes angiogenesis 
signalling pathways caused by shear stress. 
 
A completely contrasting concept is that activation of Piezo1 in the tumour 
vasculature could encourage vessel normalization and be beneficial. Vessel 
normalization improves tumour blood flow, reducing hypoxia and VEGF secretion 
leading to decreased sprouting angiogenesis through VEGF/VEGFR-2 signalling. 
Furthermore, as argued by Jain, vessel normalization could improve drug delivery 
to the tumour enhancing the efficacy of current therapeutic agents (Carmeliet and 
Jain 2011).   
 
eNOS is capable of synthesising NO, a key regulator of blood pressure, vascular 
remodelling and angiogenesis, from the amino acid L-arginine. In endothelial cells, 
NO regulates a number of cellular processes including proliferation, migration, 
extracellular matrix degradation, and angiogenesis (Cooke and Losordo, 2002). 
eNOS is a 1,203 amino acid, 133 kDa protein which has a bi-domain structure and 
functions as a dimer. It consists of an N-terminal oxygenase domain containing 
binding sites for heme, L-arginine and tetrahydrobiopterin (BH4) and a COOH-
terminal reductase domain with binding sites for nicotinamide adenine dinucleotide 
phosphate (NADPH), flavin mononucleotide (FMN), flavin adenine dinucleotide 
(FAD) and Ca2+/Calmodulin (CaM) (Fleming, 2010). During the synthesis of NO, 
NADPH derived electrons are transferred to FAD, FMN and then to the heme 
located in the oxygenase domain of the opposing monomer. This allows the heme 
iron to bind oxygen and catalyse the stepwise synthesis of NO from L-arginine. It 
was originally thought that eNOS was a CaM dependent enzyme (Fleming, 2010). 
In basal conditions caveolin (Cav) maintains eNOS in an inactivated state. 
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Increases in intracellular [Ca2+], lead to disruption of the eNOS-Cav interaction by 
Ca2+ bound CaM. Association of CaM with its binding site is generally accepted to 
activate NO synthesis by enabling the reductase domain to transfer electrons to the 
oxygenase domain (Fleming, 2010).  
 
A number of studies have shown that eNOS activity can be regulated without 
increasing intracellular [Ca2+], for instance by glycosylation, phosphorylation and 
protein partners (Fleming, 2010). eNOS can be phosphorylated at multiple sites, but 
most research has focussed on two residues, Ser-1177, which increases eNOS 
activity and Thr-495, which decreases eNOS activity. Ser-1177 is rapidly 
phosphorylated in HUVECs following application of shear stress (Dimmeler et al., 
1999) or VEGF (Dimmeler et al., 2000). The kinases involved in phosphorylation of 
Ser-1177 vary based upon the stimulant, for instance, shear stress elicits 
phosphorylation via protein kinase A (PKA) whereas VEGF acts via AKT. 
Phosphorylation of Ser-1177 is thought to disable an inhibitory control element that 
normally interferes with the interaction between the two flavin moieties and 
attenuates electron transfer in a CaM-independent manner (Balligand et al., 2009). 
 
Yoda1 was able to induce phosphorylation of the Ser-1177 residue of eNOS in 
CLMECs. This site was investigated because shear stress acting through Piezo1 is 
able to cause Ser-1177 phosphorylation (Li et al., 2014) and therefore as a Piezo1 
activator, the same would be expected of Yoda1. Exactly how Yoda1 causes Ser-
1177 phosphorylation is unclear, but the response is relatively quick, as cells were 
treated for 1 minute with Yoda1. Phosphorylation of Ser-1177 could occur through 
PKA as is the case with shear stress activation or as Yoda1 causes an increase in 
intracellular Ca2+ it could act through Ca2+/calmodulin-dependent protein kinase II 
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(CaMKII) to  cause Ser-1177 phosphorylation (Fleming et al., 2001). Further work is 
need to determine the exact mechanism by which Yoda1 causes eNOS Ser-1177 
phosphorylation. However, this result further supports that inhibition of Piezo1 could 
have anti-angiogenic effects by reducing eNOS phosphorylation and NO 
production.  
 
Piezo1 is a potentially interesting target for the development of future anti-
angiogenic therapeutics. Initial work will need to focus on the benefit of activating or 
inhibiting Piezo1 for the reasons discussed above. The discovery of Yoda1 has 
certainly helped better understand the properties of Piezo1. Work in this chapter 
has, for the first time, shown Yoda1 to specifically cause intracellular Ca2+ entry 
through Piezo1 in CLMECs. Yoda1 will therefore be integral to the development of 
small molecule Piezo1 inhibitors. 
 
6.7.4  Conclusion 
Proteomic analysis has shown both LECs and CLMECs to express a plethora of 
endothelial markers. Furthermore 157 proteins have been identified that are 
differentially expressed in CLMECs and LECs. These represent potential treatment 
targets that may be critical to the survival and expansion of CLMECs. The 
established endogenous angiogenesis inhibitor TSP-1 was the most significantly 
up-regulated protein in CLMECs and has been shown to have a role in CLMEC 
proliferation and migration. For the first time, the mechanosensitive, Ca2+ permeable 
ion channel Piezo1 has been shown to be expressed CLMECs. Modulation of the 
Piezo1 channel with Yoda1 evokes intracellular Ca2+ entry and eNOS 
phosphorylation and therefore it may be a potential anti-angiogenic target for the 
treatment of CLM. 
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Chapter 7: Conclusions and Future Work 
The aim of this study was to identify novel protein targets in CLMECs that could be 
used in the future for the development of anti-angiogenic therapies for the treatment 
of CLM. For the first time CLMECs have been isolated, cultured and characterised 
from patients undergoing curative surgery for CLM. CLMECs behave similar to 
other endothelial cell types, but harbor differences in expression levels of a number 
of proteins compared to matched LECs (Table 11). WEE1 has been identified as a 
potential anti-angiogenic target that is up-regulated in CLMECs. AZD1775, a small 
molecule WEE1 inhibitor, inhibits CLMEC proliferation, migration and tube 
formation in vitro by causing DS-DNA breaks and caspase-3 dependent apoptosis 
due to a critical nucleotide shortage. Known endogenous inhibitors of angiogenesis, 
TSP-1 and VEGFR-1 have been confirmed to be present and up-regulated in 
CLMECs. Finally, Piezo1 has been confirmed to be present in CLMECs. This 
protein, which has a critical role in vasculature development in both embryogenesis 
and adult physiology, is a mechanosensitive Ca2+ permeable ion channel. Yoda1 
has been confirmed to be a specific activator of Piezo1 in endothelial cells resulting 
in eNOS phosphorylation. Future work will, in part, involve investigating the 
importance of this channel in tumour angiogenesis. 
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7.1 Summary of Key Findings 
 Isolated CLMECs behave similarly to other endothelial cells; they grow in a 
cobblestone appearance in vitro, they form lattice like structures on 
Matrigel® and they align in response to shear stress. 
 
 CLMECs express a number of common endothelial cell markers including 
CD31, VEGFR-2, VE-Cadherin, vWF and eNOS. 
 
 CLMECs have decreased expression of VEGFR-2 and VEGF evokes 
significantly less Ca2+ entry compared to matched LECs. 
   
 WEE1 is up-regulated in CLMECs and AZD1775 is able to inhibit CLMEC 
proliferation, migration and tube formation in vitro. 
 
 AZD1775 causes DS-DNA breaks and caspase-3 dependent apoptosis in 
CLMECs as a result of critical nucleotide shortage (Figure 64). 
 
 The dominant mechanism of action of AZD1775, either as a monotherapy or 
part of a combination therapy, is through its ability to cause DS-DNA breaks 
rather than premature mitosis. 
 
 Proteomic screening has identified 157 proteins that are differentially 
expressed between matched LECs and CLMECs giving rise to potential 
further anti-angiogenic targets (Table 11). 
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 Known endogenous inhibitors including VEGFR-1 and TSP-1 have been 
confirmed to be up-regulated in CLMECs.  
 
 Piezo1 is expressed in CLMECs and activation by Yoda1 causes Ca2+ entry 
and eNOS phosphorylation 
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Figure 64 Proposed Mechanism of Action of AZD1775 in CLMECs 
CDK1 is regulated by WEE1 and controls origin firing during DNA synthesis. WEE1 
inhibition with AZD1775 prevents the inhibitory phosphorylation of cyclin B bound 
CDK1 at its Tyr15 residue. This results in increased active CDK1 and excessive 
origin firing. Nucleotide stores are exhausted due to increased DNA replication 
rates which leads to replication fork stalling and DS-DNA breaks. This results in 
caspase-3 dependent apoptotic cell death.  
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Table 11 Validated Alterations in Protein Expression in CLMECs 
Summarised data for changes in protein expression in matched LECs and 
CLMECs. All changes in protein expression have been confirmed with western blot 
and ranked according to their p value.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein
Up- or Down-
Regulated in CLMECs
Fold Change P Value
CD31 ↓ 0.36 0.001
vWF ↓ 0.37 0.006
Thrombospondin-1 ↑ 2.43 0.009
sVEGFR-1 ↑ 1.65 0.009
VEGFR-2 ↓ 0.46 0.017
VEGFR-1 ↑ 1.52 0.020
WEE1 ↑ 1.74 0.029
Fibronectin ↓ 0.46 0.047
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7.2 Future Directions 
7.2.1 The Functional Importance of WEE1 in the Endothelium in 
vivo 
Work in chapters 3 and 4 demonstrated clearly that WEE1 is upregulated in 
CLMECs and that targeted inhibition of WEE1 with AZD1775 blocked several 
angiogenic processes. Although AZD1775 is currently being investigated in clinical 
trials for its anti-cancer activity, none of these trials are set-up to review anti-
angiogenic activity. Furthermore, determining true anti-angiogenic activity may be 
difficult as AZD1775 can also kill tumour cells. What these trials can determine 
however, is cardiovascular complications that may arise due to the anti-angiogenic 
activity of AZD1775. Existing trials have reported minimal cardiovascular 
complications (Do et al., 2015) but it is important that studies look for these adverse 
events, particularly in patients with pre-existing cardiovascular disease.  
 
A murine model of CLM already exists in the University of Leeds (Hawcroft et al., 
2012). In this, 11 week old female BALB/c mice are injected with 1 x 106 viable 
Mouse Colon-26 (MC26) cells percutaneously into the spleen under ultrasound 
guidance. This reliably generates liver metastases within two weeks. AZD1775 
could be delivered orally to these mice to determine the efficacy of WEE1 inhibition 
as a treatment for CLM. Although, it would be difficult to differentiate between anti-
angiogenic and anti-tumour effects it would provide valuable insight into the overall 
oncological benefit of AZD1775 treatment in CLM patients.  
 
One way of investigating anti-angiogenic activity in vivo would be the generation of 
a tamoxifen-inducible, endothelial specific, WEE1 knockout murine model. This 
would follow the same principles of the Piezo1 murine model used in this report. 
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After induction of endothelial WEE1 knockout, colorectal cancer cells could be 
implanted subcutaneously and after a set time period tumours could be harvested 
and vessel micro-density could be measured to assess vascularisation of tumours 
compared to controls. Alternatively, MC26 cells could be injected into the splenic 
vein to generate CLM. Using this approach, WEE1 could be knocked out after CLM 
are established to see if it prevents their growth, or alternatively, prior to tumour cell 
injection to see if this prevents CLM generation. Although these latter studies could 
provide important information about when WEE1 inhibition is most effective, it is a 
genetic model and therefore is not 100% representative of what will happen with 
AZD1775 treatment.   
 
7.2.2 Optimal Dosing Strategy for AZD1775 
In chapters 4 and 5, AZD1775 was demonstrated to cause cytotoxicity through its 
ability to induce DS-DNA breaks. As CDK1 regulates origin firing during DNA 
synthesis, WEE1 inhibition causes excess origin firing, exhausting nucleotide 
stores, leading to DS-DNA breaks and caspase-3 dependent apoptosis. This is the 
case whether it is used as a monotherapy or in combination with DNA-damaging 
agents. This finding has implications upon a number of ongoing clinical trials that 
are using AZD1775 as a DNA-damaging sensitiser, suggesting that the dosing 
schedule for AZD1775 may not be optimal.  
 
The mechanism of action of AZD1775 in combination with other DNA-damaging 
agents needs to be validated in other colorectal cancer cell lines as well as other 
types of cancer. To begin with this can be investigated using the in vitro techniques 
used within this thesis. Furthermore, cancer cell types with varying p53 status 
should be investigated to confirm that this does not impact upon AZD1775 efficacy. 
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Further in vivo studies could be undertaken to determine the optimal dosing 
schedule for AZD1775 in combination with DNA-damaging agents.  
 
7.2.3 Investigation of Piezo1 as an Anti-Angiogenic Target 
In chapter 6, Piezo1 was confirmed to be expressed by CLMECs. This 
mechanosensitive, Ca2+ permeable ion channel has an important role in the 
determination of vascular structure in developmental embryology and adult 
physiology (Li et al., 2014). Its role in the generation of the tumour vasculature is 
unknown, however, a logical hypothesis would be that inhibition of Piezo1 could 
disrupt tumour angiogenesis. Work in our laboratory has already shown that 
targeted siRNA knockdown of Piezo1 in HUVECs can inhibit angiogenesis in vivo 
(Li et al., 2014).  
 
To determine the anti-angiogenic effect of Piezo1 blockade, in vitro assays could be 
performed in CLMECs to assess the importance of Piezo1 in CLMEC proliferation, 
migration and tube formation. Advantage could be taken of the tamoxifen-inducible, 
endothelial specific, Piezo1 knockout murine model in our laboratory. Pizeo1 could 
be knocked down prior to subcutaneous or intra-splenic injection of colorectal 
cancer cells. Tumour weight/growth and vessel micro-density could be measured to 
determine anti-angiogenic activity compared to control mice.  
 
At present there is no specific chemical inhibitor of Piezo1. However, work in this 
thesis has shown that Yoda1 is a specific chemical activator of Piezo1. Therefore, 
knowledge about the chemical structure of Yoda1 can be used to design and test 
chemical inhibitors of Piezo1. Work in our laboratory is underway to discover the 
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first specific chemical inhibitor of Piezo1. If discovered, this could be used as an 
alternative to genetic inhibition of Piezo1 to assess its functional relevance in 
tumour angiogenesis.  
 
7.2.4 Interrogation of Proteomic Data and Investigation of Further 
Hits  
The proteomic screen in chapter 6 generated 157 protein targets that are 
differentially expressed between LECs and CLMECs. Many of these proteins are 
not known to have a function in endothelial cells, angiogenesis or cancer. Although 
this is a valuable dataset revealing proteins that may be critical to CLMEC survival 
and angiogenesis, determining which proteins to investigate will be a difficult and 
lengthy process. There is very little known about some proteins and no specific 
antibodies, targeted siRNA, small molecule inhibitors or activators exist. 
Nevertheless, work has begun on rationalising this list of protein targets. A literature 
search is being performed to determine what is known about each protein and 
whether antibodies/inhibitors/activators for the protein exist. To begin with, proteins 
that are known to play a role in angiogenesis will be investigated alongside proteins 
that have existing antibodies and inhibitors/activators for ease of investigation.  
 
7.2.4 Future Clinical Implications 
Characterising and experimenting on isolated CLMECs is a significant step away 
from cell line based assays and helps better predict clinical responses. The 
proteomic screening has identified a number of protein targets which can be used 
to develop clinically relevant anti-angiogenic agents in the future. Considering the 
cost and time-scale required to develop a drug, this research is undoubtedly in its 
infancy. However, as has been demonstrated in this thesis, targets can be identified 
- 233 - 
 
 
that already have a role in cancer treatment such as WEE1. These targets, for 
which small molecule inhibitors may exist and already be in use or in clinical trials, 
are already well along the drug discovery pathway and the time-frame to clinical 
use will be much shorter. 
 
Since the concept was proposed by Judah Folkman in the 1970s, inhibition of 
tumour angiogenesis has proven an attractive anti-cancer treatment strategy. In the 
last decade anti-angiogenic agents have been clinically licensed for the treatment of 
metastatic colorectal cancer. However, despite extensive research and great 
promise in pre-clinical studies, these therapies have only led to a modest 
improvement in patient survival rates. Much is still to learn about tumour 
angiogenesis including what mechanisms are critical to tumour endothelial cell 
survival and how tumours develop resistance to anti-angiogenic agents. By 
targeting direct mechanisms critical to tumour endothelial cell function and survival, 
resistance to current anti-angiogenic agents, which indirectly target endothelial 
cells, may be overcome. Clinically, this could lead to meaningful improvements in 
survival rates for patients with inoperable CLM. It could also lead to an increase in  
conversion rates of patients with initially inoperable CLM who are subsequently able 
to undergo curative surgery. Finally, it may reduce the high recurrence rate 
associated with CLM resections.     
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7.3 Conclusion 
Tumour angiogenesis is critical for the growth of CLM and CLMECs form a 
genetically distinct population of endothelial cells. Better understanding of the 
cellular mechanisms critical for CLMEC survival will help overcome the problems 
associated with anti-angiogenic therapy resistance. In this research study, CLMECs 
have been successfully isolated and characterised for the first time. The WEE1 
protein has been identified as an anti-angiogenic target that is significantly 
upregulated in CLMECs. Inhibition of WEE1 with AZD1775 has been demonstrated 
to have clear anti-angiogenic effects in CLMECs. Furthermore, 157 proteins have 
been identified that are differentially expressed in CLMECs. This includes the 
established endogenous inhibitors of angiogenesis TSP-1 and VEGFR-1. The 
mechanosensitive, Ca2+ permeable ion channel Piezo1 has also been identified as 
another potential anti-angiogenic target in CLMECs. Modulation of the Piezo1 
channel with Yoda1 has been demonstrated for the first time in CLMECs and 
shown to induce phosphorylation of eNOS.  
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Appendix I: Differentially Expressed Proteins in the 
Proteomics Screen 
On the following eleven pages are the 157 differentially expressed proteins in LECs 
and CLMECs as determined by proteomic studies. In each case, the protein 
intensity in LECs and CLMECs is reported along with the LEC to CLMEC intensity 
ratio and p-value. Proteins are ranked according to their p-value.  
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Thrombospondin-1
47508.6 134408 0.356179697 0.00025449
cAMP-Dependent Protein 
Kinase Type I-Beta Regulatory 
Subunit
1234.5 392.45 3.368114727 0.000697796
Rho GTPase-Activating Protein 
7 664.164 2519.78 0.267445423 0.001026153
Vascular Endothelial Growth 
Factor Receptor 1
3265.7 8222.44 0.403526385 0.001088631
60S Ribosomal Protein L37
2103.42 4174.36 0.480491872 0.001879499
Tubulin Alpha-4A Chain
9472.1 4342.2 2.781709713 0.001927656
LIM Domain Only Protein 7
1345.32 5934.74 0.231716048 0.002053259
Solute Carrier Family 2, 
Facilitated Glucose Transporter 
Member 1
1141.878 2887.7 0.397928842 0.002208671
E3 Ubiquitin-Protein Ligase 
RBBP6 210.436 803.504 0.253763778 0.002245187
Transforming Growth Factor 
Beta-2 1313.032 12818.66 0.116912767 0.00273289
Neuronal Growth Regulator 1
305.332 770.166 0.400242361 0.002752091
Lysosome-Associated 
Membrane Glycoprotein 2 2604.78 3397.5 0.740762045 0.003172724
LIM and Cysteine-Rich Domains 
Protein 1 320.98 1872.46 0.186101686 0.003259361
Cyclin-Dependent Kinase 
Inhibitor 1 587.758 1255.236 0.455710266 0.003761478
Fibronectin Isoform 17
56968.2 192440 0.308406416 0.003766208
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Coiled-coil domain-containing 
protein 86 724.718 957.854 0.713252433 0.004068168
Isoform 2 of Sodium-coupled 
neutral amino acid transporter 2 1434.508 3904.14 0.373888007 0.004344309
Biglycan
391.128 1421.578 0.295381739 0.00478014
Importin-8
2483.78 4928.94 0.520507138 0.005825925
Isoform 8 of Double-stranded 
RNA-binding protein Staufen
homolog 2
5958.24 17718.8 0.345370839 0.005835435
Isoform 4 of Receptor-type 
tyrosine-protein phosphatase alpha 1144.052 629.182 1.848735337 0.006215804
Isoform 2 of Aldo-keto reductase 
family 1 member C3 3652.16 758.426 5.605668297 0.006699675
Protein kinase C and casein 
kinase substrate in neurons protein 
3
111.2834 739.054 0.1441083 0.006723402
Isoform 2 of EGF-like repeat and 
discoidin I-like domain-containing 
protein 3
670.978 11905.32 0.063406126 0.007037614
Alpha- and gamma-adaptin-binding 
protein p34 653.164 1463.968 0.455146068 0.007106586
Glutathione peroxidase 7
497.4486 1661.4 0.316800311 0.007569646
Isoform 5 of Neuron navigator 1
2328.84 8991.92 0.284549309 0.007720948
Protein phosphatase 
methylesterase 1 3141.22 12605.84 0.274688454 0.007742732
Isoform 2 of Protein tweety
homolog 3 6522.38 20097.4 0.3268724 0.007788754
Growth/differentiation factor 15
3585.68 6403.74 0.562366421 0.008076002
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Ribosome biogenesis regulatory 
protein homolog 1254.12 3212.46 0.407326644 0.009056148
Vesicle-associated membrane 
protein 5 3807.78 1785.064 2.539389755 0.009316384
Endothelial cell-specific molecule 1 
662.816 198.1932 4.235193186 0.009962981
Isoform PDE2A1 of cGMP-
dependent 3,5-cyclic 
phosphodiesterase
5686.98 663.948 9.505616533 0.010206262
Ubiquitin-associated and SH3 
domain-containing protein B 1003.138 5196.4 0.210718166 0.010831017
Glia maturation factor gamma
3104.86 1467.74 2.252407349 0.012125557
Isoform 11 of Dysferlin
59041.6 27907.8 2.517517756 0.012231579
Histone H1.3
2456.88 10645.16 0.26712756 0.012661688
Adhesion G protein-coupled 
receptor F5 19118.4 3424.18 6.607238943 0.012899255
Isoform 2 of Protein CDV3 
homolog 1613.21 2189.96 0.641224705 0.012997302
Isoform 2 of CB1 cannabinoid 
receptor-interacting protein 1 1637.028 2869.1 0.580130921 0.013357121
rRNA-processing protein UTP23 
homolog 191.166 377.876 0.471870502 0.013370795
THUMP domain-containing protein 
1 974.932 1671.416 0.596434161 0.013846194
Sterile alpha motif domain-
containing protein 9-like 578.952 1560.64 0.406409526 0.014494289
Procollagen-lysine,2-oxoglutarate 
5-dioxygenase 2 10332.6 44884.8 0.256392503 0.014525053
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Isoform 2 of 72 kDa type IV 
collagenase
752.012 2600.32 0.315606825 0.014552779
Isoform 5 of Multiple C2 and 
transmembrane domain-containing 
protein 1
313.352 1014.872 0.339140308 0.014685317
HLA class I histocompatibility 
antigen, A-3 alpha chain
2855.078 6975.92 0.349464243 0.014795925
Mesencephalic astrocyte-derived 
neurotrophic factor
6546.78 12655.4 0.525883654 0.015628764
Isoform 3 of RNA-binding protein 
Musashi homolog 2
449.416 1721.66 0.288453547 0.01579305
Alpha-2-macroglobulin
1256.654 164.17 7.65458975 0.016088913
Isoform 2 of Peptidyl-prolyl cis-
trans isomerase FKBP11
5558.88 8482.02 0.666936853 0.016828787
Paladin
5884.22 1256.704 6.726440925 0.017044863
Transmembrane 4 L6 family 
member 18
531.04 75.234 7.05851078 0.017504998
Adenosine deaminase
2939.02 9036.32 0.369328104 0.017669589
Low density lipoprotein receptor 
adapter protein 1
16.2066 138.0532 0.098658306 0.017746818
Isoform 2 of Vacuolar protein 
sorting-associated protein 51
2074.66 1532.58 1.433633286 0.018305016
Latent-transforming growth factor 
beta-binding protein 1
323.992 2306.8 0.167137338 0.018410987
Guanylate kinase
2340.52 3965.68 0.609399433 0.018738363
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Phospholipid scramblase 4
3251.36 7061.78 0.477115651 0.018954935
Isoform 4 of Band 4.1-like protein 3
6370.74 26672 0.269830675 0.019073238
28S ribosomal protein S6, 
mitochondrial 348.234 1063.456 0.293886526 0.019183599
Isoform 2 of Extracellular sulfatase 
Sulf-2 6545.5 2391.78 3.004041572 0.020063103
EGF-containing fibulin-like 
extracellular matrix protein 2 484.396 1304.78 0.402407864 0.020491576
Isoform 2 of Insulin-like growth 
factor-binding protein 7 9492.88 23337.8 0.433569375 0.020584888
Isoform 3 of Mediator of RNA 
polymerase II transcription subunit 
12
325.338 1108.048 0.345616678 0.020645689
High mobility group protein B3
4658.58 9523.2 0.461054208 0.020652251
Dual specificity protein 
phosphatase 23 2186.3 10055.38 0.248739991 0.021088999
Sulfide:quinone oxidoreductase, 
mitochondrial 23645.6 7662.86 4.099915442 0.021202375
Isoform 3 of Apoptosis-associated 
speck-like protein containing a 
CARD
589.38 291.726 2.02032044 0.021212955
Isoform 4 of Nucleoporin NDC1
1396.198 4185.14 0.367382492 0.021420395
Follistatin-related protein 1
2727.814 9737.66 0.317876958 0.02199752
Polypeptide N-
acetylgalactosaminyltransferase 2 8360.1 18723.6 0.480791793 0.022494818
Isoform 5 of Growth arrest-specific 
protein 297.55 598.082 0.501837117 0.022504674
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Splicing factor 45
1542.554 1979.9 0.76870575 0.022669355
Isoform 2 of Ras-specific guanine 
nucleotide-releasing factor 
RalGPS2
209.26 483.94 0.361121318 0.022690513
Protein-methionine sulfoxide 
oxidase 4464.02 8847.58 0.532623888 0.02388848
Isoform 3 of Cell adhesion 
molecule 3 12.2186 610.938 0.03306972 0.024022651
Isoform LMP2.S of Proteasome 
subunit beta type-9 3877.78 2081.62 2.134099819 0.024940775
Heme oxygenase 1
12563.08 3411.8 4.197901738 0.02502463
Tryptophan--tRNA ligase, 
cytoplasmic 71986.4 28934.4 2.936182895 0.025026045
TGF-beta receptor type-2
19308 11591.8 1.76429087 0.025102754
Isoform 3 of Phosphatidylinositol 5-
phosphate 4-kinase type-2 gamma 190.6484 462.646 0.455904701 0.025417738
Alpha-crystallin B chain
5854.966 25054.6 0.28549153 0.025609345
Sulfotransferase family cytosolic 
1B member 1 3541.42 15411.48 0.249970933 0.027371235
Isoform 3 of NAD(P)H 
dehydrogenase [quinone] 1 34462.6 18410.56 2.272456824 0.028238465
Isoform 3 of Tetraspanin-3
146.842 475.832 0.284169326 0.028797587
Isoform 2 of Splicing factor, 
arginine/serine-rich 15 43.6264 215.6516 0.174707439 0.029021641
Uridine phosphorylase 1
10801.38 2327.78 6.23766498 0.029217897
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Nucleoredoxin
802.22 2646.66 0.326288602 0.029362216
Transmembrane protein 263
4958.08 12674.94 0.427565822 0.029607408
Isoform 2 of Kinesin-like protein 
KIF2A 7241.94 12031.1 0.613482771 0.030807409
Guanylate-binding protein 2
8374.56 3034 3.357548483 0.030870993
Isoform 4 of Collagen alpha-1(XII) 
chain 9407.94 24902.8 0.434297779 0.03163561
Isoform 4 of Nexilin
4277.32 9970.6 0.447643386 0.031794821
40S ribosomal protein S19
13087.7 34889.4 0.383927191 0.031856666
Histone H1.2
999.87 5057.66 0.257122448 0.032100085
BAG family molecular chaperone 
regulator 2 3955.08 7967.12 0.523075759 0.032387614
Ankyrin repeat domain-containing 
protein 1 1126.252 2238.98 0.54060452 0.032408486
Ribonucleoside-diphosphate 
reductase large subunit 7522.56 17145.74 0.451666451 0.032994065
Isoform 3 of Galectin-9
5556.38 1026.924 7.100114932 0.03394191
Isoform BIN1-10-13 of Myc box-
dependent-interacting protein 1 687.214 1781.41 0.414670863 0.035386312
V-type proton ATPase subunit F
2344.66 4068.08 0.587194382 0.035388671
Isoform 3 of Centrosomal protein 
POC5 1532.854 3565.58 0.479514364 0.035531842
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
COMM domain-containing protein 
8 921.056 1665.534 0.610585206 0.035581682
von Willebrand factor
162997.4 67449.4 2.782607533 0.035950566
Isoform 2 of Regulation of nuclear 
pre-mRNA domain-containing 
protein 1A
731.156 1670.224 0.475753818 0.036116789
Isoform 3 of Acidic leucine-rich 
nuclear phosphoprotein 32 family 
member E
1142.92 1872.2 0.632178902 0.03613275
Lamina-associated polypeptide 2, 
isoform alpha 541.86 1745.326 0.340324002 0.036133592
DNA damage-binding protein 2
818.614 1868.26 0.495396854 0.037647896
Spermine synthase
3412.62 5310.52 0.680469675 0.0378676
Transgelin
15101.68 78022.8 0.306995577 0.038056208
Claudin-5
7378.44 1868.702 5.122690124 0.038142047
2-5-oligoadenylate synthase 3
4750.98 1681.79 4.102135698 0.038293601
Ras GTPase-activating protein-
binding protein 2 2482.4 5288.98 0.511259811 0.038795691
mRNA export factor
94.4354 341.322 0.329786579 0.039748566
Connective tissue growth factor
19785.64 38894.2 0.541921167 0.039769657
Inhibitor of nuclear factor kappa-B 
kinase-interacting protein 15260.9 27825.8 0.552701271 0.03988357
Secretory carrier-associated 
membrane protein 2 1283.336 899.99 1.538070059 0.040455832
- 288 - 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Tumor necrosis factor receptor 
superfamily member 10D 0 178.3018 0 0.040663093
Mitogen-activated protein kinase 
kinase kinase 11 895.922 628.936 1.621222102 0.04128939
Isoform 3 of UPF0585 protein 
C16orf13 1240.668 3428.92 0.430651527 0.041736248
Isoform 2 of RAB6A-GEF complex 
partner protein 1 230.552 598.546 0.443864927 0.042220921
Nucleolar protein 7
2157.16 4533.62 0.518457542 0.042709036
Isoform 2 of Serine/threonine-
protein phosphatase 2A 56 kDa
regulatory subunit alpha isoform
937.066 564.376 2.059221955 0.042747168
Synaptojanin-2-binding protein
1393.518 3377.86 0.435966767 0.042764676
Leucine-rich repeat-containing 
protein 32 373.188 94.404 3.95301047 0.043072243
Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit, 
mitochondrial
1931.06 3063.1 0.649018494 0.043153129
Nuclear cap-binding protein 
subunit 2 2073.96 4860.66 0.486492686 0.043279389
Isoform 5 of Nuclear valosin-
containing protein-like 263.074 726.68 0.41145959 0.044625389
Isoform 10 of Dystrophin
20.88 178.4382 0.060539989 0.044872151
Isoform 2 of Endothelial 
differentiation-related factor 1 5596.74 16804.4 0.356734071 0.04550145
Isoform 3 of Protein enabled 
homolog 3822.3 9065.86 0.469157909 0.045591055
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Isoform HERA-B of GTPase Era, 
mitochondrial 674.06 1332.954 0.504290318 0.045859992
Proteasome activator complex 
subunit 3 5227.58 11243.8 0.513701169 0.045950975
40S ribosomal protein S9 25967.6 38288.4 0.70246054 0.046311414
40S ribosomal protein S13 22107 44003 0.55423787 0.046357047
Myosin regulatory light polypeptide 
9 791.25 1746.58 0.486356918 0.046793222
Bisphosphoglycerate mutase 5101.28 11880.58 0.449100315 0.04718663
Endoplasmic reticulum 
aminopeptidase 1 29302 15853.82 2.154151925 0.047383219
CDGSH iron-sulfur domain-
containing protein 2 2042.8 5036.18 0.469280201 0.047809018
U1 small nuclear ribonucleoprotein 
C 357.738 548.0312 0.448393024 0.047980957
Ubiquitin-conjugating enzyme E2 
G1 550.918 879.012 0.636043993 0.048011806
Isoform 2 of FERM domain-
containing protein 6 311.562 763.636 0.448617643 0.048121889
Isoform 3 of Fatty acid desaturase 
2 3939.44 11112.04 0.355048732 0.048394822
BTB/POZ domain-containing 
protein KCTD12 35262.8 14004.64 3.53397243 0.048490204
Isoform 3 of Collagen alpha-
1(XVIII) chain 31967 16556.3 2.245111246 0.048584924
Isoform 2 of Transcription 
elongation regulator 1 1940.64 3928.28 0.549316694 0.048780593
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Protein Mean LEC Intensity
Mean CLMEC
Intensity
LEC/CLMEC Ratio LEC vs. CLMEC p value
Hexokinase-2 3069.36 9633.66 0.36631215 0.049376501
Uncharacterized protein C7orf50
75.792 192.3832 0.233871039 0.049402254
Histone H2B type 2-E
8493.54 23213.2 0.42159489 0.049423362
Isoform 2 of Mitogen-activated 
protein kinase kinase kinase MLT 667.948 2052.34 0.36756853 0.049543028
Monocarboxylate transporter 4
17263.2 33808.4 0.558376968 0.049651447
Mimitin, mitochondrial
1774.7 4065.46 0.508129698 0.049767666
Tapasin-related protein
682.39 148.432 4.59732403 0.049834907
